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Chapter 1 
GENERAL INTRODUCTION AND SCOPE OF THIS THESIS 
Plasma ACTH levels belong to the lowest values formed for circulating 
hormones in man. In the last decade numerous sensitive radioimmunoassays for 
ACTH have been described as for various other hormones. It would obviously be 
desirable that hormone levels as determined by their immunoreactivity equal 
bioassayable levels. However close parallelism between such levels would 
only be expected when the antiserum used recognizes only the biologically 
active portion of the ACTH molecule which resides in the NH -terminal ACTH 
1-10 sequence i.e. its first 10 amino acids. From scarce literature data it 
appears that differences have been observed between immunoassayable and bio-
assayable ACTH levels as has also been documented for other hormones 
(calcitonin: Roos et al 1978; prolactin: Leung et al 1978; LH: Maraña et al 
1979; PTH: Segre et al 1972). These differences could, certainly in part, be 
ascribed to the fact that commercially available ACTH antisera have their 
immunologic determinant in the central portion of the ACTH molecule. This is 
in concert with the possibility that ACTH-like peptides circulate which while 
being partially or totally biologically inactive may remain immunoreactivity. 
This thesis explores discrepancies between the steroidogenic and immuno-
logic plasma ACTH-activity, a dichotomy which could compromise the clinical 
usefulness of the radioimmunoassay. First, an adrenal cell preparation was 
developed with a markedly improved sensitivity enabling the measurement of an 
1-39 
amount of 0.85 pg synthetic hACTH (chapter II). Subsequently a radio-
immunoassay is described with the use of a commercially available and widely 
used antiserum (chapter III). A number of different ACTH moieties were 
analysed for their responses in both assays. After a detailed description of 
the critical step of extracting ACTH from plasma and validation of the 
reliability of both types of assay, radioimmunoassayable (I-ACTH) and bio-
assayable (B-ACTH) ACTH levels measured in the plasma of healthy subjects were 
compared and the observed differences discussed (chapter IV). Next B-ACTH 
and I-ACTH levels under physiological and pathological conditions are presented 
with emphasis on diurnal variation of these levels (V) . Finally, the results 
are given obtained in dynamic studies using insulin-induced hypoglycaemia as a 
stimulus to increase endogenous ACTH levels (chapter VI). 
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In this introduction first the structure of ЛСТН will be surveyed with 
respect to its bioactivity (section 1.1), secondly literature data on ACTH-
related peptides will be discussed (section 1.2), thirdly the choice of the 
bioassay which was developed is discussed in the context of historical notes 
about several ACTH bioassays (section I .3), and finally, for reason of compa­
rison with older bioassays in which the activity of ACTH is expressed in 
International Units, a short survey is presented about the assessment of the 
International Standards (section 1.4). 
1.1 The structure of ACTH 
ACTH is a linear polypeptide containing 39 amino acids and with a 
molecular weight of about 4500. In a number of mammalian species the primary 
structure of ACTH was elucidated; for porcine by Bell (1954), for ovine and 
bovine by Li et al (1954;1958), and for human ACTH by Lee et al (1961). Later 
the sequence was revised for human ACTH by Riniker et al (1972) and for ovine 
and bovine ACTH by Li (1972) and Jöhl et al (1974). Recently, Pankov et al 
(1976) and Kawauchi (1978) elucidated the structure of whale ACTH, whereas 
Drouln & Goodman (1980) predicted the sequence of rat ACTH by studying rat 
genomic DNA. Table 1.1 shows that for all these species the structure of the 
ACTH molecule is identical for the sequence 1 to 24 and 34 to 39 with minor 
species differences in the 25 to 33 sequence. 
Table 1.1 
ACTH sequence of miimialian species 
Sequence согтюп to all known 
mamnallan adrenocortkotrophlns 
Human, Whale 
Porcine 
Ovine, Bovine 
Rat 
1 ?0 
NHj-Ser-Tyr-Ser-Met-Glii-hhs-Phe-Arg-Trp-Glj.-Lys-IVo-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-
21 25 33 39 
Lys-Val-Tyr-Pro- Ala-Phe-Pro-Leu-Glu-Phe-COOH 
Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-
Asn-Gly-Ala-Glu-Asp-Glu-Leu-Ala-Glu-
Asn-Gly-Ala-Glu-Asp-Glu-Scr-Ala-Gln-
Asn-Val-Ala-Glu-Asn-Glu-Ser-Ala-Glu-
The complete amino acid sequence of porcine ACTH was for the first time 
synthesized by Schwyzer& Sieber (1963). In addition in the same laboratory 
(Schwyzer & Rappeler 1963) the 1-24 derivative was synthesized. This part of 
ACTH, common to all mammalian species as far as is known, has full biological 
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activity and its use is preferred in clinical medicine because it rarely causes 
adverse, allergic reactions sometimos черп after the use of the complete mole­
cule. After the correction by Rinikcr et al (1972) the complete revised human 
ACTH was synthesized by Sieber et al (1972). 
The conformation of ACTH is illustrated in fiq 1.1 - modified folllowina 
Schwy¿er (1977). Helical structures are formed near the NH -terminal end and 
near the COOH-terminus. Between these two regions the amino acid chain could give 
rise to a ß-turn (L5w et al 1975) as is illustrated by the sequence 20-28. 
fig 1.1 The structure of ACTH. The positions of the basic amino acids are given 
by means of the black squares, the acid amino acids by black triangles. 
Furthermore it can be observed from the figure that basic amino acids are 
localized at the NH -terminal part of the molecule. Following the current 
concept the basic amino acid sequence 15-1G plays a role in the binding and 
affinity to the receptor (Hofmann et al 1970), whereas the bioactive center of 
ACTH concerning steroidogenicity in the adrenal cortex is localized in the 
5-10 sequence (Schwyzer et al 1971). At the COOH-terminal part of the molecule 
the acid amino acids predominate. As is known from the work of Imura et al 
(1967) this part of the molecule is of interest in the protection of ACTH 
against degradation in human plasma in vitro (see also section II.3.2.5). In 
section II.3.3.2.2 a number of ACTH fragments were investigated to better 
define the structure-function relationship. 
1.2 ACTH-related peptides 
Besides the existence of the 39 amino acid polypeptide, studies both in 
human plasma and in extracts of pituitary glands or tumors (Yalow & Berson 
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1971; 1973) indicated the presence of a large molecular weight form, "big" 
ACTH, which was virtually devoid of biological activity (Gewirtz et al 1974). 
In addition Orth & Nicholson (1977) found an intermediate form of ACTH with 
an apparent molecular weight of about 8000. It was suggested that these larger 
molecules took part as precursors in the synthesis of ACTH itself. 
To eliminate the possible aggregation and non-covalent binding of ACTH to 
serum proteins, Mains S Eipper (1975; Eipper & Mains 1976) examined ACTH 
activity in mouse pituitanes and an ACTH secreting mouse pituitary cell line. 
Also they found different molecular weight forms; ЗІК, 23K, 13K ans 4.5K, the 
last also known as sequence 1-39, corresponding roughly to the heavier weight 
forms found in the human: 37K, 24K, 1ΘΚ and 4.5K (Sueoka et al 1980). 
With respect to their origin it is noteworthy that ACTH and the inter­
mediate lobe melanophore stimulating hormones (α-and g-MSH) are closely 
4-10 
related because both contain the amino acid sequence ACTH , the heptapep-
tlde core. a-MSH shares amino acid sequence 1-13 of ACTH acetylated at the 
NH -terminal end leaving ACTH (CLIP). ß-MSH, a portion of ß-LPH, shares 
4-10 
only the heptapeptide core of ACTH and is in the human only an artificial 
extraction product (Scott & Lowry 1974). The recently discovered opioid peptide 
- ß-endorphin - corresponds to the COOH-terminal part of ß-LPH (Li S Chung 
1976) . 
From the work of Mains et al (1977) and Nakanishi et al (1977) evidence 
has been obtained that ACTH and ß-LPH are derived from a common precursor 
protein. As ACTH (4.5K) and ß-LPH (12K) together account for only half the 
molecular weight of the precursor molecule, the remaining part (16K) of the 
precursor had to be elucidated. Nakanishi et al (1979) utilizing a recombi-
nant DNA technique, determined the primary structure of the bovine precursor 
molecule based on the determination of the nucleotide sequence of cDNA. As is 
shown in fig 1.2 this precursor molecule contains at its COOH-terminal portion 
ß-LPH separated from ACTH by a cleavage site lys-arg. In the cryptic 16K region 
4-9 
a sequence almost similar to the sequence ACTH in a-MSH and ß-MSH was 
found. Therefore, a part of the 16K fragment is named γ-ΜΞΗ. γ-MSH immuno-
reactivity was detected in the human pituitary by radioimmunoassay (Tanaka 
et al (1980). It contains an identical amino acid composition as bovine γ-MSH 
(Benjannet et al 1980). Recently, Pedersen & Brownie (1980) found a 
potentiation of the ACTH-induced steroidogenesis by the 16K fragment as was 
also found by Al-Du^aili et al (1981). This synergism could be mimicked by 
synthetic γ-ΜΞΗ peptides (Pedersen et al 1980). Furthermore, Bertagna et al 
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(1980), using an antibody directed against mouse 16K fragment, found 16K 
immunoreactivity in plasma of patients with Nelson's syndrome and Addison's 
disease. 
signal 
peptide 
)^ш^^^^^^^шш^^^^^г^^^ж^^т^^^^^^тш=^ш^^ш рге-ргООрОСОМіП 
proopoccrtin 
ÎÎLPH 
16К peptide ACTH yLPH ßendorphm 
trp peptide yMSH «MSH CUP ßMSH enkephalin 
Fig 1.2 Composition of the "ACTH family". It has to be noted that in the human 
not all of thesepeptides are synthesized due to a laak of a alear out inter-
mediate lobe. The open parts indicate the similarity in the amino acid sequence. 
This immunoreactivity was highly correlated with immunoreactive ACTH suggesting 
a concomitant secretion of the 16K fragment immunoreactivity and ACTH. This 
finding gives additional information about a possible, coordinate release 
of peptides derived from the common precursor, because concomitant secretion 
Of ACTH and 6-LPH in the human (Gilkes et al 1975; Krieger et al 1977, Tanaka 
et al 1978) and in the rat of ACTH and ß-endorphin (Guillemin et al 1977) was 
already demonstrated. 
Thus a large family of ACTH-related peptides might under certain condi-
tions occur in peripheral blood. Especially under circumstances of a stimu-
lated release of ACTH one has to take into account the possibility of inter-
ferences in the assessment of the pituitary-adrenal gland axis function. 
1.3 History of the bioassay of ACTH 
The classical observation of Smith (1926, 1927, 1930) that hypophysectomy 
of rats is followed by atrophy of the adrenal cortex and that transplantation 
of anterior pituitary tissue can restore the normal histology of the adrenal 
cortex led to the development of ACTH assays. Collip et al (1933) compared 
the adrenal weight in hypophysectomized rats before and after stimulation with 
anterior pituitary extracts. Moon (1937) proposed a definition of an unit of 
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adrenocorticotropic activity using adrenal weight as parameter in normal rats, 
whereas Simpson et al (1943), Sayers et al (1943) and Li et al (1957) opti­
mized this technique using hypophysectomized rats (table 1.2). 
The finding of Sayers et al (1946) that ACTH caused a lowering of the 
levels of cholesterol and ascorbic acid lead to the adrenal ascorbic acid 
depletion assay (Sayers et al 1948), which detects about 200 μυ ACTH and 
proved to be valuable for many years. However, as the relation of ascorbic 
acid depletion to corticosteroid secretion is still not well understood, it 
was desirable to use a more specific parameter of ACTH action on the adrenal 
cortex, i.e. the steroid release. Nelson & Hume (1955) developed an assay 
which actually used corticosteroid secretion from the adrenal gland into the 
adrenal vein in hypophysectomized dogs as a parameter for ACTH activity. This 
assay permits detection of 1 mU ACTH. Using a simplified technique for the 
estimation of circulating corticosteroids in the hypophysectomized rat, 
Guillemin et al (1958) measured peripheral blood corticosteroids after i.v. 
injection of ACTH which enabled detection of 0.1 mU. Lipscomb & Nelson (1962) 
perfected the ACTH assay by cannulation of the left adrenal vein, enabling 
collection of the adrenal venous blood for measuring the released cortico­
steroids and developed a retrograde technique, i.e. injection of ACTH in 
retrogade way against the adrenal vein outflow. With this technique the 
detection of even 5 μϋ ACTH was possible. However, this technique is very 
cumbersome. To avoid this Vernikos-Danellis et al (1966) measured the steroid 
contents of adrenals after injection of ACTH enabling measuring of 25 μυ. 
The first convenient in vitro bioassay for ACTH was described by Saffran & 
Schally (1955). The assay was based on the stimulation of the production of 
corticosteroids by isolated adrenal quarters and enabled detection of 3 mU 
ACTH. This method was modified by Cohen & Fürth (1959) by using transplantable 
adrenocortical tumor slices (sensitivity 0.25 mU). The development of a method 
for preparation of isolated rat adrenal cells by Kloppenborg et al (196Θ) gave 
a new impulse to the in vitro bioassay. Sayers et al (1971a) improved this 
method permitting detection of 0.1 μυ. Lefkowitz et al (1970a) utilizing purified 
receptors, described a radioreceptor assay with a sensitivity comparable to 
that in radioimmunoassays. The most cumbersome but also the most sensitive 
bioassay reported as far was developed by Chayen et al (1972) using a cyto-
chemical assay in which ACTH causes a loss of reducing potency especially in 
the cells of the zona reticularis. This technique is related to the loss of 
ascorbic acid as measured in the original Sayers bioassay. The limit of 
detection in this assay has been reported to be as low as 0.0005 μυ. 
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Table 1.2 
Historical survey of bioassays of ACTH 
Authors Method of analysis Standard Sensitivity 
Cnllip et al 1933 
Moon 1937 
Simpson et al 1943 
Sayers et al 1413 
Sayers et al 194Я 
Nelson & Hume 1955 
Saffran H Schally 1955 
[ι et al 1957 
Guillenin et al 1950 
Cohen & Fürth 1958 
Lipscomb * Nelson 1962 
tspiner et al 1963 
Vermkos-Danel hs 1966 
et al 
Kloppenborg et al 1968 
Lefkowitz et al 1970 
Sayers et al 1971 
Chayen et al 1972 
adrenal weight of hypox rats 
adrenal weight of intact rats 
adrenal weight of hypox rats 
adrenal weight of hypox rats 
ascorb.acid deplet. hypox rats 
adr. vein 17-0ΗΓ5 hypox dog 
corticost. rat adr.si ices 
adrenal weight of hypox rats 
cortirost. trunk blood hypox rats 
corticost. mice adr.tumor slices 
corticost. adr. vein hypox rats 
Cortisol dxm treated sheep 
adr. corticost.content hypox rats 
corticost. isol.rat adr. cells 
radioreceptor assay mice adr. 
corticost. isol. rat adr. cells 
cytochemical assay guinea pig 
own standard 
own standard 
own standard 
La- 1- A 
2nd Intern St 
2nd Intern St 
own standard 
2nd Intern St 
2nd Intern St 
2nd Intern St 
0.176 
П.118 
0.152 
0.26 
0.167 
0 248 
П.191 ACTHAR 
(35 Ll/mg) 
2nd Intern St 
hACTH (140 U/mg) 
3rd Intern St 
3rd Intern St 0.09 
+ S mg 
0.02 mg 
5 ug 
0.15 ug 
1 mU 
3 mU 
6 ug 
0.1 mil 
0.25 mU 
5 uU 
10 uU 
25 uU 
40 uU 
1 uU 
0.1 ι,и 
0.5 nU 
In the present study a bioassay had to be developed for measurement of 
ACTH in human plasma. Three techniques with a great sensitivity are in this 
respect available: the radioreceptor assay, the cytochemical bioassay, and 
the isolated adrenal cell assay. The radioreceptor assay depends on attach­
ment of ACTH to receptors present in adrenal cell membranes. This method is 
technically difficult and may overestimate the true biologically active ACTH 
value due to binding by biologically inactive ACTH-like peptides. The 
cytochemical bioassay is extremely sensitive, but it is technically diffi­
cult, only a few samples can be processed in one run, and it requires an 
expensive microdensitometer. Furthermore, it is noteworthy, that with this 
redox method it is not steroidogemcity that is measured but loss of reducing 
potency in the reticularis cells of the adrenal cortex (Lovendge et al 197 5). 
For these reasons we employed the isolated adrenal cell assay and made it 
sensitive enough for measuring plasma ACTH. 
1.4 The International Standard for ACTH 
For determination of ACTH in plasma samples responses should be compared 
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with those of a reference preparation. In order to validate the results of 
different methods in different laboratories International Standards have been 
established. In 1950 the First International Standard for Adrenocorticotrophin 
was established by the WHO Expert Committee on Biological Standardization. 
The material used for this standard was a relatively crude pig ACTH 
preparation (La-l-A) purified by glacial acetic acid-acetone extraction and 
prepared in 1946 by the Armour Laboratories. The International Unit was 
defined as the biological activity contained in 1 mg of the International 
Standard. After its establishment knowledge about the chemistry of ACTH in-
creased markedly. This led to the establishment of a new standard crude pig 
corticotrophin, prepared by an extraction procedure developed by Astwood et 
al (1951) but without an oxycellulose purification. This Second International 
Standard was atsayed against the First International Standard and was assigned 
a potency of 1.14 lU/mg, thus the International Unit was redefined as 0.88 
lU/mg (Mussett & Perry 1956) . As assays were used a thymus involution test 
(Bruce et al 1952) and the ascorbic acid depletion test of Sayers et al 
(1948) after infection the preparation by the intravenous (i.v.) or sub-
cutaneous (s.c.) route. The i.v.:s.c. potency ratio obtained by the adrenal 
ascorbic acid depletion assay was 1: 1 by definition. However, when an ACTH 
preparation is assayed by the subcutaneous technique, the potency may be 
quite different from the potency obtained after intravenous injection. The 
ratio of potencies obtained by the i.v. and s.c. methods is about 1:3. 
Because most of the ACTH used in clinical treatment is given subcutaneously 
or intramuscularly to the patients, a batch of porcine pituitanes, made by 
Armour Laboratories and purified by glacial acetic extraction, ethyl ether 
preparation, oxycellulose adsorption and elution, was assayed for the 
determination of the potency of the Third International Standard by 
different methods, but potency was established only in the "subcutaneous 
assay" (Bangham et al 1962). Each ampoule of the Third International Standard 
contains about 50 yg freeze-dned porcine ACTH together with 5 ng lactose 
and corresponds to a quantity of 5 IU. Although the Third International 
Standard is defined exclusively by the s.c. assay, the intravenous route 
is the most widely used for bioassays and the concentration of ACTH in the 
blood can also be expressed in i.V. Units. It is of interest, therefore, to 
note that each ampoule of the Third International Standard contains about 
1.5 i.v. units. Therefore, 1 s.c. IU = 10 pg and 1 i.v. IU = 33 yg. As the 
contents of ampoules of the Third International Standards are dilutions of 
one master ampoule, dilutions of other equivalent master ampoules were made 
8 
in the same way, and are called the Third International Working Standard (IWS). 
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Chapter II 
BIOASSAY OF ACTH 
II.1 Introduction 
The first authors who practised isolation of adrenal cells for the prepa-
ration of cell suspensions were Kloppenborg et al (1968) and Halkerston & Fein-
stem (1968). Isolating intact cells from their environment was already known 
for a long time: disaggregation of vertebrate tissue to obtain suspensions of 
free cells was reported in 1916 by Rous & Jones. Using trypsin they tested 
several tissues and obtained crops of viable cells. Evans & Earle (1947) 
isolated cells and brought them in culture. A number of other authors had done 
similar studies with several tissues (Moscona & Moscona 1952; Essner et al 
1954; Younger 1954) . 
Cultures of adrenal tissues were reportedly obtained from adrenal tumor 
tissue (Buonassisi et al 1962; Sato et al 1965) and from chopped foetal 
adrenal glands (Kahn 1966; Milner & Villee 1970). Foetal and also newborn 
adrenocortical cells lack a number of enzyme activities with which adult 
adrenocortical cells are endowed (Villee et al 1961). Armato & Nussdorfer 
(1972) cultivated adult adrenocortical cells. Electronmicroscopy and auto-
radiography revealed that ACTH could still stimulate adrenal DNA, RNA and 
protein synthesis in these cells. Cell strains cultivated in vitro for long 
periods can vary in their morphology (Evans et al 1952) and even undergo 
spontaneous malignant transformation (Moore et al 1956). Hornsby & Gill 
(1978) cultured many generations of cells and demonstrated a progressive 
loss of ACTH-responsiveness in adult bovine adrenocortical cells. In order 
to obtain reliable information on the behaviour of normal cells we preferred 
to use freshly isolated cells for the determination of ACTH. 
As is stated by Rinaldini (1958): "the preparation of undamaged cells 
from different tissues in sufficient quantities for chemical estimations must 
be based on an appraisal of 1) the nature and structure of the intercellular 
materials to be disaggregated, 2) the action of the agents used for this 
purpose, and 3) the response of the cells under the particular conditions 
employed". As is well known the rat adrenal cortex has three distinguishable 
concentric zones - a thin, outer zona glomerulosa ad]acent to the capsule 
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which surrounds the gland; a thick middle layer, the zona fasciculata; and a 
moderately thick, inner zona reticularis contiguous with the central lying 
adrenal medulla. As the cells of the zona fasciculata are thought to 
respond best to ACTH as far as the secretion of corticosteroids is concerned, 
special attention must be drawn to the histological appearance of this zona. 
The fasciculata cells are arranged in long cords disposed radially with 
respect to the medulla and in tight contact with each other. Among the 
adrenocortical cell cords intercellular spaces are present, which contain 
collagen fibers in addition to the ground substance, continuous with the 
pencapillary space (Kurosuna & Fujita 1975) . Therefore isolation of these 
cells can be achieved by attacking the collagen fibers and/or the ground 
substance . Usually the enzymes trypsin or collagenase are employed for iso-
lation of adrenal cells. The ground substance is believed to be attacked by 
the former. Use of trypsin has the advantage that its activity can be stopped 
at any time by specific inhibitors. The enzyme collagenase is available in 
purified and in crude form. The latter contains both proteinases and peptidases 
(Debellis et al 1954) and thus attacks the ground substances as well as 
collagen fibers. Therefore, disruption of the cells has been effectuated in the 
present study by means of crude collagenase. However, one should realize that 
the great variety in quality of enzyme preparations could yet cause distur-
bances. As is known from the work of Kono (1969), for instance, neither 
adipose tissue nor cardiac muscle could be dispersed by either trypsin or 
collagenase alone but only by a mixture of both enzymes. These findings 
illustrate that preparation of isolated cells is often a matter of trial and 
error. In most studies concerning isolated rat adrenal cells the digestive 
enzyme is added to quartered adrenals. In the present study, however, the 
adrenals were cut into small pieces before enzyme addition in order to give 
the enzyme optimal contact with the substrate. Besides the use of biochemical 
agents most of the techniques for the isolation of cells of the adrenal gland 
employ mechanical agents in tissue disaggregation. 
In the light of the foregoing remarks it is obvious that preparations of 
isolated cells may vary in yield of cells, sensitivity to ACTH, quantity of 
damaged cells etc. In our study we have tried to optimize the quality of the 
adrenocortical cell suspension. Bennett et al (1974) demonstrated that 
sensitivity to ACTH increased after prior purification of cells. 
In order to make the cells highly sensitive to ACTH we modified their method 
and evaluated the usefulness of pre-incubation of the suspension. 
In this chapter an isolated rat adrenal cell assay is described with a 
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sensitivity high enough to measure plasma ACTH levels. The cells - disrupted 
by means of crude collagenase - were purified by passing through a 5% ΒΞΑ 
solution at unit gravity sedimentation. To achieve an additional gain in 
sensitivity a pre-incubation step was introduced to decrease further enzyme 
activity which attacks the ACTH molecule. At the hand of testing different 
ACTH peptides the consequences of the improvements are evaluated. 
II.2 Materials and Methods 
Materials 
ACTH-related peptides 
1-39 Synthetic hACTH (revised sequence, Sieber et al, 1972, 188 lU/mg as 
1-24 1-16 
estimated by Schenkel-Hulliger et al, 1974), ACTH , ACTH , acetyl 
1-13 25-39 7-13 11-24 
ACTH NH (cx-MSH) , hACTH , ACTH NH and ACTH were generous 
1-32 
gifts from dr W Rittel and dr Ρ Desaulles (CIBA-Geigy Ltd, Basel), hACTH 
from dr G Fekete (Gedeon Richter, Budapest), ACTH ~ , ACTH ~ , ACTH 
and a highly purified human hypophyseal extract (108 lU/mg) from 
dr W Hondius Boldmgh and dr H Greven (Organon, Oss), ACTH and ACTH 
11-19 from dr Η Vilhardt (Ferring, Malmö), ACTH NH- from dr M Nakamura 
(Shionogi & Co, Osaka) , hACTH (corticotropm-like intermediate lobe 
1-4 5-7 peptide, CLIP) from dr H Yajima, ACTH and ACTH from dr К Medzihradszky, 
ACTH NH , ACTH Ala , Lys -4-aminobutylamide and its derivatives 
Arg , Norleu and Forlys from dr R Geiger (Hoechst, Frankfurt am Main) 
and ß-endorphin from dr J Morley (ICI, Macclesfield). 
1-39 
The standard (synthetic hACTH ) as well as the ACTH-related peptides were 
dissolved in ACTH-diluent, lyophilized and stored at 4 C. 
Other materials 
Vasopressin (270 lU/mg, Sandoz), Angiotensin II (Hypertensin, CIBA-Geigy) 
LHRH (Hoechst) and TRH (Hoffman-Laroche) were commercially available. 
FSH (Roos, 73/519, 8600 U/mg), LH (Ist Ref. Prep, of Pit. LH human, 68/40, 
664 U/mg), TSH (1st Intern. Ref, Prep, of ΤΞΗ, 68/38) and Prolactin (Ist Intern. 
Ref. Prep, of Prolactin human, 75/504, 3.25 U/mg) were kindly donated by 
the MRC (London), corticosterone was obtained from Steraloids, bovine 
serum albumin (BSA, ORHD 20/21) from Hoechst, nicotinamid adenin dinucleotid 
phosphate (NADPH) from boehnnger, trypan blue from BDH Chemicals Ltd and 
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collagenase (type I) from Sigma. Dimethyl-dichlorosilane was obtained from 
BDH Chemicals, methylene chloride from Baker, toluene (p.a.), sulphuric 
acid (97-99%) and ethanol (p.a.) from Merck. ACTH-diluent was made by 
dissolving 50 mg BSA in 100 ml 0.9°o NaCl after which the pH was adjusted 
to 3.5 with N HCl. Krebs-Ringer-bicarbonate buffer (KRB) was prepared 
following Umbreit (1948) and stored at 4 C. Before use 200 mg glucose/100 ml 
was added to the buffer. This buffer (KRBG) was bubbled through for 10 
minutes with a gaseous mixture of 95% 0 and 5% CO . The buffer was supplied 
with 7.65 mM Ca (KRBGCa) and 0.5% ΒΞΑ (KRBGACa). 
Equipment 
Rhesus ampoules were obtained from Vitra Form (St Gallen), polyethy­
lene tubes (17/77 mm) from Sarstedt, polystyrene tubes from Otan (Rijsbergen; 
the Netherlands), a Biopette from Schwarz-Mann, an incubation apparatus from 
Lab-line and a spectrophotofluorometer from Aminco-Bowman. 
Methods 
Silicomzation procedure 
All glass surfaces were immersed in 5% dimethyl-dichlorosilane in 
toluene for 6 hours after which the glass was thoroughly rinsed with ethanol 
and dried by air. 
Preparation of crude isolated adrenal cells 
For each experiment 5 male Wistar rats (180-200 g) were killed by 
decapitation. The adrenals were removed, freed of fat, cut in about 10 
pieces and transferred to a cold (4 C) 25 ml flask containing a solution 
of 32 mg crude collagenase and 400 mg BSA in 10 ml KRBG. The tissue was 
incubated in a metabolic shaker at 100 oscillations/min at 37 С in an 
atmosphere of 95% 0_ and 5% CO . After 50 minutes of incubation the tissue 
was disrupted by pipetting up and expelling the adrenal tissue with a 
siliconized Pasteur pipette about 50 times (Haning et al 1970). The large 
tissue particles were allowed to settle before the suspension was transferred 
to a cold 100 ml polyethylene tube. Two ml KRBGACa were added to the residue 
and the material was disrupted again. Both supernatants were combined and 
centnfuged at 100 g for 10 m m (4 С). The supernatant was discarded, the 
pellet resuspended in 10 ml KRBGACa and the suspension was centnfuged 
(100 g) again. This washing procedure was repeated once more and after the 
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final centrifugation the cells were resuspended in 4 ml KRBGACa (non-purified 
or crude cell suspension) unless otherwise stated. 
Preparation of the purified cells 
After preparing the crude suspension, as described above, this suspension 
was purified by layering 1 ml portions upon θ ml 5% BSA in KRBGCa in 4 
different polystyrene tubes as illustrated m fig II. 1. After 30 minutes the upper 
layer was removed by suction and the 5% BSA, which by then contained the purified 
cells, was diluted regularly to about 110 ml with KRBGCa. 
Imi crude cells 
30 min,Ig 
5β/ο BSA 
in 8ml KRBGCa 
purified 
cells 
fbg II.1 Purifzeatton of adrenal cells 
Incubation procedure 
After appropriate dilution of tho crude suspension incubation was performed 
by adding 0.9 ml aliquots to polyethylene tubes which contained 0.1 ml ACTH-
diluent. The tubes were placed in a metabolic shaker and the cells were 
incubated at 37 С under an atmosphere of 95% 0. and 5% CO . When the purified 
suspension was used the cells were pre-incubated in the tubes for 60 minutes, 
prior to the addition of ACTH. All observations were made in duplicate except 
otherwise stated. In a number of experiments the purified cells were not pre-
incubated m order to detect the effect of pre-incubation. Incubation time 
was 120 minutes. In some experiments 0.1 mg NADPH was added to check the 
quality of the suspension. 
Corticosterone measurement 
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To each incubation tube 6.5 ml methylene chloride was added. After 
extraction by shaking for 2 min the tubes were centnfuged at 200 g for 10 
minutes. The aqueous phase was removed by suction and 1 ml of fluorescence 
reagent (sulphuric acid: ethanol, 70:30 v/v) was added to 5 ml of the methyle-
ne chloride phase. After a contact time of 1 m m the organic phase was aspi-
rated and the fluorescence was measured after about 50 minutes using a 
spectrophotof luoroir^ter at 470 nm (exciting wavelength) and 530 nm (emitting 
wavelength). Processed corticosterone was used as the standard. 
Potency analysis 
For each peptide complete log dose-response curves were constructed. The 
potencies of the peptides were expressed as the relations of the reciprocals 
1-39 
of their molar ED50 to the reciprocal of the molar ED50 of hACTH 
1-39 Human ACTH was assigned to the potency of 100 (analogous to Schwyzer 
et al 1971). 
Cell viability 
Cell viability was tested by mixing an aliquot of the suspension with an 
equal volume of trypan blue (100 mg in 100 ml 0.9% NaCl) following Tennant 
(1964). Cells were counted using a Burker bright-line haemocytometer. Only 
those cells were counted which contained lipid droplets and excluded the dye. 
Statistical evaluation 
In the tables the mean values jH SD are given. Student's t-test was used 
to test the statistical significance of differences between groups (P). The 
correlation coefficients - denoted by r - were calculated following Spearman. 
II.3 Results and Discussion 
II.3.1 Measurement of corticosterone 
It has been shown that the rat adrenal cortex lacks the intrinsic 
capacity for 17-hydroxylation and is therefore unable to synthesize Cortisol 
or 11-deoxycortisol (Bush 1953). The most important endogenous steroids of the 
rat adrenal cortex include corticosterone, deoxycorticosterone and aldosterone 
(Giroud et al 1956; Ward & Birmingham 1960) . The fluorometnc analysis of 
corticosteroids, originally developed by Sweat (1954) had been studied exten-
sively by others (Peterson 1957; Guillemin et al 1958, Moncloa et al 1959; 
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Mattingly 1962, van der Vies 1961). Determination of the specificity, e.g. by 
Peterson (1957), revealed further that the fluorescence from rat adrenal 
steroids can be ascribed selectively to corticosterone. Furthermore Sayers et 
al (1971a) showed that 90% of the fluorescence of steroids obtained from iso-
lated rat adrenal cells was due to corticosterone as was detected before and 
after purification by thin-layer chromatography. 
After mixing with fluorescence reagent there is a steep rise of the 
fluorescent intensity of corticosterone followed by a plateau. 
f l uorescence 
intensity 
1 1 1 1 1 1 1 1 1 
005 01 1 1 ¿Jg corticosterone 
ι 1—Γ~ΓΊ 
2 A 6 81 m( suspension 
fig li.2 Calibration curve of corticosterone 
In order to increase the number of estimates which can be performed in one 
experiment the level of the fluorescence should remain constant for a period 
long enough to measure a large number of samples conveniently. In this respect 
two reagents were tested: 70% Η SO /30% ethanol versus 65% Η SO /35% ethanol. 
The former reagent reached the maximum fluorescence earlier and plateaued for 
a longer period of time than the latter reagent. For this reason the reagent 
70/30 is more convenient and was used as the reagent. The plateau period was 
also the same for extracts of cell suspension samples to which different ACTH 
doses were added, as was tested in a separate experiment. About 150 samples 
can be reliably handled in a period of about 40 minutes. 
The fluorescence intensity was linear in the range of 5 ng up to 2000 ng 
corticosterone (fig II.2). The fluorescence obtained from different volumes 
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of a pooled cell suspension, incubated with ACTH, parallels the corticosterone 
standard line. For reasons of convenience all corticosterone estimations were 
made in rhesus ampoules, whose diameters were previously screened. Only a minor 
modification of the Aminco Bowman cell holder was needed to render the use of 
these ampoules. Ten aliquots of a pooled cell suspension, containing 50 pg 
ACTH/ml were analysed for corticosterone content to estimate the error m the 
corticosterone measurement; the coefficients of variation revealed 1.27%. The 
cells were separated from the medium in order to ensure that the corticoste­
rone measurement in adrenal cell suspensions actually means the measurement 
of corticosterone released from the cells. As appears from fig II.3 the 
corticosterone content of these cells hardly increased at graded doses of ACTH 
and equalled the corticosterone content at zero ACTH. 
corticosterone (pg/ml medium or pg/cell pellet) 
0Θ-
fig II.3 Measurement of 
oorticosterone in cells and 
medium. Cells were separated 
from the medium by 
aentri fugation at 100 g for 
10 minutes. 
5 10 25 50 100 250 pg ACTH1"24 
II.3.2 Optimization of the cell suspension 
As stated earlier isolated adrenal cells are much more sensitive to ACTH 
than adrenal quarters (Kloppenborg et al 1968). The isolated cell system 
eliminates problems regarding diffusion barriers which are inherent to the 
classical adrenal quarter preparations. Yet isolated cells present some diffi­
culties. Cells are isolated by means of rather aggressive manipulations such as 
incubation with crude enzyme preparations and rough mechanical agitation like 
pipetting. Even after careful washing of the suspension in order to remove 
collagenase and cell fragments, microscopic examination reveals the presence 
of a considerable amount of non-viable cells and numerous free cell particles 
e.g. lipid droplets. 
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To develop a technique for preparing cell suspensions which are 
invariably highly sensitive for ACTH as far as the corticosterone production 
is concerned the following investigations were made: 
1. the effect of shaking during the incubation, 
2. the facilitating effect of calcium, 
3. the influence of purification of the cells, 
4. the effect of pre-incubation, 
5. the elimination of ACTH-inactivating substances by the purification and 
pre-incubation processes, 
6. the incubation time, 
7. the use of adrenals obtained from hypophysectomized rats, and 
0. the effect of different BSA batches. 
II.3.2.1 The effect of shaking 
Cells derived from one suspension were incubated without and with shaking 
for 100 oscillations / m m . Fig II.4 shows only a slight improvement in the 
response of the cells after shaking. Despite the slight effect of shaking the 
suspensions were incubated with about 100 opm. 
fig 11.4 The effect of shaking upon 
the ACTH-indwed steroidogenesis. 
Opm: oscillations per minute. 
Ó 25 '0 25 50 250 pg ACTH1 2 -
II.3.2.2 The effect of calcium 
The fact that calcium is required for the steroidogenic action of ACTH was 
first shown by Birmingham et al (1953). It seems to have various effects and 
its role is not completely clear. Lefkowitz et al (1970b) found a requirement 
for calcium in the activation of adenylate cyclase by ACTH, Parese (1971) 
observed a marked effect of calcium on adrenal protein synthesis, which is a 
prerequisite to stimulate steroidogenesis (Farese & Reddy 1963). Other investi-
gators - working with isolated rat adrenal cells - found a relation between 
coMicoslerone (pg 2 h ) -
10η 
100 opm 
0 opm 
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the ACTH-induced steroidogenesis and the external calcium concentration 
(Sayers et al 1972; Haksar & Perón 1973; Bowyer & Kitabchi 1974; Perchellet 
& Sharma 1979; Yanagibashi 1979). Using freshly isolated cells Liotta & 
Krieger (1977) found the same, but when short-term cultured cells were used, 
they observed the opposite: with a normal calcium concentration (about 2 mM) 
the cells were more responsive to ACTH than with a higher (7 mM) concentration. 
Lowry et al (1973), on the other hand, found no difference using 7.65 mM 
calcium as compared to the normal concentration. None of these authors observed 
any influence of calcium per se on the basal secretion of corticosterone. 
Recently, Neher 8 Milam (1978) described conditions at which calcium did 
induce rat adrenal steroidogenesis. Interestingly, Yanagibashi (1979) showed 
that in this respect a species difference exists. Rat adrenal cells appeared 
to be insensitive to calcium per se but the basal corticosteroidogenesis in 
bovine adrenal cells could be stimulated. 
We ourselves investigated in a single experiment the effect of calcium m the 
absence and in the presence of a range of low doses of ACTH. In this experi-
ment at 4 different ACTH doses (1-10 pg) the responsiveness at 7.65 mM calcium 
was constantly higher than at 2.55 mM, which last concentration is present in 
KRB (fig II.5). Therefore, 7.65 mM calcium was used during our experiments. 
corticosterone 0jg/2h) 
015 
010-
005-
fig li.5 The effect of 7.65 mM 
oalc-Lum upon the steroidogenesis 
znduoed by low doses of ACTH. 
II.3.2.3 The purification of the cells 
The presence of non-viable cells and of cell fragments might affect the 
sensitivity of the assay. First, ACTH may be bound to the receptors of 
damaged cells, which will not result m corticosteroidogenesis (Halkerston 
1968). Secondly, enzymes derived from the broken cells may destroy ACTH and 
its derivatives (Bennett et al 1974). Therefore we tried to get rid of the cell 
fragments and broken cells by means of purification of the cells (fig II.1). 
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The method for purification as described by Bennett et al (1974) - 2 ml of 
crude suspension layered on top of 20 ml of 2% albumin followed by centrifu-
gation at 10 g for 5 minutes - was not useful in our hands, as just layering 
the crude suspension (in a 0.5% ΒΞΑ solution) upon the 2% BSA buffer resulted 
in an intermingling at the interfase of the two layers. We therefore tried a 
higher BSA concentration and found that at 5% BSA the separation was optimal. 
We avoided centnfugation and employed unit gravity sedimentation (Tait et al 
1974) . 
To detect the influence of the time of sedimentation upon the responsi­
veness of the cells to ACTH, the cells at different ACTH concentrations were 
incubated for 2 hours, after different sedimentation times. Table II.1 shows 
Table II.1 
Influence of the sedimentation time on the responsiveness of adrenal cells 
sedimentation time 
hACTH1"39 (pg/ml) 30 min 60min 90 min 
0 0.025t 0.030 0.030 
5 0.095 0.075 0.055 
25 0.300 0.261 0.215 
100 0.565 0.500 0.435 
value expressed as yg corticosterone/2 hours incubation 
that for sedimentation a time of 30 minutes was appropriate. Periods shorter 
than 30 minutes were neglected because of the low recoveries of cells. Micro­
scopic examination also showed that after purification only a very small 
quantity of the cell fragments entered the 5% BSA layer. Recovery of the viable 
cells after purification for 30 minutes in 10 consecutive experiments varied 
from 38 to 89% with a mean of 64%. 
The quality of the cell suspension can also be assessed by the effect of 
exogenous NADPH. NADPH is not able to cross adrenal cell membranes and there­
fore it only stimulates the steroidogenesis of an adrenal homogenate and not 
that of intact cells (Halkerston et al 1968; Tsang & Stachenko 1968). In our 
study NADPH was tested and showed a distinct effect upon steroidogenesis in 
non-purified suspensions, but was hardly effective when the cells were puri­
fied (table II.2). This may led to the conclusion that passage through the 
5% BSA layer excludes interfering cell debris to a great extent. This is in 
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Table II.2 
Effect of purification and pre-incubation on the ED50 of ACTH and on the 
NADPH regulated steroidogenesis 
cells non-purified 
non-pre-incubated 
ED50 in pg/nl η 
cells purified 
non-pre-incubated 
ED50 in pg/nl η 
cells purified 
pre-incubated 
ED50 in pg/ml η 
hACTH 1" 3 9 63.6+21.7 10 31.0 + 5.6f 7 18.0 + 6.9t+ 18 
mean + SD 
ACTH1"2 4 2 0 . 7 + 1 2 . 2 10 4.6 + 0 .6 + 7 2.3 + O.Sn 11 
mean + SD 
Netto cort icosterone production in ng 
Mean + SD η Mean + SD η Mean + SD η 
0.1 mg NADPH 3 1 6 + 2 0 6 10 29 + 24* 12 13 + Ì2f 18 
s ign i f i can t d i f ference between th is value and the value of non-puri f ied 
non-pre-incubated ce l l s (P<0.001). 
s ign i f i can t d i f ference between th is value and the value of 
non-pre-incubated ce l l s (P<0.001). 
accordance with the microscopic evidence t h a t only a small quant i ty of c e l l 
fragments en te r s the BSA medium. 
Moreover, tab le I I . 2 s t r i k i n g l y shows the improvement on the qua l i ty of 
the suspension by the lowering of the ED50 values by mere sedimentation as 
the p u r i f i c a t i o n procedure. The values were ca lcu la ted from log dose-response 
curves obtained in experiments which were performed on separa te days. 
I I . 3 . 2 . 4 The e f fec t of pre- incubat ion 
As i s shown above and as i s known from the work of Bennett e t a l (1974) 
p u r i f i c a t i o n of the adrenal c e l l s removes to a ce r t a in degree fragments of c e l l s 
and enzymes derived from broken c e l l s . However, non-viable c e l l s are s t i l l 
p resen t in the pur i f i ed suspension. In order to i n a c t i v a t e ACTH-damaging 
enzymes leaked from these broken c e l l s , a pre- incubat ion s tep has been i n t r o -
duced. 
Pur i f ied c e l l s were pre- incubated during d i f f e r en t per iods of time and 
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1-39 
after addition of 25 pg hACTH a 2 hours' incubation period followed. It 
appeared that pre-incubation actually influenced the ACTH-induced 
1-39 
steroidogenesis; corticosterone production induced by 25 pg hACTH after 
zero, 30, 60 and 120 minutes' of pre-incubation reaching values of 0.332, 
0.382, 0.413 and 0.412 \ig respectively. Due to these results it was decided 
to take 1 hour as pre-incubation time. The enhancement of steroidogenesis as a 
result of pre-incubation was striking when low doses of ACTH were tested. As 
fig II.6 shows a remarkable increase in sensitivity was obtained using low 
1-39 1-24 doses of either hACTH or ACTH when the purified cells were pre-
incubated. The improved sensitivity of the purified cells is also evident from 
corticosterone ( p g / 2 h ) · 
y\-2i. 
1-39 
purified cells 
pre-mcubated 
not pre-incubated 
pg ACTH/ml 
1-39 
— ι — 
10 
fig II.6 The effect of pre-incubation for 60 min upon the ACTH-induced 
steroidogenesis гп purified cells. 
the lowering of the ED50 values (table II.2). Then the question arose whether 
pre-incubation alone - without a purification step - could effectuate the same 
sensitivity. Therefore the effect of pre-incubation for 1 hour on the ED50 
values was studied in three separate experiments. In each of these experiments 
the sensitivity was enhanced by mere pre-incubation of the cells (ED50: 49.0 
+_ 2.6 pg/ml with pre-incubation and 73 + 8.4 pg/ml without pre-incubation). 
When the purified cells were used an even higher sensitivity was reached 
(ED50: 29.6 ^ 4.0 pg/ml versus 49.0 pg/ml). 
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II.3.2.5 The elimination of ACTH inactivating substances by the purification 
and pre-incubation processes. 
The theory that the ACTH-attacking substances, present m crude adrenal 
cell suspensions are inactivated by the combination of purification and pre­
incubation, is supported by the results shown in table II.3. Suspension medium 
- without cells - derived from crude cell suspensions inactivated ACTH whereas 
such a medium derived from purified, pre-mcubated suspensions apparantly did 
not have such effect. 
Table II.3 
Effect of a 30 min incubation of the medium of adrenal c e l l s on the 
1-39 
steroidogenic a c t i v i t y of hACTH 
recovery of ACTH η 
medium of pur i f ied,pre- incubated c e l l s 90.5 + 28.5? 7 
medium of crude c e l l s 2 9 . 9 + 2 1 . 8 % 7 
Tubes which contained crude or pur i f ied,pre- incubated c e l l suspension 
were c a r e f u l l y centr i fuged and 0.5 ml a l iquots of the supernatant (=medium) 
were transferred to tubes wi th ACTH. The same had been done with 0.5 ml 
al iquots of KRBGACa as c o n t r o l . Incubation - without c e l l s - followed f o r 
30 mm whereafter the tubes were stored at -20° С u n t i l the ACTH content 
was measured. Recovery of ACTH is expressed as % of the recovery in 
KRBGACa (=100%). 
In order to assess the capaci ty of the p u r i f i c a t i o n and pre- incubat ion 
process to remove the ACTH-inactivating c e l l fragments and substances from the 
suspension and a t the same time to prove t h a t the ACTH-interfenng substances 
could be derived from the debr i s of c e l l s the following experiment was 
performed. A concentrated crude c e l l suspension (7 ml) was divided in two 
equal p a r t s . To one p a r t 0.5 ml of an adrenal homogenate (2 adrenals homo­
genized in 0.5 ml buffer) was added and t o the other p a r t 0.5 ml buffer . 
1-39 Each suspension was t e s t e d for s tero idogenic response t o both hACTH and 
1-24 
ACTH , w i t h o u t p u r i f i c a t i o n as w e l l a s a f t e r p u r i f i c a t i o n and p r e - m c u b a -
1-39 
t i o n ( f i g I I . 7 ) . The l o g - d o s e r e s p o n s e c u r v e s f o r hACTH show c l e a r l y t h a t 
t h e c r u d e s u s p e n s i o n t o which homogenate h a s been added i s f a r l e s s s e n s i t i v e 
t h a n t h e n o n - p u r i f i e d s u s p e n s i o n w i t h o u t h o m o g e n a t e . I n f a c t a d d i t i o n of 
homogenate l o w e r s t h e ED50 w i t h a f a c t o r 2 ( f i g I I . 7 ) . A f t e r p u r i f i c a t i o n and 
p r e - m c u b a t i o n , however , t h e s e n s i t i v i t i e s of b o t h t h e s u s p e n s i o n w i t h homo­
g e n a t e added t o i t and t h e s u s p e n s i o n w i t h o u t homogenate were e q u a l f o r 
1-39 1-24 
hACTH as w e l l a s f o r ACTH . T h i s means t h a t t h e p u r i f i c a t i o n and 
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hACTH and ACTH of adrenal cell suspensions with andwithout added adre­
nal homogenate. a: response to hACTH'1 "" of cells in a crude suspension with 
homogenate addition (ψ TÍ and without homogenate (9 9), and in a pre-
incubated, purified suspension with homogenate addition before purification 
1-24 (O O) or wzthout homogenate (* *). b: response to ACTH of cells 
in a crude suspension with homogenate addition Cv v) and without homogena-
te Co oj, and in a pre-incubated, purified suspension with homogenate ad-
dition before purification (9 9) or without homogenate (Δ AJ. In this 
1—24 
experiment the relative potencies of ACTH were 520 in the pre-tncubated 
purified suspension, with or without homogenate, 300 in the crude suspension and 
76 in the crude suspension with homogenate. 
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pre-incubation process is very effective as regards the elimination of the 
ACTH-inactivating substances. Furthermore, fig II.7 shows that the addition of 
1-24 hotnogenate lowered the sensitivity for ACTH to a much greater extent than 
1-39 1-24 
for hACTH . The ED50 for ACTH in the pre-incubated, purified suspension 
1-39 
was about 8.5 times lower than in the crude suspension whereas for hACTH 
the ED50 decreased only with a factor 3.5 (table II.2). This difference in 
relative decrease of the ED50 for both peptides was statistically significant 
(P <0.001). In other words the increase in sensitivity, which resulted from 
1-24 
the purification and pre-incubation procedure was more pronounced for ACTH 
1-39 than for hACTH . These results endorse those of Lowry et al (1973) who found 
1-24 
ACTH to be 5 to 7 times more potent than the complete hormone. An explana-
tion for these findings was given by Bennett et al (1974) who established that 
peptide breakdown in isolated adrenal cell suspensions occurred to a less 
1-39 1-24 
extent for ACTH as compared to ACTH . This difference in metabolism 
decreased by purification of this suspension. In view of these facts it is 
concluded that addition of adrenal homogenate to the cell suspension (fig II.7) 
enhances the breakdown for ACTH _ to a greater extent than for hACTH 
In order to delineate the cause of the difference in sensitivity change 
1-24 1-39 
for ACTH and hACTH by the use of pre-incubated, purified cells, we 
1-32 
measured the EDSO's of hACTH and of a human hypophyseal extract m crude 
and in pre-mcubated, purified cell suspensions. Table II.4 shows that the 
1-32 
change in sensitivity for hACTH and for the hypophyseal extract was 
1-39 
similar to that for hACTH . Therefore it is assumed that the observed 
1-24 1-39 
difference in potency between ACTH and hACTH cannot be explained by the 
presence of the COOH-terminal sequence 33-39 in the complete hormone. Imura 
et al (1967) studied the stability of synthetic ACTH peptides in human plasma 
in vitro and found that ACTH was more liable to degradation than ACTH 
These findings together might suggest that the sequence 26-32 is involved in 
the protection of the hormone. 
II.3.2.6 The effect of the incubation time. 
After pre-incubation of the purified cells for 1 hour the subsequent 
exposure of the cells to a maximal dose of ACTH resulted in an increased 
steroid production already within 2 m m . Afterwards an almost linear increase 
the corticosterone production was found to plateau after about 180 min. As is 
shown in fig II.8 the corticosterone production increased linearly to about 
2 hours with low doses as well. 
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Table II.4 
Relative potencies of different ACTH peptides assayed by corticosterone 
production 
hACTH1"39 
human hyp. 
hACTH1"32 
ACTH1'24 
extract 
crude 
cells 
100 
50 + 
98 + 
200 + 
6 
7 
52 
purified 
pre-incubated 
100 
47 + 7 
9 9 + 6 
528 + 74 
cells π 
5 
5 
10 
Ρ 
>0.1 
>0.1 
<0.001 
Several authors, who used high doses of ACTH, reported a lag period before a 
corticosterone production could be detected. This lag period varies from 3 
min (Sayers et al 1971b; Richardson & Schulster 1972) to about 6 m m (Kitabchi a 
Sharma (1971). We found with a dose of 200 pg ACTH an increase in corticoste­
rone production within two minutes already. The rate of steroidogenesis in 
response to maximal or low doses of ACTH was constant until about 120 minutes. 
These findings agree with those of others who reported this time to vary 
between 90 minutes (Sayers et al 1971b) and 240 minutes (Falke et al 1975). 
netto corticosterone production ( p g ) · 
0 3-, 
0 Σ­
ΟΙ 
0-
« Ю pg hACTH 1-39 
60 90 120 160 240 incubation time in min 
fig i l . 8 The effect of the incubât-ion time upon the steroidogenesis induced 
by low doses of ACTH in pre-incubated, purified cells. 
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II.3.2.7 The effect of hypophysectomy on the sensxtivity. 
Hypophysectomy m rats results in atrophy of the adrenals (Smith 1930) 
and a diminished secretion of corticosteroids after ACTH injection (Liddle et 
al 1962). Apparently in contradiction to these reports Sayers & Beali (1973) 
found that cells isolated from adrenals of rats that had been hypophysecto-
mized 2 days earlier are more sensitive to ACTH than such adrenal cells 
obtained from normal rats. 
These findings led us to investigate this phenomenon m our system. As 
is shown in table II.5 hypophysectomy of rats - performed by the parapharyngeal 
approach - two days earlier resulted in a significantly lower ED50 by about 
a factor 2, when the crude suspensions were compared to those of normal rats 
The results of our experiments show that ηδ statistically significant diffe­
rence in ED50 was observed when pre-incubated, purified cells derived from the 
same batches of cells were employed. Thus it appeared that in our system -
using pre-incubated, purified cells - hypophysectomy per se did not increase 
sensitivity. 
Using the complete hormone Kitabchi et al (1974) found a decrease of the 
ED50 from 9.0 pU in adrenal cell suspensions of normal rats to 3.2 yU in 
isolated adrenal cells of rats hypophysectomized 48 hours before. This 
decrease is comparable to the decrease we found (table II.5) in crude sus-
1-24 pensions. Sayers & Beali (1973) used ACTH and detected an ED50 of 3.34 pg 
for cells of hypophysectomized rats as compared with an ED50 of 27.3 pg for 
cells from intact rats. Ihis"decrease is greater than the decrease found with 
1-24 
the complete hormone. As is known ACTH is much more degraded by ACTH-
1-39 
attacking enzymes in isolated adrenal cell suspension than ACTH (Bennett 
et al 1974; Coverde et al 1980). 
Table II.5 
Effect of hypophysectomy on the ED50 in crude and purified, pre-incubated 
adrenal cell suspensions 
ED50, pg 
rats 
cell suspension hypophysectomized 
crude 38.8 ± 17.5 
purified, pre-incubated 13.7 ± 7.0 
hACTH 1" 3 9^! 
rats 
normal 
72.9 ± 17.2 
17.4 ± 4.0 
η 
8 
8 
Ρ 
<0.01 
>0.1 
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It is known that corticosteroidogenesis as induced by ACTH is lower after a 
2-day hypophysectomy in vivo (Liddle et al 1962) as well as in vitro (Sayers 
S Beali 1973). This implies a lower metabolic activity and presumably also 
a lower level of ACTH-degrading enzymes. So, when crude adrenal suspensions 
from hypophysectomized rats are used, fewer ACTH-attacking enzymes might be 
present as well. Consequently, this involves a higher sensitivity to ACTH. 
This hypothesis is supported by the finding that after pre-incubation and 
purification of cells no further gain in sensitivity could be observed 
(table II.5) 
Moreover, Kitabchi et al (1974) found no significant gain in sensiti-
vity when the second messenger analog dibutyryl cyclic AMP was tested (ED50 
0.07 mM in adrenal cell suspensions of normal rats versus 0.06 mM in those 
of hypophysectomized rats). These data suggest that events before cAMP 
formation are responsible for the gain in ACTH sensitivity. The finding of 
Sayers & Beali (1973) is also in agreement with the hypothesis mentioned 
above. The authors demonstrated that in isolated cells of adrenals of rats 
hypophysectomized 14 of 28 days earlier ACTH showed neglectable cortico-
steroidogenesis, although it showed about the same decrease in ED50 for cAMP 
production as compared with the cells obtained from two-days hypophysectomized 
rats against the ED50 in cells of normal rats. 
II.3.2.8 ACTH-like substances and other interfering agents m several batches 
of bovine serum albumin. 
As is known from the work of Sayers et al (1973) some BSA batches contain 
a factor which stimulates steroidogenesis in isolated rat adrenal cells. This 
will result in high control values. By means of glass powder extraction - as 
described in Chapter IV - we estimated the ACTH content of one batch of BSA 
(Sigma, fraction V ) . The value obtained proved to be 1.5 pg bioactive ACTH-
like activity/mg BSA. As 5 mg of BSA was generally used in the bioassay, the 
control value when this batch of BSA was used, contained 7.5 pg of ACTH 
activity, which obviously causes a loss in sensitivity. The use of such 
batches should be avoided. 
Furthermore,in addition to an ACTH-like activity other substances 
decreasing the sensitivity of the bioassay may be present as well. Fig II.9 
illustrates this decreasing effect of some commercially available BSA batches. 
One of them had a dramatic effect on the standard curve 
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corticosterone (iigl2h) 
0 4 
600 pg hACTH1" 
fig II.9 The effect of different BSA 
batches on the sensitivity of the 
standard curve. Concentrated crude 
cells were divided in three parts. 
Each portion was purified separately 
by passage through a 5% BSA layer. 
Each layer contained BSA derived from 
different batches. After purification 
the suspensions were diluted 
appropriately. Each final dilution 
proved to contain the same 
concentration of adrenal cells. 
II.3.3 Characteristics of the bioassay 
II.3.3.1 Reproducibility 
Cell suspensions were usually diluted evenly to a total volume of about 
110 ml. In order to find out whether the adrenal cells are equally distributed 
over the different tubes an experiment was performed in which the same ACTH 
dose was added to each 6th tube of a long series of tubes. The results are 
shown in fig 11.10. 
corticosterone -
Mg/2h 
0 9 i 
0 8· 
0 3-
0 2-
- 1 — 
25 
100 pg 
η =20 
3¡= 847 
5D=D59 
г = -0046 
25 pg 
η = 20 
x = . 2 5 2 
SD = .021 
г = -0.077 
50 75 100 115 tube number 
fbg i i . i o The reproducibility in the bioassay as measured in two separate 
1-39 
experiments for two different doses of hACTH 
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The c o e f f i c i e n t s of v a r i a t i o n were 7.0 and 8.3% f o r t h e d o s e s 100 pg and 25 
1-39 pg hACTH r e s p e c t i v e l y . 
I I . 3 . 3 . 2 S p e c i f i c i t y 
I I . 3 . 3 . 2 . 1 A c t i v i t y of o t h e r hormones 
T r o p h i c hormones o t h e r t h a n ACTH have been r e p o r t e d t o i n d u c e 
c o r t i c o s t e r o i d o g e n e s i s . The d a t a i n l i t e r a t u r e , however , a r e c o n f l i c t i n g . Some 
a u t h o r s d i d f i n d a s t i m u l a t i n g e f f e c t of FSH a n d / o r LH i n v i v o ( P h i l l i p s & 
P o o l s a n g u a n 1978) o r i n v i t r o (Vinson e t a l 1976; B e l l e t a l 1 9 7 9 ) , w h e r e a s 
o t h e r s d i d n o t ( G u i l l e m i n e t a l 1 9 5 8 ) . The s t e r o i d o g e n i c p o t e n c y of a number 
of p i t u i t a r y and h y p o t h a l a m i c hormones a s w e l l a s of a n g i o t e n s i n I I was 
t e s t e d i n t h i s s t u d y t o check t h e s p e c i f i c i t y of t h e a s s a y . I t a p p e a r s from 
t a b l e I I . 6 t h a t none of t h e hormones d e r i v e d from t h e h y p o t h a l a m i c - p i t u i t a r y 
T a b l e I I . 6 
Specificity of the bioassay 
corticosterone production ug/2 hT 
control value 
hACTH1"39 
Angiotensin II 
FSH 
LH 
TSH 
Prolactin 
Vasopressin 
LHRH 
TRH 
25 
0.1 
1 
10 
100 
0.044 
0.44 
0.77 
7.7 
0.0015 
0.015 
0.0065 
0.065 
0.37 
3.7 
0.25 
2.5 
1 
10 
pg 
ug 
v9 
ug 
ug 
vg 
ug 
ш 
IU 
III 
IU 
IU 
IU 
ug 
ug 
ug 
ug 
ug 
ug 
0.010 
0.292 
0.009 
0.011 
0.167 
0.510 
0.010 
0.008 
0.008 
0.010 
0.008 
0.014 
0.015 
0.013 
0.012 
0.008 
0.008 
0.012 
0.008 
0.007 
,tt 
tt 
values are the mean of duplicate determinations 
corticosterone production of the cells during incubation without ACTH 
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regJ-on was able to induce a steroidogenic response in the doses used. Besides 
ACTH angiotensin II is known to stimulate adrenocortical steroidogenesis as 
well, both in vivo (Laragh et al 1960; Biron et al 1961) and in vitro 
(Peytremann et al 1973; Albano et al 1974; Fredlund et al 1975). 
So, the finding that in our system angiotensin II in suprapharmacological 
doses enhanced the corticosterone production was not unexpected. 
Finally ß-endorphin was tested as well. As is shown in fig 11.11 no 
corticosterone (μς/ 2 h) 
0 2 
0 1 
0 31 25 400 ACTH pg/ml 
0 05 0 5 5 50 500 5000 
fl-endorphin ng/ml 
fig ii.ll The effect of different doses of ß-endorphin on the aorttaosteroido-
1-39 genesis without and with hACTH (12.5 pg). 
steroidogenic activity of ß-endorphin was observed up to a concentration of 5 ug. 
This result is m contrast with the finding of Shanker & Sharma (1979) who 
observed a clear steroidogenic activity with an ED50 of 0.1 ug. As is shown 
by Carter et al (1979) ß-endorphin potentiates the α-MSH activity. This 
suggested the possibility that - because α-MSH is also active m our system -
ß-endorphin may potentiate ACTH to a certain degree. Therefore we tested the 
effect of ß-endorphin in our system in the presence of ACTH (12.5 pg). By 
doses up to 5 yg of ß-endorphin the steroidogenic activity induced by ACTH 
was not enhanced. 
II.3.3.2.2 Activity of ACTH-denved peptides. 
The structure-activity relationship of ACTH-denved peptides was 
1-39 
examined using the isolated adrenal cell system. The activity of hACTH 
was compared with the biological activities of shortened ACTH molecules. 
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hACTH' 
• Π-endorphin 
ß-endorphin.l25pg hACTH ,1-39 
As table II.7 and fig 11.12 show shortening of the COOH-terminal part 
1 — ìQ 1 — 2R 
of ACTH to ACTH gave virtually no decrease in steroidogenic activity. 
1-39 A definite increase in potency occurred when ACTH was shortened to 
1-24 1-23 
ACTH and ACTH . By further shortening of the COOH-terminal part the 
potency decreased dramatically: ACTH had about 1/1000, acetyl ACTH NH 
(a-MSH) about 1/5000 and ACTH " about 1/100,000 of the potency of the 
complete hormone. Loss of three more amino acids, but now at the NH -terminal 
part of the molecule, was responsible for a further decrease of the potency, 
5-14 4-10 
whereas ACTH showed a greater steroidogenic capacity than ACTH . The 
results showed that there is no difference as far as the maximal steroidogenic 
4-10 production is concerned, when the sequence ACTH was unaltered. This in 
agreement with the report of Schwyzer et al (1971). 
From studies of Hofmann et al (1970) it appeared that the basic amino acids 
Lys Lys Arg Arg of the native ACTH molecule are very important for binding 
of the ACTH molecule to its receptor. This is in agreement with our observation 
of the very low biological activity of the ACTH moieties that had been deprived 
of all or some of these amino acids. Note the activities of the 5 ACTH mole-
cules in the right part of figure 11.12 
ac.1-13NH: 
0 -9 -Θ -7 -6 
Log ACTH (MoUr) 
fvg 11.12 Log-dose response curves for ACTH peptides which contain the 
ACTH sequence. 
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From investigations concerning ACTH conformation Low et al (1975) conclu­
ded that the acidic terminal part of the native molecule from amino acid 26 
onwards may protect the basic core 15-18 against degradation by trypsin-like 
enzymes. Thus the native hormone might be protected against degradation to a 
certain extent during its transport in blood from the pituitary gland to its tar-
1-24 
get organs. In our experiments it was found that ACTH is clearly more potent 
1-39 
than ACTH , a finding in agreement with Lowry et al (1973) but in contrast 
Table II. 7 
Potencies of ACTH-denved peptides 
peptide 
a) with the sequence 5-10 
hACTH1"39 
hACTH1"32 
ACTH1"28 
ACTH1'24 
АСТН
1
"
23!«^ 
ACTH1-16 
acetyl ACTH1-13 
ACTH1'10 
ACTH4'10 
ACTH5'14 
b) without the 
ACTH1"4 
ACTH5'7 
ACTH7-13NH. 
ACTH11'24 
ACTH U- 1 9NH, 
hACTH25"39 
hACTH18"39 
'NHg (aMSH) 
sequence 5-10 
potency 
100 
99 
77 
528 
416 
0.089 
0.022 
0.00082 
0.000021 
0.00062 
nd+ 
nd 
nd 
0.00032 
0.00067 
nd 
nd 
SD 
6 
12.5 
74 
130 
0.029 
0.004 
0.00011 
0.000012 
0.00019 
0.00011 
0.00025 
π 
5 
5 
10 
5 
7 
6 
5 
5 
4 
3 
3 
5 
9 
5 
2 
3 
highest dose 
tested 
100 ug 
100 u9 
loo ug 
1 ug 
l ug 
c) analogs with and without 
modif icat ions at posi t ion 11 
Lys peptide 
Arg peptide 
Norleu peptide 
ForLys peptide 
32 
36 
0.45 
0.46 
5 
5 
0.16 
0.09 
5 
5 
5 
5 
nd: not detectable 
+ +
 analog: a A l a ^ L y s 1 7 ACTH-(l-17)-4-aiinnobutylamide 
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with the findings of Schwyzer et al (1971) and of Liotta & Krieger (1975). 
Of course it should be realized that our data of the biological potency were 
obtained in an in vitro system in which the degradation of the ACTH mole­
cule might be obviously different from degradation in vivo. One might 
speculate that the biological activity is essentially dependent on the 
availability of the binding sites of the ACTH molecule that reach the receptor 
molecule in a system in which the enzymatic degradation plays only a minor 
role. That is how Low et al (1975) explained the stronger biological potency 
1-24 1-39 
of the ACTH molecule as compared with ACTH 
Besides the binding site of the ACTH molecule there is another part -
the active center - which is involved in the biological activation, residing 
,4-10 
4-10 in the ACTH region (Schwyzer et al 1971) 
The steroidogenic potencies of peptides without the sequence ACTH 
1-39 
were compared to the activity of the standard hACTH . The results are 
shown in table II.7 and fig 11.13. As was expected the COOH-terminal end of 
25—39 1 
ACTH, exemplified by hACTH and hACTH 
detectable response with doses up to 1 ug. 
- 8-39 
respectively, showed a non 
α) 
ε 
φ 
с 
О 
ι— 
φ 
Vi 
О 
о 
О 
Φ 
С 
о 
φ 
о 
о 
о 
ю· 
05· 
02-
г
-
13 
1-3 9У 
18-39. 
11-19NH2y/-11-24 
ι 
-12 -11 
fig 11.13 Log-dose response 
acid sequence. 
-10 
eûmes 
-9 —γ-
-θ 
— г 
-7 
-Γ 
•6 
— г 
-3 
Log ACTH (Molar) 
for ACTH peptides without the 5-10 amino 
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The peptides ACTH " , ACTH " and ACTH NH 2 
not even in doses as high as 100 ug. 
evoked no steroidogenic response, 
Our finding of an albeit low but still measurable biological activity of the 
2 
11-24 11-19 peptides ACTH and ACTH NH
n
 is m conflict with other reports. Seelig 
11-24 
et al (1971) found that ACTH was able to inhibit the steroidogenic acti-
1-39 
vity of hACTH in pharmacological doses, as was also found by Ramachandran 
11-19 (1974) with ACTH NH , whereas these peptides did not reveal steroidogenic 
ι ι _ ι ρ 
activity. Remarkably, Nakamura (1972), who used ACTH NH 2 observed a 
potentiating effect of the ACTH-induced steroidogenesis in vitro as well as in 
vivo, whereas the peptide itself showed no steroidogemcity. In our Dreoaration 
11-24 11-1У 
lower doses up to 50 nq ACTH as well as ACTH NH showed neither inhi­
bition nor potentiation of ACTH (fia IT.14). 
corticosterone (jjg/ 2 h) 
0 6 
0Д-
hACTH 11-19NH2 ι 
11-24 
7-13NH2 
•25 pg hACTH1 
10 50 100 500 
ACTH pg/ml 
5,000 50,000 
fvg 11.14 The effect of different doses of ACTE 11-19 
(^ a) and ACTH7'13NH (a 
25 pg MCTH . 
NH (o- o), ACTH 11-24 
&) upon the steroidogenesis induced by 
It is noteworthy that Glossman & Struck (1976) did find formation of cAMP 
11-24 induced by ACTH in a huge dose of 100 pg - in the presence of the GTP 
analogue Gpp(NH) . Furthermore, lipolysis in rat adipocytes could also 
Ρ 11-24 be induced by the ACTH sequence (Opmeer et al 1978) to about the sane 
degree as by ACTH . Moreover ACTH ~ contains information for CNS acti­
vity (Greven & de Wied 1977). As is known the sequence 15-18 which contains 
basic amino acids is responsible for the binding and/or the affinity to the 
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receptor (Hofmann et al 1970) and therefore the sequence 11-14 is of some 
interest. In this respect it is remarkable that Schwyzer & Eberle (1977) 
found a second active center in the molecule for ct-MSH activity being the 
sequence 10-13. 
In table II.7 and fig 11.15 some data are shown about the steroidogeni-
city of 4 analogs of ACTH with ß-ala as the NH -terminal end, the amino 
acid lysine at position 17 and a 4-aminobutylamide at the COOH-terminal 
position, whereas at the eleventh position lysin was substituted by arginine, 
norleucine or forlysme. Our data show that arginine did not delete 
steroidogenicity, whereas the replacement of the basic amino acid by norleu-
cine or by lysine neutralized by formic acid diminished the biological 
activity by about a factor 80. These observations indicate that it is the 
positive charge of lysine in position 11 that contributes to the steroidogenic 
activity of ACTH. 
corticosterone ( j jg /2h)-
05 
0.2-
0 1 -
-12 -11 -10 -9 
Log ACTH (Molar) 
-Θ 
fig 11.15 The effect of the replacement of lysine in position 11 upon the 
biological activity. The analogs are described in table TI.7. 
Our observations are in agreement with the in vivo results of Geiger & 
Schröder (1973). Similar evidence for a role of the basic amino acid in 
position 11 was obtained by Li et al (1963). These investigators synthesized 
a pentadecapeptide ACTH and found also a diminished biological 
activity as compared with a peptide without such a deletion. 
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TI.3.3.3 Sensitivity and precision 
In order to detect the lowest effective dose of ACTH in the assay, the 
responsiveness of the adrenal cells was analysed in 10 experiments performed 
on separate days. In each experiment the corticosterone response to doses of 
1-39 
hACTH ranging from 0.5 to 5 pg were measured. Each dose was analysed 5-
fold (table II.8). In 5 out of 9 experiments the addition of 0.5 pg ACTH 
resulted in a significant increase in corticosterone production as compared 
to the control values. The addition of 1 pg ACTH resulted in a significant 
increase in corticosterone production in 9 out of 10 experiments. The mean 
lowest dose which resulted in a significant response was 0.Θ5 j^  0.47 pg 
1-39 
hACTH /ml. 
Table II.8 
Effect of low doses of ACTH on cort icosterone production (ng/tube) in 
p u r i f i e d , pre-incubated suspensions 
Exoenments 
1 
2 
3 
4 
5 
6 
7 
β 
9 
10 
27 
25 
17 
11 
8 
22 
13 
4 
15 
10 
0 
± 
± 
± 
± 
+ 
± 
± 
+ 
± 
± 
Dose hACTH1" 
0.5 
51 ± 3 
29 ± 1+ 
11 ί 1 
14 ± l* 
26 i 1+ 
19 ± I* 
5 ± 1 
20 ± 1 + 
11 ± 1 
40 
28 
40 
16 
16 
34 
21 
7 
25 
15 
1 
+ 
+ 
+ 
+ 
+ 
+ 
± 
± 
+ 
+ 
5t 
jt 
jt 
jt 
3 9
 pg/ml ( 
68 
37 
86 
29 
34 
58 
40 
9 
45 
28 
2 
+ 
+ 
+ 
+ 
± 
+ 
+ 
+ 
+ 
+ 
30 
6+ 
7 
2 
3 
5 
5 
1 
2 
2 
1=5) 
101 
46 
115 
47 
55 
83 
68 
18 
78 
45 
3 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
± 
± 
± 
10 
3 
9 
4 
5 
2 
7 
2 
2 
3 
175 
73 
193 
76 
104 
111 
91 
37 
102 
77 
5 
+ 
+ 
+ 
+ 
+ 
± 
+ 
± 
± 
± 
11 
17 
13 
18 
1 
2 
9 
4 
5 
10 
lowest dose at which the value d i f f e r s s i g n i f i c a n t l y (P<0.01) from the 
control value 
1-24 
For ACTH - the doses tested were 0, 0.1, 0.2, 0.3, 0.5 and 1 pg - the 
lowest limit of detection appeared to be 0.20 + 0.10 pg/ml. 
Precision may be defined as the extent to which a given set of measure­
ments of the same sample agrees with the mean i .e . the amount of variation m 
the estimation of the hormone (Midgley et al 1969). This error is dependent 
on the standard deviation of the standard curve and also of the slope of this 
curve. In 25 experiments performed consecutively for assaying ACTH in human 
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plasma extracts (chapter IV) over a period of about 1 year, regression lines 
were calculated for the dose range where the response is linearly related to 
the log of the dose. In table II.9 are shown: 
- the corresponding slopes (b) 
- the standard deviation (s), calculated from the formula 
(Sayers et al 194В) 
in which y= the estimated value for a dose, and у = the value for a dose 
cale 
as calculated from the equation y= bx + a 
- λ= s/b (the index of precision; Gaddum 1953). 
The mean values appeared to be for s: 0.0133, for b: 0.2957 and for λ: 0.0464. 
Table II.9 
Precision of the bioassay 
Date 
Aug. 
Okt. 
Okt. 
Okt. 
Okt. 
Nov. 
Jan. 
Jan. 
Jan. 
Febr. 
Febr. 
March 
March 
March 
May 
June 
June 
June 
June 
July 
July 
Aug. 
Aug. 
Aug. 
Aug. 
Mean 
SD 
20 1979 
1 
4 
16 
24 
8 
17 1980 
22 
24 
4 
27 
7 
10 
28 
19 
19 
24 
26 
30 
2 
8 
8 
19 
20 
21 
s 
0.0093 
0.0260 
0.0490 
0.0247 
0.0096 
0.0021 
0.0072 
0.0057 
0.0158 
0.0098 
0.0133 
0.0099 
0.0060 
0.0082 
0.005В 
0.0048 
0.0215 
0.0103 
0.0066 
0.0322 
0.0164 
0.0137 
0.0093 
0.0049 
0.0098 
0.0133 
0.0105 
Ь 
0.2530 
0.4936 
0.6498 
0.4609 
0.4023 
0.2912 
0.2524 
0.2887 
0.2776 
0.3330 
0.3661 
0.2572 
0.1422 
0.2876 
0.1106 
0.1282 
0.4954 
0.2038 
0.1339 
0.5497 
0.3512 
0.2051 
0.1811 
0.1443 
0.1342 
0.2957 
0.1463 
λ 
0.0369 
0.0527 
0.0755 
0.0537 
0.0238 
0.0730 
0.0288 
0.0197 
0.0571 
0.0296 
0.0363 
0.0385 
0.0423 
0.0285 
0.0524 
0.0381 
0.0434 
0.0505 
0.0493 
0.0586 
0.0467 
0.0668 
0.0517 
0.0339 
0.0731 
0.0464 
0.0155 
II.3.4 Comparison of the bioassay with other isolated rat adrenal cell assays 
Under section II.3.3.2.2 it was already noted that the stimulating action 
of different ACTH moieties on adrenal corticosterone production differs great-
1-24 
ly. The lowest limit of detection for ACTH appeared to be 4 times lower 
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Table II.10 
Historical survev of adrenocortical cell suspensions 
Authors 
Kloppenborg et al 
Swallow & Sayers 
Haning et al 
Sayers et al 
Kitabchi & Sharma 
Nakamura & Tanaka 
Richardson & Schulster 
Moyle et al 
Lowry et al 
Sayers & Beali 
Kolanowski et al 
Kitabchi et al 
Bennett et al 
Falke et al 
Lietta & Krieger 
Monta et al 
Mulder 
Finn et al 
Porter & Heiman 
Lietta & Krieger 
Braley & Williams 
Sala et al 
Goverde et al and 
present study 
Year 
1968 
1969 
1970 
1971 
1971 
1971 
1972 
1973 
1973 
1973 
1974 
1974 
1974 
1975 
1975 
1975 
1975 
1976 
1977 
1977 
1977 
1979 
1980 
Enzyme 
cis 
t 
cis 
t 
t 
t 
cls 
cls 
t 
t 
t 
t 
t 
cls 
t 
t 
cls 
t 
t 
cls/t 
cls 
cls 
cls 
Standard 
2nd Intern St 
3rd Intern St 
pACTH 
3rd Intern St 
3rd Intern St 
ACTH (1-24) 
3rd Intern St 
3rd Intern St 
sACTH (173 lU/mg) 
hACTH 
ACTH (1-24) 
ACTH (1-24) 
ACTH (1-24) 
3rd Intern St 
ACTH (1-24) 
pACTH (75 lU/mg) 
synth hACTH (1-39) 
3rd Intern St 
ACTH (1-24) 
ACTH (1-24) 
ACTH (1-24) 
3rd Intern St 
ACTH (1-24) 
pACTH (150 lU/mg) 
synth hACTH (1-39) 
ЛСТН (1-24) 
Sensitiv 
pg/ml 
4П μΟ 
300Î 
1600T 
150+ 
10t 100+
jt 
25+ 
jt 
10+ 
200+ 
10-30 
10 
0.98± 
12.1 ± 
10 
4 
0.85± 
0.20+ 
itj 
0. 
3 
0. 
0. 
f 
10 
47 
10 
ED50 pg/ml 
4000+ 
iso1, 
200 
70t 2000* 
1200 
1750 
50 
7 
3.3±0.34 
27.3±2.2 
380 
1; 
400T 7-58 
1000т 
100-250 
850T 
35 
240 
100 
450 
18.0±6.B 
2.3±0.8 
λ 
0.078±0, 
0.009-0, 
0.06 
<0.08 
0.079 
0.057±0, 
0.05 
0.09 
0.046+0, 
.048 
.063 
.005 
,016 
Adrenal 
equivalent 
1 
0.5 
1 
1.66 
0.33 
0.66 
0.10 
0.2 
0.31 
0.27 
1 
0.083 
Manipulation 
hypox rats 
normal rats 
hypox rats 
purified cells 
hypox rats 
cultured cells 
normal cells 
pur.pre-inc. 
cells 
adrenal part present in 1 incubation tube 
estimated from figure 
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than for hACTH . So, as far as the sensitivity of a method is concerned, 
the value obtained is dependent on the standard used. The higher potency of 
1-24 
ACTH as compared to the complete hormone has been reported by various 
authors (Schwyzer et al 1971; Lowry et al 1973; Coverde et al 1980). Table 
11.10 summarizes in chronological sequence data from literature concerning 
isolated rat adrenal cell assays and includes information about the standard 
used. It is clear that the first methods had a poor sensitivity compared to 
the methods that were developed later. The detection limits of the assays 
increased dramatically, over the years, finally reaching a value as low as 
1-39 1-24 
0.85 pg/ml using hACTH and 0.20 pg/ml using hACTH . This high sensi­
tivity was reached in this study after purification and pre-incubation of 
the adrenal cells. 
A wide range of values may also be observed when we compare the more 
clearly defined parameter for sensitivity used by different investigators, 
the ED50. These values vary from 18 to 4000 pg/ml for the complete hormone 
1-24 
and from 2.3 to 850 pg/ml for ACTH . In order to obtain a higher sensiti­
vity several modifications had been made: hypophysectomy of the rats; 
purification of the cells; short-term culture of the cells; purification 
followed by pre-incubation, and mere dilution of the cells. The following 
ED50 values for the natural hormone were obtained; after hypophysectomy 
32 pg/ml (Kitabchi et al 1974) and 7-58 pg/ml (Liotta & Krieger 1975), after 
short-term culture of the cells 35 pg/ml (Liotta & Krieger 1977), after pre­
incubation of purified cells 18 pg/ml (this study), and mere dilution of the 
1-24 
cells 50 pg/ml (Lowry et al 1973). As far as ACTH is concerned (table 
11.11) it appears that the present method yields the lowest ED50: 2.3 pg/ml 
using pre-incubated, purified cells as compared with 3.3 pg/ml for the tech­
nique with hypophysectomized rats (Sayers & Beali 1973), 5 pg/ml for the tech­
nique with purified cells (Bennett et al 1974), and 7 pg/ml for the 
technique with a diluted assay (Lowry et al 1973) . 
The reported values of the index of precision (λ) are in close agreement 
with each other varying from 0.046 (present study) and 0.05 (Liotta & Krieger 
1975) to 0.09 (Liotta & Krieger 1977) with cells treated normally. These values 
are all lower than those reported in bioassays dating from before the deve­
lopment of the isolated adrenal cell system (chapter I). 
The term "adrenal equivalent" - indicating the part of one adrenal that 
is present in one incubation tube - has been employed as parameter for the 
optimal use of the quantity of tissue. This value ranges from 1.66 'Nakamura 
41 
& Tanaka 1871) to 0.083 (present study) indicating a high efficiency of the 
present method as compared to the adrenal equivalents of other reports 
(table 11.10). 
Table 11.11 
Comparison of isolated adrenal cell assays with ACTH " as standard 
Authors 
Kitabchi & Sharma 
Lowry et al 
Sayers & Beali 
Kolanowski et al 
Bennett et al 
Mulder 
Finn et al 
Porter & Heiman 
Bra ley & Williams 
present study 
Year 
1971 
1973 
1973 
1974 
1974 
1975 
1976 
1977 
1977 
1981 
Sensitivi ty 
sTpg/nl 
Ì' 
1' 
10-30 
10 
10 
0.20 
ED50 pg/ml 
70 
7 
3.3 
27.3 
380. 
100T250 
eso1, 
100 
2.3 
Manipulation 
hypox rats 
normal rats 
purified cells 
purified cells 
pre-incubated 
value estimated from figure 
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Chapter I I I 
RADIOIMMUNOASSAY OF ACTH 
111.1 Introduction 
The development of a sensitive radioiimnunochemical method by Yalow & Berson 
(I960) has led to the radioimmunoassay for the determination of many hormones 
including ACTH. As such a method involves a competition between labelled 
and unlabelled hormones for the binding to antibodies, determination of 
hormones by means of radioimmunoassay requires the availability of a labelled 
hormone, a specific antibody and a technique for separating the bound and the 
free hormones (for review: Berson & Yalow 1973). Of these prerequisites the 
production of antibodies for ACTH presents one of the main difficulties 
because ACTH has a low antigenicity, is rapidly degraded in blood, induces 
the secretion of corticosteroids, which inhibit the immune system, and 
requires antibodies with a high affinity because of the fact that molar 
levels of ACTH in human blood are rather low as compared to many other hormone 
levels. 
This chapter describes the method for the radioimmunoassay for ACTH 
per se. 
111.2 Materials and Methods 
Materials 
Peptides 
1-39 In the radioimmunoassay the same standard (synthetic hACTH , CIBA-
Geigy) was used as in the bioassay. Peptides used for crossreactivity studies 
were described in chapter II. The peptide used for labelling was a highly 
purified human ACTH hypophyseal extract (Organon, Oss). 
Reagents 
Bovine serum albumin (BSA, ORHD) was obtained from Hoechst (Frankfurt 
am Main); sodium phosphate dibasic, potassium phosphate monobasic and sodium 
acetate (p.a. ) f rom Merck (Darmstadt); diethylbarbituric acid (Barbitene), 
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diethylbarbituric sodium (Barbitene sodium) and thiomersal from BDH Chemicals 
(Poole); Quso G32 glass powder used for purification of the tracer from 
Philadelphia Quartz Co (Philadelphia); charcoal, Norit A, from Fisher Scienti­
fic Co (New Jersey); dextran Τ 70 and Sephadex G 50, fine, from Pharmacia 
Fine Chemicals AB (Uppsala); lactoperoxidase (3000 lU/mg dry weight), lot 
125 
387013, from Calbiochem AG (Luzern); Na I (11-17 Ci/mg) from the Radio­
chemical Centre (Amersham); acetone (p.a.), acetic acid (p.a.) and hydrogen 
peroxide, 30%, from Merck, diluted to 0.003% with distilled water. Standard 
and unknown samples were diluted in ACTH-diluent, which was made by solving 
50 mg BSA in 100 ml 0.9% NaCl after which the pH was adjusted to 3.5 with 
N HCl. The assay buffer (0.02 M) was prepared by adding 5.742 g sodium phos­
phate and 0.416 g potassium phosphate to 1 1 physiological salt containing 
100 mg thiomersal and 0.25% BSA (pH buffer: 7.6). lodination buffer (0.05 M) 
was prepared by adding 1.504 g sodium phosphate and 0.108 g potassium phos­
phate to 100 ml distilled water (pH buffer: 7.0). Veronal buffer (0.07 M) 
used for separation was made by adding 0.791 g Barbitene, 6.209 g Barbitene 
sodium, 4.55 g sodium acetate and 100 mg thiomersal to 1 1 distilled water 
(pH. 8.6) . As ACTH-free plasma, outdated hepannized blood bank plasma was 
used. The absence of ACTH in this plasma was tested before use. 
The antibody used was purchased from Wellcome (RD 05). It was prepared from 
a single bleeding of a rabbit immunized with repeated injections of human 
ACTH in adjuvant. Each bottle contained the lyophilized residue of 0.5 ml 
of 1:250 diluted antiserum. The antibody was reconstituted in 5 ml of phos­
phate buffer and stored in aliquots of 0.5 ml at -20 С until use. The anti­
body was diluted in phosphate buffer to 1:5,000 before addition. 
Equipment 
Polystyrene tubes, 11 χ 40 mm and 16 χ 100 mm, were obtained from Otan 
(Rijsbergen, the Netherlands); a dispenser, adjustable from 0.2 to 0.8 ml, 
from Oxford (Ireland); an acrylic column (600 χ 9 mm) from Pharmacia (Uppsala), 
a peristaltic pump (R-ll) from LKB (Sweden); a centrifuge (Ecco) from Manus 
Utrecht; a fraction collector (Retriever III) from Iseo (Linedu, Nebraska); 
a gamma counter (NE 1600) from Nuclear Enterprisers. A décantation apparatus 
as described by Vecsei (1974) was employed but with modifications suitable 
for gamma ray tubes. 
Methods 
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Radxoiodination of ACTH 
In this study highly purified human ACTH was used for radioiodination. The 
procedure is a modification of the method of Mcllhinney & Schulster (1974). One 
yg lactoperoxidase (in 1 μΐ 0.05 M phosphate buffer) was added to 2.5 vg ACTH 
125 (in 15 μΐ 0.05 M phosphate buffer) followed by an addition of 1 mCi Na I 
(in 10 μΐ NaOH ) and 10 yl 0.003% H O After a reaction time of 10 sec, 0.5 
ml phosphate buffer (0.05 M) was added. After addition of 1.5 ml ACTH-free 
plasma and subsequent vortexing, ACTH was adsorbed to Quso G 32 according to 
Berson & Yalow (1968). The mixture was vortexed for 5 minutes and centrifugad 
at 4 C. The glass sediment was washed with 2 ml aqua dest and centrifuged. 
ACTH was eluted from Quso by 1 ml of 40% acetone and 1% acetic acid in 
distilled water during rotation for 30 minutes. After centrifugation the 
eluate was transferred to another tube and concentrated by a stream of air at 
room temperature to a volume of about 0.5 ml. After addition of 1.5 ml assay 
buffer the tracer was stored in fractions of 250 μΐ at -20 C. 
In the assay the tracer was purified by means of gelfiltration immedia­
tely before addition. The SephadexG 50 column (50 χ 0.9 cm) was equilibrated 
with assay buffer, after which about 0.25 ml tracer was transferred to the 
column. The tracer was eluted with assay buffer and eluate fractions of 2 ml 
were collected. An appropriate fraction was diluted in assay buffer and added 
to the assay tubes in 50 μΐ aliquots. With this purified tracer a 100% binding 
was performed at antiserum dilution 1-250. 
Incubation procedure 
One hundred μΐ of standard or unknown sample were pipetted into each 
polystyrene tube, after which 50 μΐ antiserum as well as 300 μΐ assay buffer 
were added. Four control tubes, without an antibody, were also set up for 
the determination of the non-specific binding. The mixture was vortexed and 
pre-incubated for about 3 days at 4 . After administration of 50 μΐ of 
labelled ACTH the assay was accomplished with an incubation for 24 hours at 
4 C. The final dilution of the antibody was 1:50,000. 
Separation of antibody-bound and free hormones 
Activated charcoal (250 mg/10 ml) was suspended in Veronal buffer (0.07 
M). After mixing with ACTH-free plasma (1.5/8.5 ml buffer, v/v) 0.2 ml samples 
of the separation suspension (4 C) were brought into disposable caps, which 
were placed on the incubation tubes. After that the suspension was mixed with 
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the contents of the test tubes by inverting and shakinq all tubes -
numbering up to 145 - simultaneously. Immediately afterwards the tubes were 
centrifuged at 3000 g for 10 minutes (4 C) . After the centnfugation step 
the tubes were placed in a special décantation device and the supernatants 
were decanted into tubes and counted in a gamma counter. The percentage of 
radioactivity of the tracer that was added but not adsorbed to charcoal in 
the four control tubes in which no antibody was present revealed the amount 
of non-specific binding. Correction for this non-specific binding in other 
samples was made by subtraction. 
III.3 Resultb and Discussion 
III.3.1 Radiolabelling of ACTH 
Under the conditions described above the yield of radioiodinated ACTH 
in the acetic acid eluate of Quso, expressed as the percentage of radioactivity 
related to the total amount of radioactivity employed, was 23.7 +_ 5.3% (n=13). 
The tracer was used m the radioimmunoassay for a period of 2 months. During 
this period a gradual decrease of binding to the antibody was observed. 
Without tracer purification by means of gelfiltration, the non-specific 
binding, which represents to a certain degree the "damage" of the tracer, was 
often about 10%. To minimize this damage, the tracer was purified by gel 
chromatography (fig III.l upper panel); a small peak appeared in the albumin 
fractions (5-7) whereas the major peak was eluted in fractions 13 to 18 with 
smaller weight components collected in fractions 19 to 30. Each of those 
fractions were analysed for the В and the non-specific binding. It is shown 
in fig III.l (lower panel) that the radioactive material present in the first 
fractions binds poorly to the antibody. Using this radioactive material the 
non-specific binding appeared very great. Furthermore, it is clear that the 
tracer in fractions 13 to 18 showed a great binding with the antibody and a low 
non-specific binding. Fractions 19 to 30 contained tracer responsible for 
a high non-specific binding and а В inferior to the В obtained when tracers 
^
3 г
 о о 
from fractions 13 to 18 were used, which indicates a higher content of 
"damaged" peptides. From these results it was concluded that in fractions 13 
to 18 tracer with the lowest damage was present. The non-specific binding 
as determined in 30 consecutive experiments using fraction 15 appeared to 
be 2.98 + 0.83%. 
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fig Ill.l Chromatographic pattern of the tracer. Upper panel: chromatographic 
elution pattern of iodinated ACTH following the procedure as described in 
Materials and Methods. Lower panel: В and non-specific binding of each frac­
tion. In the assay S000 cpm radioactivity of each fraction was added to each 
incubation tube. 
On 8 different occasions the specific activity of the tracer was deter­
mined by the self-displacement method described by Chervu & Murty (1975). 
The activity amounted to 206 +_ 39 рСі/мд. As calculated by Galskov (1972) 
125 
this means an average content of about 0.5 atom I per molecule ACTH. Other 
authors who used lactoperoxidase reported specific activities of 285 + 30 
uCi/iig (Mcllhinney & Schulster 1974) and 125 + 15 yCi/gg (van Di]k 1979). In 
most studies chloramine Τ was used as oxidizing agent and the specific 
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activities obtained showed a great variety in ranges. Landon & Greenwood (1968) 
reported a wide range of 120 - 690 uCi/yg as did Matsukara et al (1971): 150 -
530 pCi/ug and Galskov (1972): 240 - 800 yCl/ug. Donald (1968) found a smaller 
range of 500 - 750 pCi/ug which was also reported by Orth et al (1973): 150 -
200 yCi/ pg and by Liotta & Krieger (1975): 260 - 340 yCi/pg. Obviously, the 
specific activity we found in our study agreed rather with the ranges as 
reported in literature. 
It is of interest that on 2 occasions when the biological activity of 
the tracer was determined, this activity amounted to 57 + 6% of the immuno-
reactive value. This is in close agreement with the findings of Mcllhinney & 
Schulster (1974) who reported this value to be between 50 and 60%. 
111.3.2 Conditions of incubation and pre-incubation 
Addition of labelled ACTH can be performed in two ways. Tracer may either 
be added to the antibody at the same time as unlabelled ACTH, or tracer may be 
added to the antibody at a later stage than the unlabelled hormone. The effect 
of the pre-incubation step, which was first described by Hales & Handle (1963) 
for insulin, was a gain in sensitivity as has been reported earlier by many 
authors. 
111.3.3 Separation of free and antibody-bound ACTH 
The last step in the radioimmunoassay is the separation of the free and 
bound hormones after which both fractions can be quantified by counting the 
radioactivity. The methods for separation are based upon differences between 
the characteristics of free and bound hormones. In this respect it is impor­
tant that free polypeptides can easily adsorb to materials like charcoal 
(Herbert et al 1965), talc and Quso (Rosselin et al 1966). The use of charcoal 
coated by plasma as developed for the radioimmunoassay of ACTH by Donald (1968) 
permits a rapid and easy method. 
In order to detect the optimal coating of charcoal by means of plasma 
in our system, several concentrations of ACTH-free plasma were added to the 
separating medium (fig III.2). It is evident from this figure that the 
addition of ACTH-free plasma definitively influenced the В . The content of 
о 
1.5 ml plasma in 10 ml of the separating suspension caused an almost maximal 
Β , whereas the non-specific binding was still acceptable. For these reasons 
this plasma concentration was employed in the separating suspension. It 
appears that the presence of plasma (-proteins) in the separation suspension 
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prevents the adsorption of the ACTH-bound antibody to the charcoal in a very 
effective way. In this respect it is of interest that Rosselin et al (1966) 
proposed that adsorption of peptide hormones to silicates has been competi­
tively inhibited by other proteins and plasma. Absence of plasma in the 
charcoal suspension might result in adsorption of the bound fraction as well 
(fig III.2). 
Bo 
non-specrfic binding 
0 0 25 0 75 
— ι — 
15 
fig III.2 The effect of the 
presence of plasma in the 
separation suspension on 
the В and the non-specific 
binding. 
ml plasma / 10 ml separation medium 
Fig III.3 shows that the contact time of charcoal influences the percentage 
of the bound fraction. Therefore the charcoal suspension was added to disposa­
ble caps which permits simultaneous addition of the charcoal to all tubes. 
·/. 
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5 
Bo 
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time (in mm) after charcoal addition 
fig 111.3 The effect of the 
contact time with ahavaoal 
on the В and the nort-
o 
specific binding. 
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Fig III.4 shows that after centrifligation in order to separate the free and 
bound fractions there was a gradual decrease of the В in time. For this reason 
о 
all bound fractions of one experiment were removed simultaneously. Therefore 
we adapted the décantation device as developed by Vecsei (1974) for the use of 
γ-ray counting tubes. In this way a simultaneous décantation of 145 tubes was 
possible. 
'lo ,25I 1 
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2 Ο­
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m m after centrifugal ion 
fig in.4 The effect of time after separation of the bound and free fractions 
after oentvifugation on the B
o
 and the non-specific binding. 
III.3.4 Evaluation of the radioimmunoassay 
111.3.4.1 Reproducibility 
When 8 standard curves were made in one run, this resulted in a mean 
standard curve as shown in fig III.5. The coefficients of variation for the 
doses 0, 10, 25, 50, 100, 200 and 400 pg were 3.3%, 4.1%, 3.0%, 7.4%, 2.8%, 
4.1% and 5.5% respectively. 
111.3.4.2 Specificity 
In order to localize the centre of the ACTH molecule which reacts 
immunologicaly with the antibody, different ACTH molecules were tested 
for crossreactivity. In order to study parallelism in reactivity of the 
molecules the percentages of binding were translated in logits: 
(в/в ) 
logit = In ° (Midgley et al 1969). It is shown m fig III.6 that 
(1-B/Bo) 
non-specific binding 
-· · · · 
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fig i n . 5 Standard curve in eightfold. 
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fbg i n . б Crossreaativity of ACTH-derived peptides in the radioimmunoassay. 
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on a molar base ACTH equalled the standard hACTH . Furthermore, 
11-24 1-32 
ACTH and hACTH showed a high crossreactivLty, whereas other ACTH 
fragments crossreacted in a negligible way. These findings extend the obser­
vation of Croughs et al (1973) and confirms that of Genazzani et al (1974) 
who found that this antibody binds mainly the ammo acid sequence 17-24. This 
means that in this assay with this antibody peptides can be detected which 
17-24 have a similar sequence of amino acids as ACTH . Such peptides may be 
devoid of a high bioactivity (chapter II) and can lead to a radioimmunologi-
cal overestimation of ACTH values. 
In order to calculate the affinity of ACTH to the antibody (Ka) and 
to calculate the total number of binding sites in the antiserum (Abo) the data 
of a standard curve were analysed according to the method of Scatchard (1949), 
and with corrections as proposed by Chamness & McGuire (1975). As is shown 
in fig III. 7 the Ka was 1.1 χ 10 M , whereas the maximal available binding 
_7 
sites appeared to be 5 χ 10 mol/1. 
15-
1 Ο-
ΟΒ-
ΟΙ-
\ Ab. 
\ Ka 
= 5x 10" M 
- Π χ 10 M 
\ 
0 5 10 15 20 25 
pg bound 
fig ni. 7 Saatahavd plot of a standard curve. 
III.3.4.3 Sensitivity and precision 
The sensitivity of a radioimmunoassay depends on the error in the 
determination and on the slope of the standard curve (Midgley et al 1969) . 
In order to estimate the percentage of binding (Bm) which is statistically 
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different from the B 0 the following formula was used (Bizollon & Faure 1976) : 
">/£ 
In this formula: t is the value of Student's t-test which belong 
XY
 2 
to the 95% probability, and σ the common variance of the standard curve. 
xy 
The Вщ was calculated and the corresponding ACTH dose was estimated from the 
standard curve. In 10 consecutive assays the lowest limit of detection appeared 
1-39 
to be Θ.8 + 2.8 pg hACTH /tube. 
The mean index of precision - λ (=s/b , Gaddum 1953) - was determined, as 
described in chapter II, in the dose range where the response is linearly 
related to the log of the dose. In 10 consecutive assays the mean index of 
precision appeared to be 0.0278 +_ 0.0081. In literature only very few indices 
of precision are reported: Voigt et al (1974) found a value of 0.0435 whereas 
Galskov (1972) found 0.0309. 
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Chapter IV 
BIOASSAY VERSUS RADIOIMMUNOASSAY OF ACTH IN HUMAN BLOOD 
IV.1 Introduction 
Most reported ACTH values in blood of normal subjects collected at about 
900 h range from 10 to about 150 pg/ml plasma as measured by radioimmunoassay 
(Berson & Yalow 1968; Landon & Greenwood 1968; Voigt et al 1974) or by bioassay 
(Vance et al 1962; Ney et al 1963; Davies 1964; Lefkowitz et al 1970a,· Daly et 
al 1974). Determination of such low values involves the use of very sensitive 
assays. Moreover many radioimmunoassays as well as bioassays still require a 
preceding extraction step - with the exception of the radioimmunoassays as 
described by Berson & Yalow (1968), Galskov (1972), Matsukara et al (1971), 
Kao et al (1979) and Thoren et al (1981), and the bioassays described by 
Lefkowitz et al (1970a) ana Wolfsen et al (1972) - radioreceptor assay - and 
Daly et al (1974) - cytochemical assay. 
Extraction not only concentrates ACTH but may also avoid the interfe-
rence with substances which are present in plasma both in bioassay (Fehm et 
al 1973; Sayers et al 1973; Liotta & Krieger 1975) and in radioimmunoassay 
(Moldow & Yalow 1980). The earliest but rather time consuming methods for 
extraction of ACTH from plasma were reported by Sydnor & Sayers (1952) who 
used the oxycellulose technique and by Williams et al (1961) who used resm 
adsorption. Recently more convenient procedures have been described. Ferrebee 
et al found in 1951 that adsorption could occur to laboratory glassware and 
Stouffer & Lipscomb (1963) observed that ACTH could be eluted from glassware 
at low pH. These findings led to the development of more simple but still 
effective extraction procedures (Donald 1967; Ratcliffe & Edwards 1971). A 
similar procedure was applied in the development of our assays to determine 
plasma ACTH. 
By a direct measurement of ACTH in human plasma disturbances were 
detected in both our assays. Therefore we applied Vycor glass particles - which 
gave the best results of the glass powders tested - for the extraction of ACTH 
ßrom plasma. As the measurement of immunoreactive ACTH (I-ACTH) in the plasma 
extracts m normal subjects resulted m much higher values than the bioactive 
ACTH (B-ACTH) values in the same plasma extracts, we scrupulously investigated 
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the methodology of both assays to establish a reliable determination of 
immunoreactive and bioactive ACTH in the plasma extracts. In this chapter a 
reflection of these investigations is presented and the immunoreactive and 
bioactive ACTH plasma levels in normal subjects are evaluated and discussed. 
IV.2 Material and Methods 
Materials 
Peptides 
For the radioimmunoassay as well as for the bioassay synthetic human 
1-39 1-24 
ACTH was used as the standard. Other ACTH preparations used were: ACTH , 
a human hypophyseal extract (Organon, Oss), the Third International Working 
Standard (IWS) - obtained from the WHO International laboratory for Biological 
Standards (Mill Hill, London) - and Cortrophin (purified porcino ACTH, Th 
lU/mg, Organon, Oss). 
Chemicals 
Heparin (5000 U/ml) was obtained from Organon (Oss), acetone (p.a.), 
acetic acid (p.a.) and hydrochloric acid (37%, p.a.) from Merck (Darmstadt). 
As extraction glass powder Vycor (code 7930, mesh 325, Corning Glass Works, 
New York) was employed. A number of other glass particles were tested: Quso 
G 32 (Philadelphia Quartz Co, Philadelphia), Silicic acid (mesh 100; 
Mallinakrodt, Trankfurt am Main), Spherosil 200 (Rhône Progil, Lyon) and Flon-
sil (60-100 mesh, BDH). Vycor, silicic acid and Spherosil were previously 
heated for 48 hours at 700 С and stored at 100 С - as were Quso and Florisil. 
Trasylol (10,000 lU/ml) was obtained from Bayer (Leverkussen). ACTH-diluent 
was used as described in Chapter II. 
Equipment 
Polypropylene tubes (75 χ 10 and 52 χ 10 mm), polyethylene tubes (100 ml, 
Sarstedt, Breda), a high speed centrifuge MSE, Hl-spin 21, Crawley, England), and 
a rotation apparatus (Heidolph) were used. 
Methods 
Plasma collection 
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Samples of 25 ml of human blood, obtained from 17 laboratory collaborators 
- 14 men and 3 women, aged 19 to 43 year - at 900 h in the morning, were drawn 
from the antecubital vein into heparmized syringes and poured directly into 
100 ml ice-cooled plastic tubes containing 50 vl heparin. Plasma was obtained 
by centnfuging without delay at 4 C, Trasylol was added and the plasma imnedia-
tely frozen at -20 С and stored until extraction. Plasma samples were centnfuged 
again immediately before extraction. A pool of outdated blood bank plasma 
without detectable ACTH activity was used as ACTH-free plasma. 
Extraction procedure 
The extraction described is a modification of the method of Ratcliffe & 
Edwards (1971). The whole procedure was performed at 4 C. Vycor glass parti­
cles - 25 mg suspended in 0.25 ml distilled water - were added to plasma 
samples up to 4 ml. After a 10 sec agitation of the glass powder-plasma mixture 
the tubes were rotated for 30 min and subsequently centnfuged at 5000 g for 10 
min. The supernatant was discarded, the pellet resuspended in 2 ml distilled 
water and the suspension centnfuged again at 5000 g for 10 m m . The supernatant 
was again discarded and the pellet washed by vortexing with 2 ml N HCl. After 
centri fugation the supernatant was discarded and ACTH eluted from the pellet by 
rotation for 30 m m with 1 ml of acetone: distilled water (50:50, v/v) . After 
centnfugation 0.9 ml aliquots of the supernatants were transferred to other 
tubes. These supernatants were placed in a water bath at 50 С and evaporated 
to dryness overnight under a fine stream of air. 
Immediately before the assay the dried extract was regularly reconstituted 
in 0.25 ml of ACTH diluent by vortexing. In order to minimize the presence of 
ultrafine glass particles in the supernatant the tubes were subsequently 
centnfuged now at 30,000 g for 60 minutes. In the bioassay as well as in the 
radioimmunoassay 0.1 ml aliquots were employed. 
Construction of standard curves with the use of Vycor extraction 
Extracts of unknown plasma samples were calibrated against a processed 
standard curve m the bioassay as well as in the radioimmunoassay. This standard 
curve was constructed as follows; to an appropriate volume of ACTH-free plasma 
(2 or 4 ml samples) a solution of 0.1 ml ACTH-diluent - containing 2000 pg of 
1-39 
standard (hACTH ) - was added and extracted as described. The extract of 
this standard sample (usually performed in duplicate) was reconstituted in 
0.5 ml diluent. After agitation and centnfugation at 30,000 g for 60 minutes, 
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0.25 ml was transferred to a polystyrene tube containing already 0.25 ml diluent. 
This tube was agitated and serially diluted through 6 more tubes each containing 
0.25 ml diluent. From each dilution 0.1 ml was transferred to assay tubes, ob­
taining the processed standard curve. In order to control whether an acceptable 
recovery was obtained non-processed standard curves as described in chapter II 
and III were constructed as well. 
Assays 
Details of the bioassay and the radioimmunoassay have been described in 
chapter II and III respectively. 
Statistics 
Statistical significance between two means of groups was determined by 
using Wilcoxon's two sample test (P). Correlation coefficient (r) was calcula­
ted using Spearman's rank correlation test. 
IV.3 Results and Discussion 
IV.3.1 The effectiveness of the extraction of ACTH from human plasma using 
Vycor, and the influence of the plasma extracts on the standard curves 
Using Vycor the recovery of tracer added to ACTH-free plasma appeared 
to be + 75%, which is quite satisfactory when compared to the recoveries 
obtained with other glass powders (fig IV.1 and table IV.1). 
Many ACTH extraction procedures have reportedly been performed at room 
temperature. ACTH can degrade in plasma (White & Gross 1957; Mirsky et al 1959; 
Imura et al 1967) , which is mainly observed when measuring bioactive ACTH. 
Using Vycor the effect of room temperature during the extraction procedure has 
been compared with the procedure at 4 C. It is shown in table IV.2 that in 
the bioassay standard ACTH, added to two ml ACTH-free plasma, is recovered 
о 
to a greater extent at 4 С than at room temperature. In a single experiment 
о 
the recovery as measured in the radioimmunoassay was also higher at 4 С than 
at 20OC. 
The influence of plasma extracts on the standard curves in the radio­
immunoassay as well as in the bioassay is shown in fig IV.2. As appears from 
the figure the Vycor extraction did not influence the radioimmunoassay 
standard curve. Plasma extracts in which other glass powders (Quso, silicic 
acid) were used did interfere with the standard curve in the radioimmuno-
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fig IV.1 The extraction recovery of tracer ACTH, added to 4 ml ACTH-free plasma 
sampleo, using different quantities of different types of glass powder. The 
extraction procedure for Spherosil and silicic acid was the same as described 
for Vycor. Using Quso and Fioristi the procedure was modified as follows: 
after the water wash step ACTH was eluted with 1 ml acetic acid: acetone: 
distilled water (1:40:59; υ/υ); to avoid the presence of an insoluble residu 
0.9 ml eluate aliquote were mixed with 1 ml acetone: HCl (40:1; υ/ν) and 30 
min later a centri fugation step followed after which the supematants were 
dried as described. 
Table IV.1 
Comparison of the effect of different materials and their activation at 
7000C upon tracer extraction from 4 ml ACTH-free plasma as performed at 40C 
adsorption HUO wash HCl wash sediment recovery 
% loss % loss t loss % loss % 
60 mg sil.acid" 
60 mg sil.acid (700 0C) T 
100 mg Spherosil" 
100 mg Spherosil (700 oC) T 
25 mg Vycor" 
25 mg Vycor (700ocy 
22. 
21. 
39.1 
36.3 
15.0 
12.1 
3.2 
2.6 
4.4 
3.8 
2.8 
2.1 
19.2 
4.7 
8.6 
3.3 
16.0 
1.4 
3.9 
4.0 
2.7 
2.9 
8.1 
6.3 
51.1 
67.2 
45, 
53. 
58.1 
78.1 
'glass not activated; values are the mean of triplicate estimations 
Tg1ass activated at 7000C before use; values are the mean of triplicate 
estimations 
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T a b l e IV.2 
1-39 The e f f e c t of temperature during extract ion upon the recovery of hACTH 
in ACTH-free plasna as measured by bioassay 
% recovery π 
2 ml plasma f 250 pg hACTH1"39 (20° C) 59.1 ± 4.9 5 
iden ( 4° C) 70.2 ± 7.5 " 5 
+
 Ρ <0 01 versus 200C 
assay. The influence of the Vycor extract on the bioassay standard curve can 
be seen in the same figure. Again the Vycor extracts of ACTH-free plasma per 
se did not influence the bioassay standard curve at all, in contrast to the 
extract obtained with silicic acid. The results described m fig IV.2 show 
that Vycor glass powder is to be preferred to the silicic acid or Quso pre­
paration for the extraction of ACTH from plasma. Furthermore, the effective­
ness of extraction of unlabelled ACTH was analysed. Increasing doses of ACTH 
were added to ACTH-free 4 ml plasma samples. After ACTH extraction the ACTH 
contents of these extracts were analysed by radioimmunoassay and bioassay 
and the responses (% bound or corticosterone production) were plotted against 
the amount of ACTH theoretically present in 0.1 ml of reconstituted extracts, 
which had been added to the assay tubes. In this way we obtained real pro­
cessed standard curves. These are given in fig IV.2 as well (lines through 
the black squares). As far as the Vycor extraction is concerned the figure 
shows that both in the radioimmunoassay and in the bioassay the processed 
standard curves parallel exactly the normal i.e. the non-processed standard 
curves. This implies that the recovery of ACTH over a range of values is 
the same. 
In another experiment very high doses of ACTH - up to 4000 pg/ml - were 
observed to yield recoveries equal to those m the low doses. 
With respect to the recovery loss of ACTH has been tested by addition 
of tracer and unlabelled standard to different volumes of ACTH-free plasma. 
When processing tracer ACTH the recovery was about equal in plasma volumes 
up to 7 ml. This is illustrated in fig IV.3. Addition of 200 pg synthetic 
1-39 hACTH to different volumes of ACTH-free plasma (1-4 ml) showed similar 
recoveries for immunological ACTH for each of the volumes used as well as 
for biological ACTH. It appeared however in these experiments that the 
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fig iv.2 The influence of plasma extracts using different glass powders upon 
the standard curves in radioimmunoassay and bioassay. Vycor and silicic acid 
extraction was performed as is described in materials and methods. Quso 
extraction is described in fig iv.l. Graded doses of ACTE were added to dried 
extracts of 4 ml ACTU-free plasma samples, after which 0.1 ml aliquots were 
transferred to assay tubes (Ό Qj; graded doses of ЛСТН were also added 
before the extraction to 4 ml ACTU-free plasma samples^ after the extraction 
0.1 ml aliquots of the reconstituted extracts were assayed, resulting in a 
processed standard curve (Ш Ш), Both curves were compared with a non-
processed standard curve (O o), 
recovery of bioactive ACTH was statistically significantly lower (P<0.05) 
than the recovery of immunoreactive ACTH. Measuring the recoveries of immuno-
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reactive ACTH and bioactive ACTH concomitantly m ACTH-free plasma pools in 
50 experiments over a period of about 4 years, loss of B-ACTH was again found 
to be significantly greater than the loss of I-ACTH (P<0.001; fig IV.4). 
In order to get information about the recovery of ACTH in different patient 
plasma samples, tracer was added to 10 different plasma samples of 4 ml. As is 
shown in fig IV.5 the percentages of adsorption and recovery did not vary great-
ly (adsorption loss: 9.4 + 1.8%; recovery 87.3 +_ 2.2%). The losses in the wash 
1 ÌQ 
·/. recovery at tracer and hACTH ·" in ACTH-free plasma 
100т 
20 
tracer 
'•rV-
ml plasma ' - ' s ' ' 
η I 
mean 
I-ACTH B-ACTH 
1
 Ι ι 
665 6a0 651 570 567 6H 
fig IV. 3 The recovery of tracer and standard ACTH in different volumeo of ACTH-
free plasma as measured by radioactivity
л
 radioimmunoasoay and bioassay res­
pectively. 5000 Cpm of the tracer and 200 pg hACTH 
in each of the experiments. 
1-39 were added in duplicate 
7. recovery of hACTH1"39 in Ami ACTH-free 
plasma over a U years period 
100 
50-
l-ACTH 
B-ACTH 
η 50 50 
mean 693 571 
SD 74 99 
Ρ <00001 
fig IV.4 The percentage of standard ACTH, 
added to 4 ml ACTH-free plasma, as 
measured by radioimmunoassay and bioassay. 
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fig IV.5 The percentage recovery of tracer ACTE in different plasma samples. 
10,000 Cpm tracer was added to 4 ml plasma samples from 9 different patients 
and to 4 ml of ACFH-free plasma (P). The values are the mean of duplicate 
estimations. 
steps with distilled water and HCl were neglectable. Recovery in ACTH-free 
plasma and patient plasma was also tested with unlabelled ACTH. In 5 indivi­
dual experiments with 12 different patient plasma samples the recoveries of 
ACTH in patient plasma as measured in the radioimmunoassay were found to be 
virtually the same as the recoveries in ACTH-free plasma (table IV.3). The 
same was observed when the recoveries in the bioassay were measured.The table 
also shows that between the experiments individual resurgences vary conside­
rably especially in the bioassay. Therefore the use of a processed standard 
curve measuring the recovery in each experiment is obligatory. 
Plasma extraction by means of glass particles is generally used nowadays 
to measure plasma ACTH in the radioimmunoassay. Data about recoveries as 
measured in the radioimmunoassay, however, are often incomplete. Usually 
recoveries of I-ACTH are reported when standard ACTH had been extracted from 
ACTH-free plasma. Only - as far as we know - Ichikawa et al (1971), using 
silicic acid, reported recoveries of I-ACTH in different patient plasma 
specimens (94 +_ 8%) . Recoveries of I-ACTH in ACTH-free pool plasma varying 
from 42.1 +_ 3.8% to 76% were found by Croughs et al (1973) and Landon & 
Greenwood (1968), both using Fuller's earth as the extractant. By means 
of 35 mg Vycor, Ratcliffe & Edwards (1971) found a mean recovery of 58 + 10%. 
Other authors reported the recovery of tracer ACTH in different patient plasma 
samples: Donald (1967): 78 +0.66% (n=16) and Liotta & Krieger (1975): 72-76% 
(n=24). 
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Table IV.3 
1-39 
Recovery of hACTH in 12 different patient plasma samples as compared 
with the recovery in ACTH-free plasma in the same experiments 
experiment plasma sample % recovery I-ACTH % recovery B-•ACTH 
1 ACTH-free 78 60 
patient a 70.5 54 
, Ь 72 59 
„ с 84 52 
, d 75 49 
2 ACTH-free 68 50 
patient e 68 
.. f 41 
3 ACTH-free 80 37 
patient g 80.5 47 
„ h 76 37 
, ι 78.5 47 
4 ACTH-free 85 36 
patient j 69 37 
„ к 88 38 
5 ACTH-free 88 43 
patient 1 96 55 
„ m 84 42.5 
t 1-39 
To each plasma samples 50 pg hACTH /ml plasma was added. 11 Patient 
plasma samples contained 30-122 5 pg I-ACTH/ml and 8-53 pg B-ACTH/ml 
One sample contained 922 pg I-ACTH/ml and 363 pg B-ACTH/ml plasma. 
Data about measurements of bioactive ACTH in human plasma are relatively 
scarce m literature. Ney et al (1963), using r e s m column chromatography for 
ACTH extraction and the Lipscomb-Nelson bioassay - reported a mean recovery 
of 102 + 41% in 11 runs in ACTH-free plasma. Cowan (1976), using glass 
particles of a commercially available radioimmunoassay kit, reported a 
recovery of 4.6 +_ 0.3% in an isolated adrenal cell bioassay in human plasma. 
Liotta & Krieger (1975), however, using silicic acid as the extractant and 
isolated adrenal cells, found a considerably higher recovery; addition of 
different doses of standard to ACTH-free plasma resulted in recoveries 
ranging from 64 to 76% in one experiment. These recoveries were virtually 
the same as those of tracer ACTH in the same experiment. Due to the lack of 
data on the recovery of immunoreactive ACTH a possible deactivation of 
biological activity during the extraction cannot be concluded from their 
study. Neither are there any data available about the recovery of B-ACTH 
in different plasma specimens. In our study the mean recovery of B-ACTH as 
measured over a period of 4 years appeared to be reliable, though lower 
than the recovery of I-ACTH, indicating a small loss of bioactivity during 
the extraction procedure (fig IV.4). Furthermore this study shows that the 
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recoveries are virtually the same in ACTH-Lree plasma as in patient plasma 
both ror B-ACTH and for I-ACTH (table IV.J). 
In order to obtain information about the behaviour of the standard during 
the extraction procedure in comparison to that of native ACTH, recoveries of 
1-39 
synthetic hACTH and of a human pituitary extract were evaluated in two 
experiments with 10 plasma samples obtained from different patients. Neither 
1-39 in the radioimmunoassay (recovery standard hACTH : 86.4 + 8.6%; human 
1-39 pituitary extract: 88.6 + 7.8%) nor in the bioassay (recovery hACTH : 44.8 
+ 8.0°; human pituitary extract. 43.6 + 11.5%) discrepant results were ob-
tained. 
Besides recovery loss plasma extracts may interfere in the radioimmuno-
assay as regards to the non-specific binding in a different way as compared to 
the non-specific binding of the extracts of ACTH-free plasma. Therefore the 
variability in the non-specific binding of 30 different plasma extracts was 
investigated, according to the method as described in chapter III. In these 
experiments the non-specific binding of the plasma extracts obtained from 
different patients as well as the non-specific binding of the extracts of 
ACTH-free plasma had been measured. The ACTH values in the plasma samples were 
calculated twice: both with a correction for the non-specific binding of the 
ACTH-free plasma extract and with a correction for the non-specific binding 
of the patient plasma extracts itselves. The two series of ACTH values 
obtained were compared with each other. The differences appeared to be low 
as is shown by a low coefficient of variation: 1.38%. 
IV. 3. 2 Further validation of the assays for measurement of human plasma ACTH 
IV.3.2.1 Reproducibility 
Reproducibility was assessed by calculating the intra-assay and inter-
assay duplicate variations both for the bioassay and for the radioimmunoassay 
for different concentration ranges of ACTH. The mean intra-assay variation 
for I-ACTH ranged from 6.3% to 6.5% and for B-ACTH from 7.2% to 10.9%. The mean 
inter-assay variation ranged from 10.4% to 12.3% for I-ACTH and from 10.5% 
to 14.9% for B-ACTH (table IV.4). Fig IV.6 illustrates the replicate inter-
assay variation that occurred when a pooled plasma was measured 10 times 
in a period of 6 months. The coefficient of variation was calculated to be 
11.1% for I-ACTH and 20.5% for B-ACTH. 
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fig IV.6 The replicate ¿nter-assay variation in a patients plaana pool. 
Table IV.4 
Reproducibi l i ty of the assays 
Radioimmunoassay 
range of ACTH levels in 
the plasma samples/ml 
:100 pg <1000 pg >1000 pg 
>100 pg 
Bioassay 
range of ACTH levels in 
the plasma samples/ml 
<100 pg <1000 pg >10Q0 pg 
>100 pg 
Intra-assay 
duplicate variation 
η 
coefficient of var. 
Inter-assay 
duplicate variation 
η 
coefficient of var. 
40 
6.3 
50 
12.3 
40 
6.4 
30 
11.1 
40 
6.5 
25 
10.4 
40 
10.9 
40 
14.9 
40 
7.2 
20 
10.5 
40 
10.5 
10 
14.0 
IV.3.2.2 Specificity 
Amongst other conditions (chapter II, III) a prerequisite for specifici­
ty is that the estimated ACTH values in the plasma extracts decrease linearly 
with dilution of the extract (Berson S Yalow 1968); i.e. there should be a 
lack of interference by substances other than ACTH or ACTH-like peptides. 
Because of a limited sensitivity the specificity could only be extensi­
vely evaluated when plasma samples with high ACTH levels were used. In the 
bioassay as well as in the radioimmunoassay (fig IV.7) a parallelism is shown 
between on the one hand a dilution of an extract of ACTH-free plasma to which 
2000 pg standard had been added and a diluted extract of plasma of an Addison 
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fig IV.7 Parallelism of tuo types of vroaessed standard curves - graded doses 
added to 4 ml ACTH-free plasma samples (Ш m), and diluted extracts of 
4 ml ACTH-free plasma samples to which 2000 pg standard had been added 
(Δ Δ; - and a diluted extract of a plasma specimen of a patient with 
Addison's disease (9 »J with the non-processed standard curve (o о J 
both for bioassay and for radioimmunoassay. 
patient, and on the other hand the non-processed standard and the true proces­
sed standard curve. 
The specificity of the assays for lower ACTH values was approximated by 
using 1:1 and if possible 1:3 dilutions. Table IV.5 shows that the ACTH values 
calculated from such dilut^î extracts from different patient plasma specimens 
were virtually the same. 
IV.3.2.3 Sensitivity 
Unknown samples can only be estimated from the linear part of the 
standard curve. In the bioassay and in the radioimmunoassay the lowest values 
to be observed reliably from the standard curves amount to about 3 and 10 pg 
respectively. Assuming a mean recovery of 57% (fig IV.4) and measuring 40% 
of a 90% eluate of 4 ml plasma, a quantity of about 3 χ 100/40 χ 100/90 χ 
100/57 χ 1/4 = 3.5 pg/ml plasma could routinely be detected by the bioassay. 
In the radioimmunoassay - with a mean recovery of 69% - this value is 10 pg/ml. 
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Table IV.5 
Parallelism in radToimmunoassay and ínoassay with diluted extracts of 
different volumes of plasma of different patients 
pat. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Π 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
plasma 
, in 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
3. 
3. 
3. 
3. 
3 
2. 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
1. 
1. 
ml 
5 
5 
S 
5 
5 
5 
5 
I-ACTH 
0.1ml 
25 
50 
37 
39 
74 
300 
61 
131 
144 
43 
66 
47 
161 
27 
56 
174 
110 
513 
124 
63 
71 
61 
500 
137 
69 
174 
155 
146 
in pg/m' 
0.05ml 
25 
45 
34 
37 
64 
325 
58 
113 
148 
43 
61 
46 
123 
34 
50 
184 
120 
650 
138 
70 
74 
68 
436 
144 
73 
153 
157 
158 
1 plasma 
0.025ml 
48 
38 
84 
313 
105 
143 
40 
69 
pat. 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
plasma 
, in ml 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
3 
3 
3 
3 
3 
3 
2 
2 
2 
2 
2 
2 
2 
B-ACTH 
0.1ml 
4 
24 
8.5 
3.5 
3.5 
7 
86 
17.5 
11 
8 
4.5 
6 
6 
67 
12.5 
7 
8 
25 
45 
33 
29 
65 
23 
40 
16 
in pg/m' 
0.05ml 
5 
27 
11 
4 
3.5 
9 
70 
16 
10.5 
8.5 
6 
6 
8 
63 
15 
9 
9 
29 
39 
40 
28 
65 
24 
44 
17 
1 plasma 
0.025ml 
32 
9 
73 
16 
23 
44 
38 
32 
60 
24 
Extracts were dissolved in 0.25 ml ACTH-diluent 
IV.3.3 Choice of standard 
A lot of different ACTH standards have reportedly been used in litera­
ture (table IV.6 and IV.7). 
In this study a number of ACTH standard preparations available from different 
sources have been compared. In both assays each of these preparations were 
analysed by their response curves and the quantities of the different 
preparations - on weight basis - were related to the response of 100 pg 
hACTH ~ . The I-ACTH to B-ACTH ratio (l/B ratio) of hACTH was therefore 
fixed at 1.00. The data of 5 standard preparations are summarized in table 
IV.8. All standards showed a parallelism with each other both in the radio­
immunoassay and m the bioassay. In the radioimmunoassay the activity of the 
IWS is 1.8 times as low as compared to the activity of the synthetically 
1-39 
prepared standard hACTH . It is of importance to note that when the IWS 
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Table IV.6 
Compaiison of 1Θ bioassays for the determination of plasma ACTS 
Authors 
Sydnor et al (1953) 
Fuji ta (1957) 
Lipscomb &Nelson (1962) 
Vance et al (1962) 
Cooper & Nelson (1962) 
Ney et al (1963) 
Espiner et al (1963) 
Davies (1963) 
Vermkos-Danellis et al (1966) 
Lefkowitz et al (1970) 
Binoux et al (1971) 
Wolfsen et al (1972) 
Holdaway et al (1973) 
Daly et al (1974) 
Fleisher et al (1974) 
Raux et al (1975) 
Liotta & Krieger (1975) 
present study 
bioassay 
ascorbic acid 
depletion 
idem 
Lipscomb-
Nelson assay 
idem 
idem 
idem 
modified L & N 
assay in sheep 
ascorbic acid 
depletion 
adr corticost. 
content 
radioreceptor 
Lipscomb-
Nelson assay 
radioreceptor 
cytochemical 
assay 
idem 
Idem 
Lipscomb-
Nelson assay 
isolated adr 
cells 
idem 
extraction 
procedure 
oxycellulose 
idem 
-
-
-
carbox resin 
-
oxycellulose 
-
-
-
-
-
-
-
-
silicic acid 
Vycor 
standard 
2nd Int St. 
2nd Int St 
Lerner-Upton 
pur pACTH 
3rd Int.St 
3rd Int St 
3rd Int St 
3rd Int St 
3rd Int St. 
synth hACTH 
sensitivity 
/ml plasma 
4 gU 
5 uU 
+
 5 pg 
1 1 μ U 
10 pg 
« 1 pg 
<<1 pg 
<<1 pg 
2 pg 
3 5 pg 
control morning 
η 
27 
13 
10 
13 
8 
6 
7 
9 
12 
10 
18 
6 
17 
/ml pi 
mean 
10 uU 
7 gU 
2 ΒμΙΙ 
7 uU 
9 5UU 
75 pg 
28 pg 
70 pg 
60 pg 
1 6μυ 
32 pg 
15 pg 
plasma levels 
isma 
range 
<5 pU 
22 not detectable 
not detectable 
4- 10 μΙΙ 
- 9 μΙΙ 
7 not detectable 
1- 6 μΙΙ 
2- 3 gU 
5- 12 uU 
6 5-12 5UU 
- 88 pg 
1.1-1 4
 VU 
7 not detectable 
12-100 pg 
12- 42 pg 
24-110 pg 
15- 50 pg 
5 5- 36 pg 
highly purified human ACTH 
Comparison of 21 radioimnunoassay techniques for the determination of plasma ACTH 
Authors 
Felber (1963) 
Yalow et al (1964) 
Demura et al (1966) 
Berson & Yalow (1968) 
Landon & Greenwood (1968) 
Besser et al (1971) 
Matsukara et al (1971) 
Ichikawa et al (1971) 
Donald et al (1972) 
Galskov (1972) 
Kendall et al (1973) 
troughs et al (1973) 
Genazzam et al (1974) 
Voigt et al (1974) 
Horgan i Rlley (1974) 
Fleisher et al (1974) 
Liotta & Krieger (1975) 
Kao et al (1979) 
Krieger et al (1979) 
Thoren et al (1981) 
present study 
extraction 
procedure 
acetone/HCl 
acetone/HCl 
-
Fuller's 
earth 
" 
-
sil.acid 
sil .acid 
-
Vycor 
Fuller's 
earth 
Vycor 
Quso 
Fuller's 
earth 
Vycor 
sil.acid 
-
sil.acid 
-
Vycor 
coeff. 
Intra-
assay 
11 
14 
12 
20 
3.5 
7.6 
11.3 
5.1 
5.6 
7.6 
12.1 
6.4 
of var. 
inter-
assay 
16 
16.1 
10.3 
14 
16 
13.6 
16.9 
10.6 
21 
11.3 
standard 
pur.pACTH 
pur.hACTH 
pur.pACTH 
Lerner-UptonT 
sensitivity 
pg/ml 
1000 
25 
1 
synth. hACTH" 10 
Lerner-Upton] 4. 
synth.hACTH!! 10 
synth.hACTH' 
Lerner-Upton 
synth.pACTH 
Lerner-Upton} 
Lerner-Upton 
10 
7 
synth.hACTH' 10 
pur.pACTH^ 
synth.hACTH' 
Lerner-Upton^ 
3rd Intern.St 
pur.hACTH 
6 
30 
synth.hACTH- 20 
synth.hACTH 10 
control morm 
in 
η 
9 
10 
69 
36 
50 
30 
18 
11 
106 
23 
14 
44 
50 
18 
4 
103 
24 
39 
17 
mean 
260 
50 
22 
70 
46 
41.6 
125 
17 
30 
72 
34 
41 
88 
147 
49 
ng plasma levels 
pg/ml 
range 
3,000-25.000 
150-380 
30- 70 
-±80 
12- 55 
15- 70 
22-175 
20- 93 
60-250 
15-100 
-±60 
7.5-28 
-120 
6- 68 
30-140 
19- 50 
-136 
30-156 
81-270 
16-127 
+
 highly purified human ACTH preparation 
obtained from Gedeon Richter 
obtained from CIBA-Geigy 
Table IV. 8 
Quantities of standard preparations as compared to the activity of 100 pg 
1-39 
synthetic hACTH in radioimmunoassay and bioassay 
Standard in 
hACTH1"39 
hum.hyp.extract 
3rd Intern.St.(IWS)+ 
Cortrophin 
ACTH1"24 
P9 
rad-
standard 
loirimunoassay 
100 
98 
180 
240 
65 
pg 
in 
standard 
bioassay 
100 
212.5 
365 
275 
12.5 
I/E 
to 
1 ratio relative 
the ratio of 
1-19 
hACTH1 " 
1 00 
0.46 
0.49 
0 67 
5.20 
pituitary extract of porcine origin 
would be used as the standard the values of unknown samples would be 1.8 times 
as high as the values recorded in this thesis which were obtained using the 
1-39 
synthetic hACTH as the standard. Besides the IWS another porcine ACTH 
preparation, Cortrophin, showed lower immunoreactivity than the standard 
1-39 
hACTH . This suggests the presence of other than ACTH-like material in 
these pituitary extracts. This is the more striking, when the biological 
1-39 
activity of these extracts are compared to hACTH 
Using the IWS as standard in the bioassay the values of unknown samples 
will be scored 3.65 times higher than the values obtained using the synthetic 
1-39 
hACTH as the standard. The activity of a human pituitary extract was almost 
identical to that of the standard in the radioimmunoassay but showed a lower ac-
1-39 
tivity in the bioassay than the standard hACTH . This might indicate that some 
ACTH-like material present in this human pituitary extract evinces crossreactivi-
ty with the ACTH antibody but is devoid of high steroidogenic potency. 
Of course the choice of the standard has large implications not only on 
I-ACTH and B-ACTH values but also on the l/B ratio. In the most extreme cases 
1-24 
first - when ACTH would be used in the radioimmunoassay and the IWS in 
the bioassay - an I/B ratio about 0.18 would be obtained, secondly - when 
1-24 
Cortrophin would be used in the radioimmunoassay and ACTH in the bioassay -
an I/B ratio of about 20 would be observed. This has to be considered when 
I/B values of different laboratories are compared. 
In this study it was chosen to calibrate I-ACTH and B-ACTH values against 
1-39 
the same standard. The choice of standard was synthetic hACTH for a number 
of reasons: 
- it contains the human ACTH amino acid sequence 
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1-24 
- it is more stable than ACTH 
- it is not a pituitary extract, which might contain ACTH precursor or ACTH-
like side-products 
- it is widely available (it is distributed now by the National Pituitary 
Agency of the U.S.A.). 
IV.3.4 Normal plasma ACTH levels at 900 h: radioimmunoassay versus bioassay. 
The plasma ACTH levels of 17 healthy subjects measured by both assays 
are depicted in table IV.9. In each subject immunoreactive ACTH was higher 
than the bioactive value, which results in an I-ACTH to B-ACTH ratio (l/B 
ratio) higher than unity. It should be noted that in both males and females 
the range of the l/B ratio was rather wide (2.00 to 6.30). However, when 
the I-ACTH values are compared with the B-ACTH values a correlation is ob­
served (r=0.874) which reaches a statistical significance (P<0.001). In spite 
of the observed dichotomy between the I-ACTH and B-ACTH levels this high 
correlation indicates the usefulness of the radioimmunoassay in normal 
subjects. 
Table IV.9 
Plasma ACTH levels in 17 normal subjects at 900 h 
males 
1 
г 3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
females 
13 
14 
15 
16 
17 
mean 
SD 
Immunoreactive 
pg/ml 
63 
83 
48 
57 
19 
80 
57 
30 
127 
38 
24 
69 
27 
18 
33 
16 
39 
48.7 
29.4 
ACTH Bioactive ACTH 
pg/ml 
10 
30 
15.5 
16.5 
9.5 
19.5 
11.5 
10.5 
36 
14 
11 
29 
9.5 
5.5 
8 
6 
15.5 
15.1 
8.8 
I-ACTH/B-ACTH ratio 
6.30 
2.77 
3.10 
3.45 
2.00 
4.10 
4.96 
2.86 
3.53 
2.71 
2.18 
2.38 
2.84 
3.27 
4.13 
2.67 
2.52 
3.28 
1.09 
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As far as the question is concerned why these immunoassayable ACTH values 
exceed the bioassayable values several causes might contribute to this pheno-
menon. The specificity study in chapter II revealed that in the bioassay only 
ACTH moieties which contain both the bioactive center and the receptor binding 
sequence evoked a biological response in a physiological range. In the 
radioimmunoassay (chapter III) an antibody is used which recognizes the 
midportion sequence (17-24) of the ACTH molecule which is virtually devoid 
of a biological response. This certainly could result in an overestimation 
of ACTH by radioimmunoassay, because it is possible that different ACTH-like 
peptides occur with an intact sequence (17-24). This suggestion is in 
accordance with the observations of Bennett et al (1977) who reported that 
peptide inactivation occurs as a result of catabolism by peptidases. Their 
high pressure liquid chromatography disclosed such peptide fragments. There 
is, however, according to these investigators another important route for the 
inactivation of ACTH. From their results they conclude that sulphoxidation 
converts ACTH to a product that has very low biological activity. As this 
sulphoxidation concerns only methionine, the ammo acid localized in 
position 4 of the ACTH molecule, it is highly probable that the product has 
immunoreactivity. This suggestion is in accordance with the results obtained 
by Nicholson et al (1978) who observed transformation of injected radioactive 
1-39 
methylated hACTH to a product which remained immunoreactive and is 
described to loss biological activity by a rather subtle alteration at the 
N-terminal sequence. 
Other possible explanations for the observed higher I-ACTH as compared 
to B-ACTH values are less likely: 
i) interferences of plasma substances in the assays. As was shown above no 
such interferences were observed in the radioimmunoassay or in the bioassay 
(fig IV.7; table IV.5) . 
n ) the standard employed. As was stated in section IV.3.3 the use of a 
particular standard could be influence the I/B ratio. However, when a 
standard with a lower I/B ratio is used - the human hypophyseal extract 
(table IV.8) - the I-ACTH values calculated are still higher than the B-ACTH 
values. 
in) interferences of ACTH-related peptides in the assays. In this respect 
a possible presence of the socalled "big ACTH" (section 1.2) in the circu-
lation could be detected in the radioimmunoassay but not in the bioassay 
( Gewirtz et al 1974). However "big ACTH" is thus far detected in plasma 
without the Vycor extraction procedure. Nothing is known about the 
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extractibility of "big ACTH" by using Vycor glass powder. Moreover, using 
a chromatographic procedure which prevents the non-specific binding of ACTH 
to plasma proteins. Ratter et al (1980) found no "big ACTH" present in plasma 
of normal subjects, patients with pituitary-dependent Cushing's syndrome, 
Addison's disease and Nelson's syndrome but did find "big ACTH" in the plasma 
of patients with an ectopic ACTH syndrome. For these reasons it is not likely 
that "big ACTH" was measured in one of our assays. As ACTH-related peptides 
did not influence the bioassay ( (3-endorphin: section II.3.3.2.1) or even 
enhanced ACTH-induced steroidogenesis (16K fragment, γ-MSH: Pedersen & Brownie 
1980; Pedersen et al 1980; Al-Dujaili et al 1981), the activity of these 
peptides would not influence the I/B ratio or even cause a low l/B ratio. 
Only two reports exist comparing I-ACTH with B-ACTH. Fleisher et al (1974) who 
used the cytochemical assay as the bioassay found a mean l/B ratio (1.20) 
which was much lower than in our study, but they used different standards in 
each assay. As a bioassay system Liotta & Krieger (1975) used trypsin dispersed 
adrenal cells derived from hypophysectomized rats and they found l/B ratios 
varying from 1.10 to 1.39 using the 3rd International Standard as the standard. 
It has to be emphasized that using this standard in our assays the l/B ratio 
amounted to about 1.60, a value similar as found by Liotta S Krieger (1975). 
Furthermore it is of interest that for other hormones immunoreactivity and 
bioactivity may also show a dichotomy (Solano et al 1979; Robertson et al 
1979; Maraña et al 1979; and Mukhopadyay et al 1979 for LH, Segre et al 1972 
for PTH, Leung et al 1978; and Asawaroengchai & Nicoli 1977 for prolactin, 
Roos et al 1978 for calcitonin). 
The mean morning plasma I-ACTH value and its range are in close agreement 
with most of the recently reported values (table IV.7). Where differences still 
exist in the reported values these may be due to the use of different 
antibodies detecting different ACTH metabolites (chapter VI), or to the use 
of different standards (vide supra) or to different extraction procedures. 
Before the development of a radioimmunoassay for ACTH, bioassays were 
performed with a relatively low sensitivity which required a large amount of 
plasma and time consuming extraction procedures (Ney et al 1963; Davies 1963). 
Using the ascorbic acid depletion test and 200 ml plasma Fujita (1957) detected 
ACTH activity in only 5 out of 27 subjects, whereas Binoux et al (1971), who used 
the Lipscomb-Nelson assay, did find detectable ACTH activity in 2 out of 9 
subjects. Table IV.6 summarizes the normal values obtained by several authors 
using different techniques. Seven of the authors listed performed bioassays 
using steroidogenic activity of ACTH. Liotta & Krieger (1975) were the first 
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who presented data about the ACTH bioactivity m plasma of normal human 
subjects as measured in an isolated rat adrenal cell assay after glass powder 
extraction. The reproducibility of their assay was similar to that of our 
study. They reported an mtra-assay and an mter-assay coefficient of variation 
of 9.8% and 12.7% respectively (cfr table IV.4). The B-ACTH values reported 
in our study are somewhat lower than those in other reports (table IV.6). 
Table IV. 10 
I/B r a t i o ' s in 8 normal subjects at 4 times on the same day 
Subject 
1 
2 
3 
4 
5 
6 
7 
8 
mean 
SD 
900 h 
2.00 
4.96 
3.27 
3.53 
2.71 
4.13 
3.02 
3.11 
3.34 
0.90 
930 h 
2.38 
3.47 
3.40 
3.77 
2.61 
2.88 
3.34 
2.32 
3.02 
0.55 
1600 h 
2.12 
2.28 
2.74 
2.57 
2.35 
4.66 
2.15 
2.12 
2.62 
0.85 
1630 h 
2.31 
3.33 
2.16 
2.04 
2.76 
5.00 
4.03 
2.50 
3.01 
1.04 
This may be due to the use of a different standard. For instance, a B-ACTH 
value almost similar to that reported by Fleisher et al (1974) could be 
calculated from our data when the International Working Standard was used 
as a standard (cfr tables IV.6 and IV.Θ). 
As the I/B ratio varied widely mterindividually - from 2.00 to 6.30 in 
our study - we studied the intra-individual change in I/B ratio at four sets 
of time during the day in 8 normal subjects (table IV. 10). No statistically 
significant variations between the mean I/B ratios could be observed at the 
different sampling times. 
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Chapter V 
BIOACTIVE VERSUS IMMUNOREACTIVE ACTH IN PLASMA: CLINICAL STUDIES 
V.l Introduction 
Before a sensitive radioiramunoassay was available (Berson & Yalow 1968) 
the assessment of the pituitary-adrenal gland function was hampered by the 
inherent insensitivity of bioassays requiring large samples of blood (chapter 
IV). Therefore the number of reports dealing with bioassayable ACTH levels in 
normal subjects and patients with disturbances in the pituitary-adrenal axis 
is relatively small (cfr Ney et al 1963; Liddle et al 1962) compared to the 
numerous studies in which ACTH was measured by radioimmunoassay. Only very few 
reports exist which compare immunoreactive and bioactive ACTH levels (Fleisher 
et al 1974; biotta & Krieger 1975). In both these studies higher ACTH levels 
were detected by immunoassay than by bioassay. The availability of a very 
sensitive bioassay as described in this thesis enabled us to compare immuno-
reactive ACTH (I-ACTH) and bioactive ACTH (B-ACTH) in plasma in normal and 
pathological conditions, as in pituitary-dependent Cushing's disease, Nelson's 
syndrome and Addison's disease. 
V.2 Materials and Methods 
Subjects studied 
Control subjects. In order to delineate normal ranges for I-ACTH, B-ACTH and 
Cortisol, plasma was obtained from 17 laboratory collaborators - 12 men and 
5 women (mean age: 31.1 + 6.7 year, range 19 to 43 year) - and from 23 
hospitalized patients without clinical and chemical evidence of pituitary-
adrenal axis dysfunction. This group included 3 men and 20 women (mean age: 
27.8 +_ 10.7 year, range 16 to 48 year). 
Patients with Cushing's disease. In 21 hospitalized patients with pituitary-
dependent Cushing's disease the profile of the pituitary-adrenal axis was 
studied: 18 female patients (mean age: 41.6 +_ 12.2 year, range 18 to 65 year) 
and 3 male patients (age 24,56 and 59 year). 
Five patients were studied after bilateral adrenalectomy without substitution 
for 24 hours: 4 female patients (mean age. 37.5 +_ 19.1 year, rancie 18 to 62 
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year) and 1 male patient (age 55), and 9 other patients on substitution 
(25 - 37.5 mg hydrocortisone acetate and 0.1 to 0.2 mg α-fluorohydrocortisone 
at Θ00 h): 6 women (mean age: 44.θ + 8.0 year, range 30 to 51 year) and 3 men 
(age 24, 37 and 59 year). Nine patients were studied before as well as after 
total adrenalectomy. 
Patients with Nelson's syndrome. Three female patients with proven Nelson's 
syndrome (age: 35, 36 and 41 year) also participated in this study. These 
patients had been bilaterally adrenalectomized for Cushing's disease between 
9 and 18 years previously. 
Patients with Addison's disease. Ten hospitalized patients with proven 
adrenocortical insufficiency were studied: nine male patients (mean age: 45.1 
+ 16.6 year, range 24 to 61 year) and one female patient (61 year). With the 
exception of one male patient who had had a deoxycorticosterone acetate (DOCA) 
implantation, all patients had received their last substitution - hydrocortisone 
as the glucocorticoid and 9 α-fluorohydrocortisone as the mineralcorticoid -
the day before blood was sampled. One patient had a "Sertoli cell only" syndrome 
in addition. This patient will be discussed separately. 
Clinical studies 
Basal Values at 900 h. From all subjects studied blood was obtained between 
800 and 1000 h. From some patients with Cushing's disease, Addison's disease 
and from the three patients with Nelson's syndrome blood was collected on 
several days and therefore their basal value was calculated as the mean of 
these different values. Individual values were employed only in calculations 
of the correlation coefficients between I-ACTH and B-ACTH or between ACTH and 
Cortisol. 
Ciroadian variation. 1. Blood was obtained at 800 or 900 h, 1200 h, 1600 h, 
2000 h, 2400 h and at 400 h respectively from 11 patients without clinical 
and biochemical evidence of pituitary-adrenal axis dysfunction who volunteered 
as control subjects, from 13 hospitalized patients with untreated Cushing's 
disease and from 3 hospitalized patients with Addison's disease without sub­
stitution therapy. 
2. From 13 laboratory collaborators blood was obtained 
at 900 h and 1600 h. Plasma I-ACTH and B-ACTH values of these control subjects 
were compared to those of 15 patients with a normal pituitary-adrenal function, 
15 patients with untreated Cushing's disease, and 6 patients with Addison's 
disease. 
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Short-term Variation. In order to assess the effect of short-term variations 
blood was sampled twice at 900 h and at 930 h from 13 laboratory collaborators, 
11 patients without pituitary-adrenal disorders (three of them on two occasions), 
and 15 patients with Cushing's disease (four of them on several occasions). 
Dexamethasone suppression test, in 10 laboratory collaborators, 11 patients with 
untreated Cushing's disease and in one patient after bilateral adrenalectomy 
the effect of dexamethasone was studied: on day 1 blood was collected at 900 h 
and 1 mg dexamethasone was administered at 2300 h. On day 2 blood was collected 
at 900 h. On day 3 two mg dexamethasone were administered at 2300 h, after 
which blood was collected on day 4 at 900 h. 
Assays 
Bioactive ACTH (B-ACTH) and Immunoreactlve ACTH (I-ACTH) levels were 
determined in plasma samples as described previously. Plasma Cortisol levels 
were determined by radioimmunoassay as described by Smais et al (1978). In 
short this procedure was as follows. Corticosteroid binding globulin was 
denaturated by incubation at 70 С for 1 hour after dilution of the plasma with 
ethanol/water (1:20). The antibody, raised in sheep against cortisol-21-hemi-
succmate coupled to bovine serum albumin, and tracer H-cortisol were added. 
After incubation at 4 С for 18 h bound and free hormones were separated by 
dextran-coated charcoal. Replicate analysis of a plasma pool with a Cortisol 
level of 0.20 umol/l disclosed intra- and inter-assay coefficients of variation 
of 5 and 10% respectively. The inter-assay duplicate variations of 8.6%, 7.4% 
and 4.3% were calculated from determination of samples containing 0.10 - 0.20, 
0.20 - 0.30, and 0.30 - 0.60 цтоі/і respectively (n=17). 
Statistics 
Statistical significance between the means of two groups was determined 
by the Wilcoxon's two-sample test (P). Patterns in rhythmicity were established 
by way of Friedman's non-parametric analysis of variance (P ), whereas diffe­
rences in ACTH and Cortisol between the different time intervals were 
xx 
statistically assessed by using Wilcoxon's signed rank test (P ). Correlation 
coefficients (r) were calculated using Spearman's rank correlation test. Using 
the χ -test the significance was denoted by Ρ . It has to be noted that in the 
figures each significance was denoted by P. 
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V.3 Results and Discussion 
.3.1 Basal plasma levels of Immunoreactive ACTH, Bioactive ACTH and Cortisol 
at 900 h 
V.3.1.1 I-ACTH levels 
The I-ACTH levels are depicted in fig V.l. The patients without disorders 
Immunoreactive ACTH (pq/ml) 9 0 0 h 
icf-
icf-
io3-
io2 
10' 
τ I ι ι ι ι 
controls Gushing Nelson Addison 
labcoll. patients untreated bil.adx 
x 487 ¿,13 1351 612 97,800 1,890 
SD 29Д 296 1041 687 127,700 1,657 
fig v . l The immunoreaotive ACTH values at 900 h. Open circles indicate patients 
on svbstitution therapy. The cross points to the patient with a "Sertoli cell 
only" syr.dt'cme in addition to Addison's disease. Lines connect values of the 
same patient before and after adrenalectomy. 
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of the pituitary-adrenal axis had virtually the same mean I-ACTH value as the 
laboratory collaborators: 43.3 + 29.6 pg/ml versus 48.7 + ',9.4 pg/ml. Moreover, 
the ranges were in close agreement with each other: 10-130 pg/ml versus 16-127 
pg/ml. Therefore the "normal" I-ACTH levels at 900 h were somewnat arbitrarily 
chosen to range from 10-130 pg/ml. 
Although numerous data are reported about normal I-ACTH values, only a few 
reports exist in which I-ACTH values of non-hospitali/ed normal subjects are 
compared to those of '" ^spitalized patients with a normal pituitary-adrenal 
function. Berson & Yalow (1968) pointed out that in hospitalized patients with 
minor disorders as well as in more seriously ill patients, much higher concen-
trations - up to 500 pg/ml - were to be found as compared to those in hospital 
personnel and in hospitalized subjects without serious illness (highest levels 
of about 80 pg/ml). Horgan & Riley (1974) comparing seriously ill patients and 
out-clinic patients found a mean I-ACTH value twice as high as in laboratory 
personnel. At variance with their data we found almost similar basal I-ACTH 
levels at 900 h m our hospitalized and non-hospitalized control groups. 
The I-ACTH values in 21 patients with untreated Cushing's disease ranged 
from 49.5 to 462 pg/ml. The mean value of 135 pg/ml was significantly higher 
(P <0.001) than the mean value (45.6 + 29.3 pg/ml) taking both "normal" 
populations together. Fourteen of these 21 Gushing patients (67=) showed values 
overlapping the normal range. This finding confirmed data of Besser & Landon 
(1968). They studied 20 patients with untreated Cushing's disease and found 
that in the majority of the patients the I-ACTH levels were within or slightly 
above their normal range (12-60 pg/ml), whereas only 6 plasma levels were 
detected above 100 pg/ml. Other reports (Berson & Yalow 1968; Landon ft Greenwood 
1968; Croughs et al 1973; Voigt et al 1974; Kao et al 1979) also stressed the 
overlapping of ACTH plasma levels in pituitary-dependent Cushing's syndrome and 
in normal subjects. Therefore, as is well known, the I-ACTH values at 900 h are 
of limited value to diagnosis of pituitary-dependent Cushing's syndrome. 
In all 5 patients with pituitary-dependent Cushing's disease after 
bilateral adrenalectomy and off substitution for at least 24 hours I-ACTH 
levels exceeded those in both control groups (range: 385-2295 pg/ml; mean: 
1266 +_ 796 pg/ml). This mean value was significantly higher than the I-ACTH 
level before adrenalectomy (P <0.01). The I-ACTH levels ranged from 45 to 550 
pg/ml (mean: 248 +_ 186 pg/ml) in the 9 patients who took their substitution 
therapy about 1 hour before blood sampling in the morning. This value was 
significantly lower than that in patients off substitution for 24 hours (P < 
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0.02). Three of these patients on substitution therapy had I-ACTH levels in the 
normal range. When comparing only those 9 patients who were studied before 
as well as after bilateral adrenalectomy it appeared that in the three patients 
after adrenalectomy without substitution higher I-ACTH levels are present than 
before the operation. On regular substitution therapy, 4 patients showed 
higher and two showed lower I-ACTH levels. 
In three patients with classical Nelson's syndrome - bilaterally 
adrenalectomized 9 to 18 year earlier for Gushing's disease - I-ACTH values 
ranged from 7,850 to 244,000 pg/ml. In literature a similarly wide range has 
been reported, from 700 pg/ml (Donnadieu et al 1976) to 100,000 pg/ml (Croughs 
et al 1977). 
In the present study the I-ACTH levels in the plasma of patients with 
Addison's disease off substitution therapy for 24 hours ranged from 408 to 
5,806 pg/ml. The highest value was of the patient with a concomitant "Sertoli 
cell only" syndrome. The morning levels reported in literature show a similarly 
large range in patients with Addison's disease varying from as low as 82 pg/ml 
(Donald et al 1972) to about 8,000 pg/ml (Oliver et al 1971). 
V.3.1.2 B-ACTH levels 
The B-ACTH levels in the plasma of both control groups ranged from 5.5 
to 36 pg/ml (mean 15.1 +_ 8.8 pg/ml) for the laboratory collaborators and from 
3.5 to 45 pg/ml (mean 12.5 +_ 11.7 pg/ml) for the hospitalized patients without 
pituitary-adrenal axis disorders (fig V.2). Both mean values did not differ 
significantly (P >0.10) and the ranges were also in close agreement with each 
other. Therefore B-ACTH levels for normal subjects were chosen to range, 
somewhat arbitrarily, from 3.5 to 45 pg/ml. 
The plasma B-ACTH levels in untreated Gushing's disease ranged from 10 
to 117 pg/ml. Although the mean value of 33.8 +_ 30.8 pg/ml was significantly 
higher (P <0.001) than the mean value of both control groups together (mean: 
13.8 +_ 10.3 pg/ml), fourteen out of 16 B-ACTH values were in the normal range. 
Data comparing B-ACTH levels in Gushing's disease with those in normal 
subjects are rather controversial. Some authors reported invariably elevated 
levels whereas others found normal or only slightly elevated levels with a wide 
overlap with the normal range. Jailer et al (1975) and Segal et al (1970) 
who used the adrenal weight maintenance assay found corticotropic activity 
in almost all patients but in none of the normal subjects. A similar finding 
was reported by Davies (1964) who used the ascorbic acid depletion test. On 
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Bioactive ACTH (pq/ml) 900h 
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fig .2 The ЪгоааЬг е ACTH levels at 900 h. Open circles гпаісаіе patbents on 
substotutzon therapy, x: patient with a "Sertoli cell only" syndrome in 
addition to Addison's dtsease. Lines connect values of the same patients before 
and after adrenalectomy. 
the other hand other authors (Vance et al 1962; Liddle et al 1962; Ney et al 
1963) who used the Lipscomb-Nelson assay found most of the B-ACTH values of 
untreated Gushing's disease in the normal range. Using the same assay Raux 
et al (1975) did not find any difference either between 49 patients with 
Cushing's disease and 63 controls as regards the B-ACTH levels. Using isolated 
adrenal cells for measuring B-ACTH and using a multiple sampling procedure in 
two patients with untreated Cushing's disease Liotta & Krieger (1975) found 
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B-ACTH levels from 65-210 and 113-200 pg/ml between 900 and 1200 h. In one normal 
subject sampled between 1000 and 1300 h at 5 min time intervals they reported 
a range of B-ACTH from 14-93 pg/ml and in 4 additional control subjects from 
14.5 to 54.5 pg/ml between 900 and 1000 h. In our studies in which single 
blood samples were taken at 900 h from 16 untreated patients with Gushing's 
disease most of the B-ACTH levels were within the normal range. 
In the 14 patients treated for Cushing's disease by bilateral adrenalec­
tomy B-ACTH levels ranged from 12 to 637 pg/ml. The mean value of 179.5 pg/ml 
was significantly higher than the mean of the untreated patients (P <0.01). The 
B-ACTH levels in the patients on corticosteroid therapy ranged from 12 to 205 
pg/ml (mean. 80 +_ 63 pg/ml, Ρ >0.10 versus untreated patients with Cushing's 
disease),whereas the patients off substitution therapy for at least 24 hours 
showed B-ACTH levels ranging from 145 to 637 pg/ml (mean: 359 +_ 207 pg/ml), 
values which were significantly higher than those in untreated Cushing's 
disease (P <0.01). In 6 out of 7 patients with Cushing's disease B-ACTH levels 
after bilateral adrenalectomy - 6 patients on and 1 off substitution therapy -
were higher than before treatment. 
In the three patients with Nelson's syndrome the bioactive ACTH levels were 
1670, 19950 and 46288 pg/ml respectively and they were without exception 
higher than those in treated or untreated patients with Cushing's disease or 
in patients with Addison's disease. Nelson et al (1958) using the Nelson & 
Hume (1955) bioassay found similarly high values - up to 4000 pU/ml (+ 40,000 
pg/ml) - as in our study. Using the isolated adrenal cell assay Liotta s Krieger 
(1975) reported a value of 1029 pg/ml in one patient with Nelson's syndrome, 
whereas Espinoza et al (1975) using the Lipscomb-Nelson assay reported levels 
of 280 to 600 |ju/ml in 6 patients. 
In Addison's disease B-ACTH levels ranged from 450 to 1225 pg/ml. In 
contrast with I-ACTH, the mean B-ACTH level (780 + 331 pg/ml) in the Addison 
patients was significantly higher (P <0.05) than in the bilaterally adrenalec-
tomized patients with Cushing's disease off substitution therapy (359 +_ 207 
pg/ml). Other authors, however, reported somewhat lower B-ACTH values in 
patients with Addison's disease. Using the classical Lipscomb-Nelson assay 
Graber et al (1965) found values ranging from 5 to 50 pU/ml and Williams et 
al (1961) from below 5 to 13 μυ/ml. Liotta & Krieger (1975) reported a B-ACTH 
value of 102Θ pg/ml in one patient. 
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V.3.1.3 The ratio of I-ACTH to B-ACTH 
As is shown in fig V.3 the I-ACTH to B-ACTH ratio (l/B ratio) was about 
the same for both groups of control subjects (3.28 + 1.09 and 3.47 + 1.19), 
although the range was rather wide for both groups (1.39 to 6.30, cfr chapter 
IV). 
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fig v.3 The I/B ratio at 900 h. Open circles indzcate patients on substitution 
therapy, x: patient with a "Sertoli cell only" syndrome in addition. Lines 
connect values of the same patients before and after adrenalectomy. 
In untreated patients with Gushing's disease the mean I/B ratio (4.40 +_ 
1.43) was slightly though significantly higher (P <0.05) than in the group of 
laboratory collaborators, whereas in comparison with patients without 
pituitary-adrenal axis dysfunction, this difference lacked statistical 
significance (0.05< Ρ <0.10). In two patients with untreated Cushing's disease 
in whom I-ACTH and B-ACTH were measured repeatedly, the I/E ratio - varying 
from 5.20 to 12.00 - was always higher than 5.00. Only scarce reports have 
appeared comparing I-ACTH and B-ACTH levels in patients with untreated 
Cushing's disease. Liotta & Krieger (1975), who used the isolated adrenal 
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cell system as bioassay, reported mean I/B ratios in two patients with Gushing's 
disease similar to those of control subjects, whereas Ratter et al (1977), who 
used the cytochemical assay as bioassay preliminarily reported a mean I/B ratio 
of 1.1 in 25 patients with pituitary-dependent Cushing's disease against 0.97 
in normal subjects. These authors also observed in one patient a much higher 
I/B ratio ranging from 3 to 13. Taken together, these findings suggest that 
m a minority of patients with a pituitary-dependent Cushing's disease the 
physiologically occurring discrepancy between I-ACTH and B-ACTH is even more 
expressed. 
After bilateral adrenalectomy the I/B ratio in the 14 Gushing patients 
studied was similar to that in both control groups (P>0.10). The I/B ratio 
in 4 patients off substitution therapy for at least 24 hours (3.49 +_ 0.73) 
was almost identical (P>0.10) to that in patients on corticosteroid therapy 
(3.51 + 0.74). 
In Nelson's syndrome the I/B ratio ranged from 3.95 to 6.97. Ratter et 
al (1977) found a mean ratio of 7.8 in Nelson's syndrome, about eightfold 
higher than their mean control value (0.97). In contrast Liotta & Krieger 
(1975) reported an I/B ratio of 1.33 in one patient, a value similar to their 
control value. 
The finding of a high I/B ratio in some patients with Cushing's disease and 
Nelson's syndrome suggests the accumulation of immunoreactive but biologically 
inactive ACTH fragments or precursors in blood. This relative accumulation of 
immunoreactive ACTK as compared to bioactive ACTH in the plasma of these patients 
might be due to the release of ACTH-like peptides by the pituitary, and/or 
due to differences in the metabolism of ACTH peripherally. 
The mean I/B ratio in plasma of patients with Addison's disease (2.71 + 
1.14) was significantly lower than the ratio in patients with Cushing's 
disease, untreated as well as after bilateral adrenalectomy (P <0.001). 
Although the ratio in Addison's disease also tended to be lower than in both 
control groups this difference lacked statistical significance (0.05< Ρ<0. 10). 
After excluding the patient with the combination of Addison's disease and the 
"Sertoli cell only" syndrome the mean I/B ratio (2.34 + 0.56) proved to be 
significantly lower than the mean value in both control groups (P <0.05). In 
contrast to our data Liotta & Krieger (1975) reported an I/B ratio of 1.19 in 
one patient with Addison's disease, a value similar to that found m normal 
subjects. To illustrate the discrepancies in this field further Ratter et al 
(1977) preliminary reported an even increased I/B ratio of 4.3 against 0.97 
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for normal subjects. Our finding of a lowered I/B ratio in the group of 7 
patients with Addison's disease, due to the presence of relatively higher 
amounts of B-ACTH m this disease, may be a physiological response of an 
essentially normal pituitary - though at a much higher gear - to a failing 
adrenal gland. The phenomenon of a persistently low I/B ratio m Addison's 
disease is reminiscent of a similarly lowered I/B ratio observed shortly 
after insulin-induced hypoglycaemia in control subjects (cfr chapter VI) . 
V.3.1.4 Cortisol levels 
The mean plasma Cortisol values in both control groups (0.426 + 0.102 
цто1/1 for the laboratory collaborators and 0.362 ;+ 0.09 pmol/l for the 
patients without pituitary-adrenal disorders) did not differ significantly, 
whereas the ranges were similar as well (0.26 - 0.61 and 0.19 - 0.59 ymol/l 
respectively) as is shown in fig V.4. 
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The mean plasma Cortisol level in the untreated Gushing patients was 
significantly higher than the mean of the whole control group (0.389 ;+ 0.100 
ymol/l; Ρ <0.01). However, only in 7 out of 20 (35%) patients with Cushing's 
disease plasma Cortisol levels at 900 h a.m. exceeded the normal range. 
V.3.1.5 Relations between I-ACTH and B-ACTH levels in plasma 
Using the individual basal 900 h values a highly significant correlation 
was found between I-ACTH and B-ACTH in both groups of control subjects (fig 
V.5 and .б; r= 0.874, Ρ <0.001 in the laboratory collaborators, and r= 0.879, 
Ρ <0.001 in the patient control group). 
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fig V.5 The relation between I-ACTH 
and B-ACTH in the plasma of the 
normal subjects. 
fig V.6 The relation between I-ACTH 
and B-ACTH in the plasma of the 
patient control group. 
A statistically significant correlation was also found in the patients 
with untreated and treated Cushing's disease (fig. V.7 and V.8; r= 0.796, 
Ρ <0.001 and r= 0.975, Ρ <0.001 respectively). Fig V.7 further illustrates 
that only 7 out of 42 (16.7%) ACTH levels exceeded the normal range for both 
I-ACTH and B-ACTH, whereas 30 early morning values were within the normal range. 
Fig V.8 demonstrates in addition that substitution with corticosteroids 
obviously did not influence the relation between I-ACTH and B-ACTH values. 
In the patients with Addison's disease a statistically significant 
correlation between I-ACTH and B-ACTH was found as well (fig V.9,· r= 0.762, 
Ρ <0.01). 
Data on the relation between I-ACTH and B-ACTH are scarce. Fleisher et 
al (1974), using the cytochemical assay as a bioassay, reported a correlation 
coefficient of 0.94 In normal subjects between basal B-ACTH and I-ACTH. 
Liotta & Krieger (1975) using a multiple sampling procedure reported 
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fig V.8 Relation between I-ACTH and 
B-ACTH in the plasma of patients 
after bilateral adrenalectomy for 
Cushing's disease with and without 
substitution therapy. 
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fig V.9 Relation between I-ACTH and B-ACTH in the plasma of patients with 
Addison's disease. The open circle indicates the patient on substitution. 
x: values of the patient with a "Sertoli cell only" syndrome in addition 
to Addison's disease. 
correlation coefficients between 0.86 and 0.98 in two normal subjects, and in 
the same study mean values of 0.76 and 0.95 respectively in two patients 
with untreated Cushing's disease. Scrutinizing the data of Matsuyama et al 
(1972), who used the Lipscomb-Nelson assay as bioassay correlation coefficients 
ranging from 0.40 to 0.85 could be calculated from their data in patients 
bilaterally adrenalectomized for Cushing's disease, subjects treated with 
metyrapone, and in patients undergoing open heart surgery. 
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V. 3.1.6 Relations between plasma I-ACTH or B-ACTH and plasma Cortisol 
Several considerations must be kept in mind when relating I-ACTH or 
B-ACTH with Cortisol levels in plasma: the inherent biological variation in 
these relations, and more importantly so the facts that increases of ACTH 
levels precede increases of Cortisol levels, and that the half-lives of 
Cortisol (about 70 m m ; Peterson et al 1955) and ACTH (below 30 m m ; cfr 
review Bennett & McMartin 1979) differ greatly. 
Table V.l shows the correlation at 900 h a.m. between I-ACTH or B-ACTH 
and Cortisol levels in the same plasma samples of control subjects and of 
patients with Cushmg's disease. In the control group an albeit low but 
significant correlation (r= 0.346; Ρ <0.05) was found between I-ACTH and 
Cortisol levels. Despite a tight relation between I-ACTH and B-ACTH (fig V.5 
and V.6) such a statistically significant correlation between B-ACTH and 
plasma Cortisol was not found in the control subjects (r= 0.173). In the 
patients with untreated Cushmg's disease with their much higher ranges of 
ACTH and Cortisol both I-ACTH and B-ACTH levels were significantly correlated 
with plasma Cortisol levels (r= 0.460 for I-ACTH, and 0.451 for B-ACTH). 
Table V.l 
Correlation between I-ACTH or B-ACTH and Cortisol at 900 h 
controls 
patients wi th 
Cushmg's disease 
1-
η 
40 
51 
-ACTH vs 
r 
0.346 
0.460 
Cort isol 
P+ 
<0.05 
<0.005 
B· 
η 
35 
36 
-ACTH vs 
r 
0.173 
0.451 
Cort isol 
P+ 
ns 
<0 01 
In fig V.10 and V.ll the relations between I-ACTH or B-ACTH and plasma 
Cortisol in 29 patients with Cushmg's disease are shown together with the 
upper normal ranges for both hormones. At 900 h 60% of both hormone levels 
were within the normal range for I-ACTH and Cortisol (fig V.10). The percen­
tages of values exceeding the normal range amounted to 22% for I-ACTH and to 
31% for Cortisol. Only in 14% of the values the levels of both hormones were 
elevated. Comparing B-ACTH and Cortisol values in 36 plasma samples of 
patients with Cushmg's disease, about 60% of both hormone levels fell within 
the normal range (fig V.ll). The percentages of values exceeding the normal 
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range for each of the hormones amounted to 28%. These data (fig V.10 and V.ll) 
illustrate that neither measurement of I-ACTH alone nor measurement of B-ACTH 
in the morning are diagnostic for the presence of Cushing's disease. 
In the normal subjects of the present study a statistically significant 
correlation was found between plasma I-ACTH and Cortisol but not between plasma 
B-ACTH and Cortisol. This finding may be explained by the difference in half-
life between B-ACTH and I-ACTH (Besser et al 1971b). As the half-life of I-ACTH 
is reportedly longer than that of B-ACTH, measurement of I-ACTH may reflect 
preceding ACTH stimulation to a greater extent than measurement of B-ACTH. 
In contrast to the findings in normal subjects we did find a statistically 
significant correlation between B-ACTH and Cortisol in plasma of patients with 
untreated Cushing's disease. A longer half-life of B-ACTH relative to I-ACTH 
in patients with Cushing's disease as compared to control subjects, a more 
tonic release of ACTH from the pituitary gland, a larger range of both B-ACTH 
and Cortisol in these patients all might account for the statistically signifi­
cant correlation that was found. However, there is no evidence that the decay 
of B-ACTH is lower in plasma of patients with untreated Cushing's disease than 
in control subjects. Furthermore, the release of Cortisol and ACTH in Cushing's 
disease is not a tonic but an episodic event showing irregular oscillatory 
patterns (Krieger et al 1971 ; Krieger & Allen 1975). Therefore the most likely 
explanation of the finding of a statistically significant correlation between 
plasma B-ACTH and Cortisol in patients with Cushing's disease is simply the 
wider range of both hormones. 
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V.3.2 Circadian rhythmicity of plasma Immunoreactive ACTH, Bioactive ACTH and 
Cortisol 
V.3.2.1 Control subjects 
The diurnal changes in plasma I-ACTH, B-ACTH and Cortisol during a 24 
hours cycle were studied in 11 patients without clinical or biochemical evi­
dence of pituitary-adrenal dysfunction (fig V.12). A circadian rhythmicity 
could be demonstrated for I-ACTH (PX <0.05), B-ACTH (PX <0.005) and Cortisol 
P X <0.005). 
Circadian rhythm ot controls (patients) 
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fig V.12 Ciraadian rhythmioity of I-ACTH, B-ACTH and oortisol in plasma of 
control patients. Individual ( ) as well as the mean values ( ^ " ^ ^ " J 
are presented. 
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The mean I-ACTH levels (+ SD) fell from 58.7 + 21.4 at 800/900 h to 42.9 
+_ 21.8 at 1200 h, 47.9 + 25.6 at 1600 h, 40.7 + 20.3 at 2000 h, 35.1 + 22.4 
at 2400 h, and 35.7 + 16.2 pg/ml at 400 h respectively. Only the mean I-ACTH 
XX XX XX 
values at 2000 h (Ρ <0.05), 2400 h (Ρ <0.01) and 400 h (Ρ <0.02) were 
significantly lower than the mean 800/900 h level. Although there was a 
tendency for the mean I-ACTH level at 1600 h to be lower than at 800/900 h, 
this difference lacked statistical significance (0.05 <P <0.10). 
Plasma B-ACTH levels also showed circadian rhythmicity with mean levels 
of 16.7 + 10.9 pg/ml at 800/900 h,12.0 + 6.2 at 1200 h, 9.0 +5.1 at 1600 h, 
8.3 +_ 3.8 at 2000 h, 7.7 + 6.2 at 2400 h and 9.2 + 4.8 pg/ml at 400 h respec­
tively. The mean B-ACTH levels at 1600 h, 2000 h and 2400 h were all signifi­
cantly lower than the 800/900 h levels (PXX<0.02). 
The mean I/B ratio ranged between 3.76 + 1.65 at 800/900 h to 5.10 + 
2.72 at 1600 h without overt circadian rhythm (PX>0.10; fig V.13). 
I/B ratio during 2Λ hours 
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fig v.13 The I/B ratio during a 24 hours cycle in control patients (* · ; 
n=7) and in patients with Cushing's disease (O O; n=9). The mean values 
are presented + SD. 
Plasma Cortisol levels in the control subjects showed the well-known 
circadian variation with an acme at 800/900 h and a nadir at 2400 h. At all 
time intervals the mean plasma Cortisol values were significantly lower than 
at 800/900 h (PXX<0.01). 
It has to be emphasized that the diurnal rhythmicity of I-ACTH, B-ACTH 
and Cortisol could be demonstrated despite the reported occurrence of episodic 
bursts of these hormones throughout the day (Hellman et al 1970; Weitzman et 
al 1971; Krieger et al 1971; Gallagher et al 1973; Krieger & Allen 1975). 
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V.3.2.2 Patients with Cushing's disease 
In fig V.14 the individual and mean plasma I-ACTH, B-ACTH and Cortisol 
levels at the time intervals mentioned above are shown and compared to the 
ranges in the control subjects. 
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fig v.14 Individual (- •) levels of I-ACTH, B-ACTH and eovtisol in 
plasma of patients with Cushing 's disease. The shaded areas indicate the ranges 
of respective hormone levels in the control patient group. 
In contrast to the clearcut diurnal variation in control subjects no 
circadian rhythmicity for I-ACTH, B-ACTH or Cortisol could be detected for 
this group of patients (P >0.10). No significant changes in the hormone 
values could be demonstrated in the time interval studied. 
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As in the control patient group the I/B ratio did not show a distinct 
rhythm (P >0.10). The mean I/B ratios ranged from a lowest value at 1200 h 
(4.73 + 3.02) to a maximal value of 6.30 + 4.35 at 400 h (fig V.13). 
To assess the most appropriate time for discriminating between control 
subjects and patients with Cushmg's disease, the percentages of hormone 
values exceeding the normal range were calculated at each time interval. The 
data compiled in table V.2 show that 800/900 h is the least appropriate time 
for discriminating. Measurement of Cortisol in hospitalized patients at 2000 h 
and at 2400 h is the most discriminating. 
Table V.2 
Percentages of plasma I-ACTH, B-ACTH and Cortisol levels in Cushmg's 
disease exceeding the normal range at different times 
I-ACTH 
B-ACTH 
Cort isol 
800/900 h 
38.5 І 
11.1% 
25.0% 
1200 h 
66.7% 
50.0% 
33.3% 
1600 h 
61.5% 
77.8% 
33.3% 
2000 h 
54.5% 
60.0% 
83.3% 
2400 h 
76.9% 
55.6% 
91.7% 
400 h 
75 % 
62.5% 
16.7% 
Calcula t ing the mean of a l l plasma I-ACTH, B-ACTH and Cor t i so l values a t the 
d i f f e r e n t time i n t e r v a l s throughout the day, i t appeared t h a t I-ACTH values 
were elevated in 79%, B-ACTH values in 75%, and Cor t i so l in 77% of the p a t i e n t s 
with Cushmg's d i s e a s e . 
V.3.2.3 P a t i e n t s with Addison's d i sease 
Scarce data on the d i u r n a l changes of I-ACTH and B-ACTH are shown in 
fig V.15. Similar to the p r o f i l e in contro l subjects both I-ACTH and B-ACTH 
values were highest in the morning, decreased a f t e r t h a t time and reached 
t h e i r nadir a t midnight. At a l l time i n t e r v a l s both I-ACTH and B-ACTH l e v e l s 
were higher than in c o n t r o l s . 
Due t o the paucity of data meaningful c a l c u l a t i o n s of the I/B r a t i o were not 
p o s s i b l e . 
Krieger and Gewirtz (1974) using a frequent sampling technique - sampling 
took place every half hour - a l s o demonstrated the presence of a d i u r n a l 
v a r i a t i o n of I-ACTH in plasma d e s p i t e i n t e r f e r i n g episodic ACTH p u l s e s . Other 
authors sampling blood a t l e s s frequent sampling times a l so found a nycthemeral 
ACTH v a r i a t i o n (B-ACTH: Graber e t a l 1965; I-ACTH: Besser e t a l 1971; Oliver 
e t a l 1971) as in our s tudy. 
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Orcadian rhythm m Addisons disease 
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fig V.15 Circadian variation in patients with Addzson's disease. Numbers 
indicate the I-ACTH and B-ACTH values obtained from the same patient. Patient 
1 had a "Sertoli cell only" syndrome in addition. 
V.3.3 Cxrcadian variation of plasma Immunoreactive ACTH, Bioactive ACTH and 
Cortisol between 900 h and 1600 h 
For reasons of convenience circadian variation was additionally studied 
by measuring ACTH and Cortisol in the morning and afternoon. It is noted that 
in the control patient group 11 out of 15 data and in the groups of patients 
with Gushing disease and Addison's disease all data were taken from rhythm 
studies, whereas m the laboratory control group casual samples were studied. 
97 
• > 
Diurnal variation (9°°-16°0h) 
E 
controls Cushmg s Addisons 
lab coll patients disease disease 
v . 
4** 
^ 
r ^ 
/ 
- / , 
- ^ 
• / - = 
,,f.. 
.,,*. 
• -
* 
t/Ls-ì 
К 
• 
„, 
ч^ 
\ J t -
-^—'' 
ч 
л 
1 - ι 
υ.оо с-об 
fig . і б Variat-Lons -in plasma I-ACTH, B-ACTH and Cortisol between 900 h and 
1600 h. Open airóles point to the patient with substitution, crosses point to 
the patient with a "Sertoli cell only" syndrome in addition to Addison's disease. 
V.3.3.1 I-ACTH 
In fig V.16 the individual plasma I-ACTH, B-ACTH and Cortisol levels at 
900 h and at 1600 h in control subjects, in patients with untreated Gushing's 
disease and in patients with Addison's disease are given. 
In both control groups the mean I-ACTH values decreased significantly 
between 900 h and 1600 h (from 55.3 +_ 30.5 pg/ml to З .З + 17.4 pg/ml for the 
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laboratory collaborators, Ρ <0.05; from 63.9 +_ 28.4 pg/ml to 48.6 +_ 23.6 pg/ 
XX 
ml for the control patients, Ρ <0.05). In 11 out of 13 (85%) laboratory 
collaborators and in 13 out of 15 subjects (87%) in the control patient group 
plasma I-ACTH levels were lower at 1600 h than at 900 h. If we consider only 
the data derived from the rhythm study in 9 out of 11 (82%) patients I-ACTH 
levels proved to be lower than at 900 h. 
In the hospitalized patients with untreated Gushing's disease the mean 
I-ACTH value did not change significantly between 900 h and 1600 h. The 1600 h 
values in these patients ranged from 31 to 325 pg/ml. As is shown in fig V.17 
the 1600 h values were lower in only 8 out of 18 patients (44%). 
In the patients with Addison's disease I-ACTH levels were invariably 
lower at 1600 h than at 900 h (P X X <0.05) with a range varying from 320 to 
5000 pg/ml at 1600 h. The mean relative decrease (28%) in Addison's disease 
throughout the day was similar to that in both control groups (31% for the 
laboratory collaborators; 24» for the control patients). 
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fig v.17 Relative variation of I-ACTH in plasma between 900 h and 1600 h. 
V.3.3.2 B-ACTH 
In both control groups the B-ACTH levels also decreased significantly 
between 900 h and 1600 h from a mean value of 16.5 + 9.5 pg/ml to 13.5 + 7.8 
pg/ml (P <0.05) in the laboratory collaborators and from 19.2 + 13.7 pg/ml 
XX 
to 11.6 +_ 9.9 pg/ml (P <0.01) in the patient control group. The 1600 h values 
in the control subjects ranged from 4.5 to 35 pg/ml (fig V.16). The relative 
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changes m B-ACTH values in all groups of control subjects and patients are 
given in fig .1 . In 10 out of 13 (77%) non-hospitalized laboratory collabo­
rators and 9 out of 9 control patients B-ACTH values at 1600 h were lower than 
at 900 h. 
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fig .1 Relative variation of B-ACTH in plasma between 900 h and 1600 h. 
In the hospitalized patients with untreated Gushing's disease the mean 
B-values at 1600 h (42.5 +_ 38.4 pg/ml) did not differ significantly from the 
900 h value (31.8 +_ 38.6 pg/ml, P X X >0.10). The 1600 h values in these patients 
ranged from 9 to 105 pg/ml. In the patients with untreated Gushing's disease 
only 4 out of 11 B-ACTH values (36%) were lower at 1600 h than at 900 h. 
In all but one of the patients with Addison's disease a diurnal decrease 
occurred. Only in the patient with Addison's disease in combination with the 
"Sertoli cell only" syndrome the B-ACTH value remained virtually unchanged. 
In none of the groups of the control subjects, the patients with Gushing's 
disease or Addison's disease, a statistically significant change in I/B ratio 
was found between 900 h and 1600 h (P X X >0.10,· table V.3). 
Table V.3 
I/B ratio's at 900 h and 1600 h 
900 h 1600 h 
laboratory c o l l . 13 
control patients 9 
patients with Cush.Dis.ll 
patients with Add.Ois. 6 
3.50 ± 1.16 
3.98 ± 1.38 
5.77 ± 2.73 
2.85 ± 1.38 
3.02 ± 0.73 
4.88 ± 2.58 
4.77 ί 2.73 
2.96 ± 0.89 
>0.10 
>0.10 
>0.10 
>0.10 
100 
V.3.3.3 Cortisol 
In both control groups plasma Cortisol significantly decreased between 
XX 
900 h and 1600 h (Ρ <0.01). The relative changes of plasma Cortisol between 
900 h and 1600 h are shown in fig V.19. In 12 out of 13 (921) laboratory 
collaborators as well as in 12 out of 13 patient controls (92%) Cortisol values 
at 1600 h were lower than the 900 h values. 
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fig v.19 Relative variation of Cortisol in plasma between 900 h and 1600 h. 
In the patients with untreated Gushing's disease the mean Cortisol value 
at 1600 h (0.460 +_ 0.188 pmol/l) did not differ significantly from the 900 h 
value (0.456 + 0.239 pmol/l, P X X >0.10). As is shown in fig V.19 in only 10 
out of 21 patients the 1600 h values were lower. If we take a decrease of at 
least 25% (Krieger et al 1971) between 900 h and 1600 h as a criterium, 22 out 
of 26 (85%) control subjects of the present study fulfilled this criterium. 
This percentage is similar to that reported by Krieger et al (1971) who found 
22% of the plasma Cortisol levels to be less than their morning value. In 
Cushmg's disease 4 out of 21 values (19%) were below this 25% criterium, as 
was confirmed in the present study. 
In fig V.20 the relation between plasma Cortisol and both I-ACTH and B-
ACTH at 1600 h in patients with untreated Gushing's disease together with the 
upper control values are depicted. If we compare the I-ACTH and Cortisol levels 
it appears that about 35% of the values are within the normal range. The 900 h 
values of the same subjects on the same day show that the percentage of hormone 
levels falling within the normal range of 900 h was as high as about 60% (cfr 
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correlations of I-ACTH and B-ACTH w i t h Cortisol in Cushing's 
disease at 16°°h 
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fig v.20 The relations of I-ACTH and B-ACTH with Cortisol in plasma of patients 
with Cushing's disease. The broken lines point to the upper values of I-ACTH, 
B-ACTH and Cortisol in plasma of the control subjects at 1600 h. 
fig V.10). If we compare the B-ACTH and Cortisol values in the same way the 
percentage of hormone levels overlapping the normal range appears to be 63% 
for 1600 h and 73% for 900 h. Therefore, the absolute Cortisol and I-ACTH or 
B-ACTH values even at 1600 h do not discriminate completely between euadreno-
corticism and hyperadrenocorticism. 
V.3.3.4 Comparison with literature 
In spite of the occurrence of episodic bursts of both ACTH and Cortisol 
secretion (Hellman et al 1970; Krieger et al 1971), casual measurement of these 
hormones yet can give further information about the pituitary-adrenal gland 
function. Already m 1963 Ney et al using the Lipscomb-Nelson bioassay, found 
that in 10 out of 12 normal subjects the mean 1800 h ACTH values of the group 
were lower than at 600 h. Using radioimmunoassays a similar diurnal decrease 
of ACTH was observed by several other authors (Demura et al 1966; Besser & 
Landon 1968; Berson & Yalow 1968; Matsukara et al 1971; Ichikawa et al 1971). 
Wolfsen et al (1972) - using a radioreceptor assay - also found lower ACTH 
levels in the afternoon. The present study also showed a statistically 
significant decrease of I-ACTH, B-ACTH and Cortisol between 900 h and 1600 h. 
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In patients with Gushing's disease no circadian variation exists (Doe et 
al 1960). Therefore, in these patients the 1600 h plasma ACTH values are also 
expected to occur at random above or below the 900 h values. Summarizing the 
data of fig V.17, V.18 and V.19, we could state that about half of all 1600 h 
I-ACTH, B-ACTH and Cortisol values were below the 900 h values in patients with 
Cushing's disease, whereas in the total control group about 90% of all 1600 h 
values were below the 900 h values. It should be noted again that in these 
studies most of the 900 h and 1600 h values of patients were taken from series 
of diurnal variations. 
Our observations about rhythtnicity of I-ACTH and B-ACTH in patients with 
Addison's disease reconfirm data of Graber et al (1965), who used the Lipscomb-
Nelson assay, and of Besser et al (1971), who used a radioimmunoassay. 
V.3.4 Short-term variation in plasma Immunoreactive ACTH, Bioactive ACTH and 
Cortisol between 900 h and 930 h. 
In order to study the effect of repeated veinous puncture in a short time 
interval two blood samples were taken; the first at 900 h, the second at 930 h 
in a group of collaborators of the laboratory, in the patient control group and 
in patients with Cushing's disease. 
V.3.4.1 Short-term variation in plasma I-ACTH levels. 
The changes in plasma I-ACTH values between 900 h and 930 h are depicted 
m fig V.21. In both control groups I-ACTH levels decreased significantly from 
54.5 + 35.4 pg/ml at 900 h to 39.9 + 26.1 pg/ml at 930 h for the laboratory 
Immunoreactive ACTH at S ^ a n d 9'°(pg/mD 
4 
- N 
^ 
2 0 -
-
10-
^ 
α -
-
Í0 -
" --
1 - ^ . 
\^ 
ЧЙР 
З^ч 
goo дю 
9 0 0 545 bik 
9· ° 399 42 8 
Ρ <001 <005 
c o n t r o l s 
lab cdl patients 
1147 
1090 
> 0 1 
Cushmgs 
disease 
fig v.21 Short-term variation of 
I-ACTH in human plasma between 
900 h and 930 h. 
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collaborators (Ρ <0.01), and from 52.4 +_ 19.1 pg/ml to 42.θ + 21.8 pg/ml 
for the patient control group (P <0.05). In fact, 21 out of 27 I-ACTH values 
(78%) in the total control group were lower at 930 h than at 900 h. 
In contrast, in the group of patients with Gushing's disease the plasma 
I-ACTH levels remained virtually unchanged (114.7 +_ 70.8 pg/ml at 900 h and 
109.0 + 62.0 pg/ml at 930 h; P X X >0.10). Fourteen out of 26 samples (54%) 
showed lower levels at 930 h than at 900 h. 
V.3.4.2 Short-term variation in plasma B-ACTH levels. 
The B-ACTH values are shown in fig V.22. In the laboratory collaborators 
B-ACTH values decreased from 16.1 + 8.7 pg/ml at 900 h to 12.5 + 6.8 pg/ml 
at 930 h (Ρ < 0 . 0 5 ) . In the patient control group B-ACTH levels also decreased: 
from 15.9 + 9.1 pg/ml at 900 h to the lower value of 11.5 +_ 6.2 pg/ml at 930 h 
(P X X <0.05). In fact, 20 out of 25 (80%) B-ACTH levels in the total control 
group were lower at 930 h than at 900 h. 
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fig v.22 Short-term variation of B-ACTH 
in human plasma between 300 h and 930 h. 
The l/B ratio in the whole control group virtually did not change between 
the two sampling times (3.62 + 1.19 at 900 h versus 3.64 + 1.62 at 930 h). 
In the patients with Cushing's disease the mean B-ACTH levels were almost 
identical at 900 h and at 930 h (values: 26.4 +_ 30.0 pg/ml and 26.5 +_ 27.2 
pg/ml respectively). In 10 samples B-ACTH levels were lower at 930 h than at 
900 h. 
As in the control group, no statistically significant change in I/B ratio 
was found between 900 h (5.45 + 2.97) and 930 h (5.71 +_ 2.97) in the patients 
with Gushing's disease. 
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V.3.4.3 Short-term variation in plasma Cortisol levels 
The changes in plasma Cortisol levels between 900 h and 930 h are given 
in fig V.23. The mean plasma Cortisol level in the laboratory collaborators 
decreased from 0.457 + 0.102 pmol/l at 900 h to 0.402 + 0.096 ymol/l at 930 h 
(Ρ <0.01). In the control patient group plasma Cortisol significantly 
decreased as well, from 0.352 +_ 0.143 pmol/l at 900 h to 0.279 + 0.118 pmol/l 
at 930 h (Ρ <0.01). Only on two occasions the plasma Cortisol values were 
higher at 930 h than at 900 h (9%). 
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fig V.2 3 Short-term variation of 
aortisol in human plasma betueen 
900 h and 930 h. 
In the patients with Gushing's disease the plasma Cortisol levels were 
similar at 900 h (0.372 + 0.212 μπιοΐ/ΐ) and at 930 h (0.397 + 0.202 pmol/l; 
xx 
Ρ >0.10). In these patients 14 out of 26 Cortisol levels were lower at 930 h 
than at 900 h. 
V.3.4.4 Comparison of the short-term variation between 900 h and 930 h and the 
circadian variation between 900 h and 1600 h of hormone levels 
In tables V.4 and V.5 data are given about the number of control subjects 
and patients with Gushing's disease showing lower hormone levels at 1600 h and 
930 h than at 900 h. 
It is remarkable that the number of subjects and patients showing a 
decrease between 900 h and 930 h is almost similar to that between 900 h and 
1600 h. In the control subjects about 80% of the 1600 h and 930 h values for 
I-ACTH and B-ACTH were below the 900 h value and 90% of the plasma Cortisol 
levels. In the patients with Cushing's disease about 50% of the I-ACTH, B-ACTH 
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T a b l e V.4 
Percentages and numbers of plasma samples with hormone levels at 1600 h 
below the 900 h levels 
control groups pat ients with 
l a b . c o l l i p a t i e n t s x x Cushing's disease 
I-ACTH 11/13= 84.6% 9/11= 81.8% 8/18= 44.4%a 
B-ACTH 10/13= 76.9% 7/7 = 100.0% 4/11= 36.4%b 
Cortisol 12/13= 92.3% 10/11= 90.9% 10/21= 47.6%c 
casual blood sampling 
blood samples obtained from the circadian rhythm study 
a
 Ρ >0.10 versus the control groups 
Ρ <0.025 versus the pat ient control group and »O.10 versus the lab. c o l l . 
Ρ <0.025 versus the l a b . c o l l . group and <0.05 versus the pat ient control 
group 
T a b l e V.5 
Percentages and numbers of plasma samples wi th hormone levels at 930 h 
below the 900 h levels 
I-ACTH 
B-ACTH 
Cortisol 
lab. 
9/13= 
9/12= 
11/12= 
con 
coll. 
69.2% 
75.0% 
91.7% 
trol groups 
patients 
12/14= 85.7% 
11/13= 84.6% 
13/14= 92.9% 
patients with 
Cushing's disease 
14/26= 53.8%a 
10/22= 45.5%a 
14/26= 53.8%b 
Ρ >0.10 versus control groups 
P+ <0.05 versus p a t i e n t control group and >0.10 versus the l a b . c o l l . 
and C o r t i s o l l e v e l s a t 1600 h and 930 h were below the 900 h va lues . 
For t h i s s i m i l a r i t y of the 930 h and 1600 h values two reasons might be 
considered: f i r s t , the d i u r n a l v a r i a t i o n per se, s t a r t i n g in the ear ly morning 
and, secondly, the inf luence of adaptat ion t o repeated veinous puncture. As 
i s well known from other s t i m u l i of the hypothalamic-hypophyseal-adrenal system, 
m p i t u i t a r y - d e p e n d e n t Cushing's disease an i n t r i n s i c e x t i n c t i o n of such 
s t i m u l i as mentioned above could be expected. 
Surveying these data we might conclude t h a t sampling of blood a t 900 h and 
930 h could be valuable in eva luat ing the p i t u i t a r y - a d r e n a l gland funct ion. 
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V.3.5 Dexamethasone suppression test 
V.3.5.1 I-ACTH 
The results of the suppression of I-ACTH by dexamethasone are shown in 
fig V.24. In 9 out of 10 control subjects I-ACTH precipitously decreased over­
night to an undetectable value (<10 pg/ml) after administration of 1 respecti­
vely 2 mg of dexamethasone at 2300 h the late evening before. 
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Fig V.24 I-ACTH plasma levels in the 
single dose overmight dexamethasone 
suppression test. Limit of detection 
about 10 pg/ml. 
In the patients with pituitary-dependent Cushing's disease the mean plasma 
I-ACTH level virtually remained unchanged: 131.1 + 63.3 pg/ml before dexame­
thasone treatment, 12S.5 + 111.9 pg/ml after 1 mg, and 106.0 + 63.4 pg/ml 
after 2 mg of dexamethasone (P >0.10). In all patients plasma I-ACTH levels 
both after 1 and 2 mg dexamethasone were higher than in the control subjects. 
Together these data confirm the well-known loss of appropriate feedback in 
Cushing's disease. 
The present findings augment data from literature on 1 or 2 mg single dose 
dexamethasone suppression of I-ACTH.In our study all but 1 control subjects 
showed a virtually complete suppression of I-ACTH after 1 mg dexamethasone, 
whereas post-treatment I-ACTH levels in control subjects were invariably lower 
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than in any of the patients with Gushing'Ξ disease. It should be emphasized, 
however, that lack of complete suppression of I-ACTH does not seem pathogno­
monic for the diagnosis of Gushing's disease. Landon & Greenwood (1968) 
administered 2 mg of dexamethasone the night before and found a detectable 
I-ACTH in 1 out of 14 control subjects, whereas Krieger et al (1979) reported 
detectable values in 3 out of 6 normal subjects after 1 mg of dexamethasone. 
V.3.5.2 B-ACTH 
To our knowledge no reports exist about B-ACTH in normal subjects after 
single dose overnight dexamethasone administration. As was noted earlier for 
I-ACTH, overnight administration of 1 mg respectively 2 mg dexamethasone 
decreased B-ACTH to undetectable B-ACTH values in 9 out of 10 control subjects 
(fig V.25). In one control subject both I-ACTH and B-ACTH remained detectable. 
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fig V.25 B-ACTH plasma levels ъп the single dose overmght dexamethasone 
suppression test. Limit of detection about 4 pg/ml. 
In the patients with Gushing's disease the mean B-ACTH level was 47.4 
;+ 29.θ pg/ml before dexamethasone treatment, 44.5 + 42.2 pg/ml after 1 mg, and 
24.θ + 11.9 pg/ml after 2 mg. In all patients with Cushmg's disease B-ACTH 
levels both after 1 and 2 mg dexamethasone were higher than in the control 
subjects. 
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The mean I/B ratio in patients with Gushing's disease virtually remained 
unchanged before and after 1 or 2 mg dexamethasone (4.09 + 2.10 before treat­
ment, 4.14 +_ 2.14 after 1 mg, and 4.97 + 0.93 after 2 mg; Ρ >0.10 between all 
values) . 
V.3.5.3 Cortisol 
The effect of dexamethasone administration on plasma Cortisol is shown 
m fig 4.26. All plasma Cortisol values were below 0.07 ymol/l after 
administration of 1 mg dexamethasone overnight. Administration of 2 rag of 
dexamethasone did not decrease the plasma Cortisol level any further. 
Dexamelhasone suppression 
fig V.26 Cortisol plasma levels inthe 
singlp dose overnight dexamethasone 
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In the patients with Gushing's disease Cortisol levels after 1 mg 
dexamethasone were invariably higher than 0.1 ymol/l (mean Cortisol level 
0.572 + 0.232 ymol/l before treatment, and 0.430 •*_ 0.300 pmol/l after 1 mg; 
Ρ >0.10). After administration of 2 mg the mean plasma Cortisol level did 
not change significantly either (0.384 + 0.287 |imol/l; Ρ >0.10 versus basal 
level). In three patients plasma Cortisol levels after two mg dexamethasone 
were higher than before treatment, whereas in two of these patients the 2 mg 
dexamethasone Cortisol level exceeded the 1 mg dexamethasone value. It should 
be emphasized that in 1 patient with Gushing's disease plasma Cortisol was 
below the arbitrarily chosen value of 0.1 ymol/1. In this patient, however, the 
suppression of I-ACTH and B-ACTH was not complete. 
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Chapter VI 
I-ACTH AND B-ACTH RESPONSE TO INSULIN-INDUCED HYPOGLYCAEMIA 
VI.1 Introduction 
It is generally accepted that plasma ACTH levels measured by 
radioimmunoassay are higher than those measured by bioassay (chapter IV) . 
In this chapter the relation of I-ACTH to B-ACTH will be described and 
discussed in situations in which endogenous ACTH levels change rapidly in 
control subjects as a consequence of insulin-induced hypoglycaemia. 
The insulin tolerance test has been in use for as long as 40 years as 
a test of hypothalamo-pituitary-adrenal function (Fraser et al 1941), an 
msulin-mduced hypoglycaemia being followed by an increase of plasma Cortisol 
after a preceding rise in plasma I-ACTH (Berson & Yalow 1968). Data on B-ACTH 
during insulin-induced hypoglycaemia are scarce in spite of the availability 
of very sensitive bioassays (isolated adrenal cell assays, Sayers et al 1971a; 
Lowry et al 1973; and cytochemical assays, Chayen et al 1972). Fleisher et 
al (1974), using both a radioimmunoassay and a cytochemical bioassay, found 
that after insulin-induced hypoglycaemia the mean I-ACTH to B-ACTH ratio further 
increased. After reaching the highest ACTH concentration at 60 minutes this 
ratio remained virtually unchanged during the next 30 minutes. On the other 
hand Liotta & Krieger (1975) - using the isolated rat adrenal cell system as 
a bioassay - showed preliminary data suggesting a further increase of the 
I/B ratio between 30 and 90 minutes after reaching both the I-ACTH and 
B-ACTH peak. 
This study demonstrates the occurrence of a biphasic response in I/B ratio 
of endogenous ACTH in normal subjects during insulin-induced hypoglycaemia: 
the expected decrease of B-ACTH relative to I-ACTH was preceded by a temporary 
increase. 
VI.2 Materials and Methods 
Endogenous ACTH stimulation as induced by insulin-induced hypoglycaemia 
in control subjects 
In twelve women without pituitary-adrenal gland dysfunction, hypoglycaemia 
was induced by intravenous injection of 0.1 Ü insulin/kg body weight. The 
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hypoglycaemia stimulus was considered adequate if the plasma glucose levels 
fell below 2 mmol/l. In all subjects the test was started between 900 and 
1000 h. Blood samples were drawn twice before (-15 and 0 minutes) and at 20, 
30, 45, 60 and 90 minutes after insulin injection. Blood was collected and 
plasma obtained as described before. In 7 other women without pituitary-
adrenal gland axis dysfunction blood samples were drawn in the same period 
of the day at only time zero (between 900 and 1000 h) and at 20, 30 and 60 
minutes after injection of physiological saline. 
Assays 
ACTH and Cortisol assays were performed as described above. Blood glucose 
was measured by Autoanalyzer. 
Statistics 
Statistical analysis was performed by using Friedman's non-parametric 
analysis of variance (P), Wilcoxon's signed rank test (P ), and Spearman's 
rank correlation test (P ). Correlation coefficients are denoted by r. Unless 
otherwise stated the mean values were given +_ SD. All sapiples from one subject 
were measured in the same assay. 
Half-lives 
Rough estimates of biological and immunological half-life of ACTH were 
made by plotting plasma ACTH against time and constructing a straight line 
to fit the points (Matsuyama et al 1972a). 
VI.3 Results and Discussion 
The effect of insulin-induced hypoglycaemia on plasma I-ACTH, B-ACTH and 
Cortisol levels and on the l/B ratio are summarized in table VI.1 and fig VI.1. 
χ 
No statistically significant difference (P >0.10) has been found between the 
mean plasma ACTH levels at -15 and 0 minutes, neither in the radioimmunoassay 
(t= -15: 21.3 + 6.5 pg/ml and t= 0: 23.6 + 11.0 pg/ml), nor in the bioassay 
(t= -15: 6.7 + 2.8 pg/ml and t= 0: 7.1 + 3.4 pg/ml). In each subject a distinct 
increase in both I-ACTH and B-ACTH levels was observed 30 minutes after the 
insulin injection i.e. 10 minutes after the onset of hypoglycaemia (I-ACTH: 
104.3 + 80.5 pg/ml, P X <0.001 versus t=0 and B-ACTH: 62.3 + 66.6 pg/ml, 
Ρ <0.001 versus t=0). After that the mean I-ACTH and B-ACTH plateaued until 
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fig vi.l Individual (- -) and mean (· -) response of plasma 
glucose, I-ACTH, B-ACTH and aortisol and of the I/B ratio in control subjects 
upon insulin administration. 
113 
Table VI.l 
Simultaneous plasma hormone p r o f i l e s during insul in-induced hypoglycaemia 
in an example subject 
time (mm) 
-15 0 ZO 30 45 60 90 
I-ACTH (pg/ml) 19 23 16 67 195 128 55 
B-ACTH (pg/ml) 5 10.5 5 34 99 33 5 
I/B ratio 3.80 2.19 3.20 1.97 1.97 3.88 11.00 
Cortisol (umol/l) 0.39 0.38 0.32 0.34 1.07 1.26 0.96 
45 minutes and then gradually fell. The I-ACTH levels remained significantly 
elevated until the end of the test (t=90: 43.7 +_ 22.2 pg/ml versus t-0, P X 
<0.05), whereas the bioactive levels returned to baseline values at t=90 
minutes (6.8 +_ 3.2 pg/ml versus t=0, Ρ >0.10). Table VI.2 shows that at most 
sampling times the individual I-ACTH and B-ACTH levels were significantly and 
tightly correlated. 
The mean I/B ratios at -15 and 0 minutes did not differ significantly 
(3.43 +_ 1.19 versus 3.45 +_ 1.08, Ρ >0.10). Insulin-induced hypoglycaemia 
elicited a biphasic response in the I/B ratio (P <0.001): initially the mean 
ratio decreased from 3.45 + 1.08 at t=0 minutes to a lowest value of 1.98 + 
0.51 at 30 minutes (P <0.01). The 30 minutes value was also significantly 
lower than the 20 minutes value (3.32 +_ 0.66, Ρ <0.01). After that the mean 
ratio gradually rose (P <0.005) from 1.98 +_ 0.51 at 30 minutes to 2.69 + 1.08 
at t=45 minutes, 4.19 +_ 1.57 at 60 minutes (P X <0.01 vs 30 minutes) and 6.54 +_ 
2.55 at 90 minutes (P <0.01 vs 30 minutes). Only the 90 minutes value was 
significantly higher than the value at time zero (P <0.01). 
The effects of injection of physiological saline in control subjects 
on plasma I-ACTH,B-ACTH and Cortisol as well as on the I/B ratio are shown 
in fig VI.2. The Cortisol levels showed the downward trend as presumably 
caused by the diurnal rhythmicity (P <0.005). The I-ACTH and B-ACTH levels 
did not change significantly during the test nor did the mean I/B ratio 
(I/B ratio at t=0: 3.22 +_ 1.28; t=20: 3.45 + 0.70; t=30: 3.39 + 1.20 and t=60: 
3.20 + 0.79; Ρ >0.10). 
As discussed earlier (chapter IV s V) the bioactive ACTH values in the 
subjects studied are lower than the immunologically assayed ACTH values under 
basal circumstances. The hypoglycaemic stimulus immediately induced a release 
of ACTH. At the same time a 40% decrease of the I/B ratio from 3.45 at t=0 to 
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Table VI.2 
Correlations of plasma I-ACTH, B-ACTH and Cortisol during insulin induced 
hypoglycaeraia 
time η 
I-ACTH vs B-ACTH 
P+ 
I-ACTH vs Cortisol 
P+ 
B-ACTH vs Cortisol 
P+ 
-15 
0 
20 
30 
45 
60 
90 
9 
12 
12 
11 
11 
11 
10 
0.442 
0.823 
0.816 
0.909 
0.664 
0.721 
0.700 
ns 
<0.005 
<0.005 
<0.001 
<0.025 
<0.025 
<0.025 
0.504 
-0.273 
-0.461 
0.460 
0.209 
0 755 
0.873 
ns 
ns 
ns 
ns 
ns 
<0.01 
<0.001 
0.225 
-0.132 
-0.593 
0.477 
-0 176 
0.464 
0 600 
ns 
ns 
<0.05 
ns 
ns 
ns 
<0.05 
1.98 at t=30 minutes was observed which was transient and was followed by an 
increase of this ratio far exceeding the pre-treatment value (fig VI.1). After 
reaching a plateau the mean B-ACTH level rapidly declined - with a roughly 
estimated half-life of 11.6+1.8 m m - so that at t=90 minutes the B-ACTH 
level did not differ further from the baseline value. But in contrast to 
B-ACTH, I-ACTH disappeared more slowly - half-life being 19.6 +_ 5.6 min - so 
that the mean I-ACTH level at 90 minutes was still higher than the pre-treat­
ment value. The most plausible explanation for this difference in disappearance 
rates for B-ACTH and I-ACTH is that at the decay phase ACTH metabolites arise 
which are still immunoassayable but not bioassayable. 
Only two reports exist dealing with the effect of insulin-induced 
hypoglycaemia on the I-ACTH, and B-ACTH levels in plasma. Fleisher et al 
(1974) observed a rise of the I/B ratio 60 minutes after the insulin injection, 
but did not find a decrease of the l/B ratio. It should be noted that these 
authors used the cytochemical assay as a bioassay and collected blood at 
half hour intervals. Liotta & Krieger (1975), using isolated adrenal cells 
for bioassay, did not find a significant decrease either of the I/B ratio 
in an admittedly small group of subjects. 
In view of the time course required for ACTH to stimulate Cortisol 
production and in view of the differences of the half-lives of both compounds, 
the quantitative relation between B-ACTH and I-ACTH on one hand and Cortisol 
on the other hand was expectedly poor, confirming data of Daly et al (1973) 
and Krieger & Allen (1975). 
Analogous to the hypoglycaemia-induced ACTH release in normal subjects 
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0
 0 20 30 60 mm 
Τ sham injection 
fig vi.2 The effect of injection of physiological saline upon the individual 
( ) and mean ( ) response of plasma I-ACTH, B-ACTH and corti-
sol and of the I/B ratio in control subjects. 
another experiment was performed in our laboratory in a sub-group of patients 
with Gushing's disease, who evinced a paradoxical rise of plasma Cortisol 
(Pieters et al 1979) as well as ACTH (Pieters et al, in preparation) after a 
non-specific stimulus such as TRH and/or LHRH. Remarkably a similar transient 
decrease of the l/B ratio was observed in these patients. It is striking that 
in this condition release of B-ACTH and I-ACTH from the pituitary gland was 
also accompanied by a transient decrease of the I/B ratio again by about 
40% (from 3.27 + 0.58 at t=0 minutes to 1.Θ5 + 0.66 at t=10 minutes after the 
ACTH stimulus). 
Together the data in the ACTH stimulation tests in normal subjects and 
m patients with Gushing's disease indicate that under basal circumstances 
ACTH levels determined by radioimmunoassay overestimated the levels measured 
by bioassay. 
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SUMMARY 
In this thesis the development of a biological as well as of a radio-
immunochemical method for the determination of ACTH in human blood has 
been described. The study included the comparison of biological and 
immunological ACTH concentrations in blood under different physiological, 
pathological and experimental conditions. 
The extensive literature data concerning characteristics of ACTH and 
its regulation were briefly surveyed in the general introduction (chapter I). 
The aim of the study and the reason for choosing the isolated adrenal cell 
system as a bioassay have also been explained in this chapter. 
In chapter II the development and the evaluation of the bioassay has 
been described. Cells were isolated from the adrenal tissue by collagenase 
disruption and suspended in buffer. In order to obtain an as sensitive assay 
as possible several modifications in the original assay - as reported in 
literature - were applied and evaluated. The most important improvements, which 
have resulted in a gam in sensitivity, were the purification of the isolated 
adrenal cells - by passage through a 5% BSA layer - followed by a pre-incubation 
of these cells. The gain in sensitivity was not the same for all ACTH peptides 
tested. After purification and pre-in<5ubation of the cells, which involves 
presumably a removal and/or deactivation of ACTH-attacking enzymes, it appeared 
1-24 
that the gain in sensitivity of the assay was more pronounced for ACTH 
1-39 1-32 
than for the complete molecule hACTH or for hACTH . This finding is in 
agreement with the hypothesis that the COOH-terminal part of ACTH protects 
the molecule to a certain degree especially against enzymatic degradation and 
at the same time inhibits the activity of the peptide itself by interaction with 
the receptor. Our study suggests that it is highly probable that these 
characteristics are caused by the sequence 25-32 of the molecule. 
In addition to the well-known bioactive center of the molecule, the sequence 
4-10, another centre in the peptide, within the sequence 11-19, has been found 
to induce corticosteroidogenesis as well. 
1-39 
Using the synthetic hACTH as the standard the lowest limit of 
1-24 detection appeared to be 0.85 ¿0.47 pg/ml and using ACTH as the standard 
the lowest limit was 0.20 + 0.10 pg/ml. The ED50 in the assay proved to be 
1-39 1-24 
18.0 + 6.9 pg/ml for hACTH and 2.3 + 0.8 pg/ml for ACTH (4.0 + 1.5 
1-39 1-24 
fmol/ml for hACTH and 0.8 + 0.3 fmol/ml for ACTH ). The precision of 
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the assay - expressed as the quotient of the standard deviation and the slope 
of the regression line of the standard curve - was 0.046 + 0.016. 
Chapter III describes the development of a sensitive radioimmunoassay for 
ACTH. The commercially obtained antibody was directed against the sequence 
17-24. ACTH was lodinated by way of an enzymatic procedure using lactoperoxidase. 
The tracer was purified by extraction with glass powder and immediately before 
addition in the assay also by column chromatography with Sephadex G 50. The 
free hormone was separated from the antibody-bound hormone with the use of 
plasma coated charcoal. The sensitivity of the assay proved to be 8.8 + 2.8 
1-39 
pg hACTH /tube. 
Chapter IV deals with the evaluation of the determination of ACTH in blood 
of normal subjects with aid of the assays described in chapter II and Ііт. A 
direct measurement of ACTH in plasma was impossible due to interfering 
substances present in the plasma. Therefore, an extraction procedure has been 
developed for a reliable separation of ACTH from the interfering plasma 
substances. Several glass powders were tested, of which Vycor proved to be the 
only extractant useful for the measurement of ACTH in the bioassay and the 
radioimmunoassay. Dilutions of plasma extracts showed a parallelism with the 
standard curves both in radioimmunoassay and in bioassay. The mean intra-assay 
coefficient of variation ranged - dependent on the concentration of ACTH in 
plasma - in the radioimmunoassay from 6.3 to 6.5% and in the bioassay from 
7.2 to 10.9%. The mean inter-assay coefficients varied in the radioimmunoassay 
from 10.4 to 12.3% and in the bioassay from 10.5 to 14.9%. The lowest detectable 
concentration of ACTH in plasma in the bioassay amounted to about 3.5 pg/ml 
and in the radioimmunoassay to about 10 pg/ml. It has been found that various 
standards show different responses both in the radioimmunoassay and in the 
bioassay. This implies that the standard to be chosen would strongly influence 
the height of the ACTH values measured. Much more is this true for ratios 
I-ACTH over B-ACTH when in each of these assays different standards would be 
1-39 
employed. For this and other reasons synthetic hACTH was used as the 
standard in both the assays. Using this standard in 17 normal subjects at 
900 h in the morning a mean I-ACTH concentration of 48.7 +_ 29.4 pg/ml plasma 
was found, and a mean B-ACTH concentration of 15.1 j^  8.6 pg/ml plasma. The 
mean l/B ratio amounted to 3.28 +_ 1.09. These values point to the fact that 
only a part of I-ACTH is bioactive. This may be due to circulating ACTH meta­
bolites which are recognized by the antibody but have an only very low bio-
activity. As a result a dichotomy between the I-ACTH and B-ACTH plasma values 
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was observed. Τη spite of such dichotomy, I-ACTH values showed a correlation 
with B-ACTH values which reached a high statistical significance, indicating 
the usefulness of measuring ACTH by radioimmunoassay which for practical 
considerations has been chosen by many laboratories already. 
The results of the clinical studies are described in chapter V. It 
appeared that the mean basal plasma concentrations as well as the ranges of 
I-ACTH, B-ACTH and Cortisol in the control group of normal sub]ects yielded 
about the same values as in a control group of patients without clinical or 
biochemical evidence of disturbances in the pituitary-adrenal gland axis. The 
group of patients with untreated pituitary Gpendent Cushing's disease had 
significantly higher mean plasma levels for I-ACTH, B-ACTH and Cortisol than 
both control groups. However, most of these values showed a wide overlap 
with the control levels. As might be expected the patients who had been treated 
for Cushing's disease by bilateral adrenalectomy and were off substitution 
therapy for at least 24 hours, had higher mean plasma ACTH levels than patients 
with Cushing's disease before treatment; in the patients treated and on substi­
tution plasma ACTH levels were not significantly different from those of untreated 
patients with Cushing's disease. In the patients with Nelson's syndrome and in the 
patients with Addison's disease without substitution for at least 24 hours the 
mean plasma ACTH level was higher than in both control groups as well as in 
the group of patients with untreated Cushing's disease. No significant dif­
ference in the I/B ratio was found between both control groups. Patients with 
Cushing's disease showed a slightly higher l/B ratio than the normal subjects. 
After bilateral adrenalectomy the I/B ratio was no longer different from both 
control groups. Remarkably, the I/B ratio was significantly lower in the patients 
with Addison's disease as compared to that in the patients with Cushing's di­
sease, but not lower than in the control subjects. In all groups studied a tight 
correlation was found between I-ACTH and B-ACTH. As was mentioned above the plas­
ma levels of I-ACTH, B-ACTH and Cortisol in patients with Cushing's disease 
showed a wide overlap with control subjects. Measuring both ACTH and Cortisol in 
the same plasma samples it appeared that as many as 60% of the patients with 
Cushing's disease still had "normal" hormone levels. This indicates that such 
measurement in blood, collected at 900 h only, is of limited value for the diag­
nosis of Cushing's disease. The diurnal variation of the plasma hormone levels 
was studied m samples which had been collected at time intervals of 4 hours 
during the day. In the control patient group a circadian rhythm could be detec­
ted for I-ACTH, B-ACTH and Cortisol. At 900 h the values were at their highest 
after which time these hormones were found to decrease and to reach their lowest 
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level at midnight. No such variations could be found in the patients with 
Cushing's disease. The I/B ratio did not show a circadian rhythmicity neither in 
the control patient group, and nor in the patients with Cushing's disease. A com-
parison of all values brought out that the plasma Cortisol level is most valuable 
for discriminating for the diagnosis Cushing's disease. 
For reasons of convenience the variation of the hormone plasma levels were 
studied at 900 h and 1600 h as well. Although the mean plasma I-ACTH, B-ACTH 
and Cortisol levels were significantly lower at 1600 h than at 900 h in both 
control groups, individual values were higher at 1600 h than at 900 h in some 
control subjects. In the patients with Cushing's disease the 1600 h values were 
not significantly different from the 900 h values: the number of lower values 
almost equalled the number of higher values. In the patients with Addison's 
disease all I-ACTH levels and 5 out of 6 B-ACTH levels were lower at 1600 h 
than at 900 h. 
In none of the groups studied a significant difference in the I/B ratio could 
be detected between the 1600 h and 900 h values. 
It appeared that the plasma I-ACTH, B-ACTH and Cortisol levels in the 
control groups were significantly lower at 930 h than at 900 h. In the patients 
with Cushing's disease no such short-term variation was observed. In none of 
the groups studied a statistically significant change in I/B ratio was found 
in this time interval. The variations in the hormone levels found between 900 h 
and 1600 h were also found between 900 h and 930 h. The question arises whether 
this short-term variation is caused by the diurnal biological clock or by a 
repeated veinous puncture. If the former is true, investigation of diurnal 
rhythmicity of ACTH and Cortisol could be made more convenient by blood 
sampling in the morning at half hour intervals. If this short-term 
variation is a reflection of the diurnal rhythmicity investigation of this 
circadian variation could be made more convenient for practical reasons. 
Overnight single dose dexamethasone administration decreased ACTH levels 
to not detectable levels in 9 out of 10 control subjects, whereas all ACTH 
and Cortisol levels were much lower than the day before. In the patients 
with Cushing's disease all I-ACTH and Cortisol values were higher than in the 
control subjects. 
In chapter VI the relation between I-ACTH and B-ACTH was studied in 
control patients during insulin-induced hypoglycaemia. As expected a rapid 
increase of ACTH occurred about 10 minutes after the hypoglycaemia. Maximal 
ACTH levels were detected at 30 and 45 minutes after insulin administration. 
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Thereafter the ACTH levels decreased, B-ACTH disappearing faster than I-ACTH. 
Remarkably, the I/B ratio decreased (1.9Э) at rising ACTH levels. After 
reaching the maximal ACTH value the I/B ratio rose significantly to a value 
(6.54) exceeding the pre-treatment value (4.35). This effect might be explained 
as follows: in conditions in which ACTH is released the proportion of B-ACTH 
to I-ACTH increases. However when ACTH is decreasing after activation by 
hypoglycaemia the proportion of I-ACTH increases largely. This increase of 
I-ACTH relative to B-ACTH can be explained by a lower half-life of B-ACTH as 
compared to that of I-ACTH. 
The results in this thesis can be summarized as follows 1) determination of 
ACTH by radioimmunoassay gives higher ACTH values than determination by bio-
assay. 2) close correlation between the values obtained by both assays both 
under normal and pathological conditions makes ACTH determination by 
radioimmunoassay as valuable as determination by bioassay for clinical 
diagnostic purposes. 3) the specific value of biological determination only 
becomes evident in conditions in which ACTH release from the pituitary gland 
is stimulated; under these circumstances increases of Cortisol levels in 
blood are always preceded by a transient increase of bioactive ACTH relative 
to immunoreactive ACTH. 
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SAMENVATTING 
In dit proefschrift is de ontwikkeling van een biologische en een 
radioimmunologische meetmethode ter bepaling van ACTH concentraties in 
humaan bloed beschreven. Het onderzoek omvatte de vergelijking van concentra-
ties van immunologisch ACTH met die van biologisch actief ACTH in bloed onder 
verschillende physiologische, pathologische en experimentele omstandigheden. 
De omvangrijke literatuurgegevens met betrekking tot een aantal eigen-
schappen van ACTH en diens gereguleerde afgifte uit de hypophyse zijn op 
beknopte wijze behandeld in de inleiding (hoofdstuk I). Hierin wordt ook inge-
gaan op het doel van de studie en wordt tevens een verantwoording gegeven voor 
de keuze van de gebezigde biologische meetwijze. 
In hoofdstuk II volgt een uitvoerige beschrijving en evaluatie van de 
bioassay van ACTH zoals deze ontwikkeld werd. Met behulp van collagenase 
werden cellen geïsoleerd uit bijnierweefsel en vervolgens gesuspendeerd in 
een buffer. Teneinde een zo gevoelig mogelijke meetmethode te verkrijgen is een 
dantal wijzigingen in de oorspronkelijke assay - zoals deze in de literatuur het 
meest beschreven is - aangebracht en vervolgens getoetst. De belangrijkste 
verbeteringen die hebben geleid tot winst in gevoeligheid betroffen de zuivering 
van de geïsoleerde bijniercellen - door passage door een 5% BSA laag - gevolgd 
door een pre-incubatie van deze cellen. De winst in gevoeligheid ten gevolge 
van deze combinatie van zuivering en pre-incubatie bleek niet voor alle 
ACTH-peptiden even groot. Na zuivering en pre-incubatie, waardoor waarschijn-
lijk eiwitsplitsende enzymen worden verwijderd, was de winst in gevoeligheid 
1-24 1-39 
van de assay groter voor ACTH dan voor het volledige hormoon hACTH 
1-32 
of voor hACTH . Dit is in overeenstemming met bestaande hypothesen die aan 
het COOH-terminale deel van ACTH zowel een beschermende functie toeschrijven met 
name tegen enzymatische afbraak als ook een remmende functie met betrekking 
tot de interactie van de betreffende peptiden met de receptor. Onze studie 
heeft aannemelijk gemaakt dat deze functies op rekening komen van de sequentie 
25-32. 
Wat betreft de inductie van de synthese van corticosteroiden werden aanwijzingen 
verkregen dat niet alleen de sequentie 4-10 maar ook de sequentie 11-19 hiertoe 
in staat is. 
Bij de ontwikkeling van de biologische meetmethode werd, bij gebruik maken 
1-39 
van synthetisch hACTH als standaard, een onderste gevoeligheidsgrens 
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vastgesteld van О, 85 ¿ О, 47 pg/ml en, bij gebruik maken van ACTH als 
standaard, van 0,20 + О, 10 pg/ml. De ED50 in de bepaling bleek 18,0 + 6,9 
1-39 1-24 
pg/ml te bedragen voor hACTH en 2, 3 + O, O pg/ml voor ACTH . De precisie 
van de assay - op de gebruikelijke wijze uitgedrukt als het quotient var 
standaarddeviatie en helling van de regressieli]n van de standaardcurve 
was 0,046 +_ 0, 016. 
Hoofdstuk III beschrijft de ontwikkeling van een gevoelige radioimmuno­
assay voor ACTH. Hierbij werd gebruik gemaakt van een in de handel verkrijg­
baar antilichaam dat gericht is tegen de aminozuur-sequentie 17-24. Voor het 
bereiden van met radioactief jodium gemerkt ACTH werd een enzymatische proce­
dure toegepast gebruik makend van lactoperoxidase. Het aldus gejodeerde ACTH 
werd vervolgens gezuiverd door extractie met glaspoeder en ббг elke bepaling 
ook nog via kolomchromatografie met Sephadex G-50. Het vrije ACTH werd 
gescheiden van het aan antilichaam gebonden ACTH met behulp van met plasma 
behandelde koolstof. De gevoeligheid van de methode bleek 8,8 + 2,8 pg 
1-39 hACTH per buis te bedragen. 
Hoofdstuk IV behandelt de problemen die bij het meten van ACTH in bloed 
van normale proefpersonen met behulp van in hoofdstuk II en III beschreven 
methoden aan het licht traden. Een directe meting van ACTH in plasma bleek 
niet mogelijk, gezien de storingen door factoren uit het plasma zelf. Daarom 
werd een extractie-methode ontwikkeld waarmee ACTH betrouwbaar kan worden ge­
scheiden van storende bestandddelen m het plasma. Bij dit onderzoek werden 
een aantal soorten glaspoeders getest, waarvan als enige Vycor zowel in de 
bioassay als in de radioimmunoassay bevredigende resultaten te zien gaf. 
Verdunningen van plasma extracten gaven zowel in de biologische als in de 
radioimmunologische bepaling "parallelle" resultaten. De reproduceerbaarheid 
binnen één meetserie varieerde, afhankelijk van de concentratie ACTH in het 
plasma, voor de radioimmunoassay van 6,3 tot 6,5% en voor de bioassay van 
7,2 tot 10,9%. Tussen de verschillende meetsenes waren deze waarden voor 
de radioimmunoassay 10,4 en 12,3% en voor de bioassay 10,5 en 14,9%. De mini-
maal te detecteren hoeveelheid ACTH bleek bij de biologische meting ongeveer 
3,5 pg/ml plasma en bij de radioimmunologische meting ongeveer 10 pg/ml plasma 
te bedragen. 
Uit het onderzoek bleek dat de keuze van de standaard een grote invloed 
heeft op de verhouding van de gemeten hoeveelheid I-ACTH (immunoreactief ACTH 
tot B-ACTH (bioactief ACTH). Uitgaande van verschillende standaarden werden 
verschillende I-ACTH/B-ACTH (I/B) ratio's gevonden. Gebruik makend van synthe-
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txsch hACTH als standaard werden bij 17 normale proefpersonen te 900 uur 
's morgens een gemiddelde I-ACTH concentratie gevonden van 48,7 + 29,4 pg/ml 
plasma en een B-ACTH concentratie van 15,1 +_ 8,8 pg/ml. De gemiddelde l/B ratio 
bedroeg 3,28 +_ 1,09. De vermelde waarden suggereren dat slechts een deel van 
I-ACTH biologische activiteit bezit. 
De resultaten van klinische studies zijn besproken in hoofdstuk V. Het 
bleek dat de gemiddelde basale plasma concentraties evenals de spreidingsbreedte 
voor I-ACTH/ B-ACTH en Cortisol bi] normale proefpersonen te 900 uur 's morgens 
ongeveer dezelfde waarden bereikten als die bij een controle groep van patiënten 
zonder stoornis in de hypophyse-bijnier as. De groep van patiënten met een 
onbehandelde hypophyse-afhankelijke ziekte van Cushing hadden significant ho-
gere gemiddelde waarden voor plasma concentraties van I-ACTH, B-ACTH en corti-
sol dan beide controle groepen. Niettemin was er geen scherpe scheiding tussen 
de waarden in belde groepen voor het merendeel van de gemeten spiegels. Volgens 
verwachting hadden patiënten, die waren behandeld voor de ziekte van Cushing 
door middel van bilaterale bijnierextirpatie en die gedurende tenmmsfce 24 uur 
niet gesubstitueerd waren met corticosteroiden, gemiddeld hogere plasma ACTH 
spiegels dan patiënten met de ziekte van Cushing vóór de behandeling; bij de 
groep van behandelde patiënten die wel corticosteroiden gebruikten bleken de 
ACTH concentraties niet te verschillen van die bi] de groep van patiënten met 
een onbehandelde ziekte van Cushing. De patiënten met een syndroom van Nelson 
hadden ACTH spiegels die veel hoger lagen dan die van alle andere groepen. 
Patienten met de ziekte van Addison, zonder substitutie tijdens tenminste 24 
uur, hadden gemiddeld hogere plasma ACTH spiegels dan de personen in de beide 
controle groepen en de patiënten met de ziekte van Cushing die niet waren 
behandeld. 
Tussen de beide controle groepen werd geen significant verschil gevonden 
in de I/B ratio. Patienten met de ziekte van Cushing hadden echter gemiddeld 
een hogere I/B ratio dan normale proefpersonen. Na bilaterale adrenalectomie 
was de I/B ratio niet verschillend van die van de controle groepen. Opvallend 
was dat de gemiddelde I/B ratio bij de patiënten met de ziekte van Addison 
lager was dan die bij de patiënten met de ziekte van Cushing maar niet lager 
dan in de controle groepen. In alle bestudeerde groepen bestond er een hoge 
correlatie tussen I-ACTH en B-ACTH waarden. 
Boven is reeds vermeld dat de spiegels van I-ACTH, B-ACTH of Cortisol bi] een 
groot deel van patiënten met de ziekte van Cushing niet verschillen van die in 
de controle groepen. Ook indien men zowel ACTH als Cortisol in hetzelfde 
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bloedmonster meet blijkt dat +_ 60% van de patiënten met de ziekte van Gushing 
"normale" spiegels in bloed te hebben. Dit geeft aan dat dergelijke metingen 
in bloed dat rond 900 uur ' s morgens werd verzameld van geringe waarde zijn 
voor de diagnose ziekte van Gushing. 
De diurnale variaties in de hormoon spiegels werden bestudeerd in bloed 
dat in een etmaal om de 4 uur werd afgenomen. De controle personen toonden 
een dag/nacht rhythme voor 1-ACTH, B-ACTH en Cortisol. Bij deze proefopstel-
ling werden om 900 uur 's morgens de hoogste waarden gevonden en te midder-
nacht de laagste. Voor de groep van patiënten met de ziekte van Gushing 
konden dergelijke rhythmen voor plasma I-ACTH, B-ACTH of Cortisol niet worden 
aangetoond. De I/B ratio gaf noch voor de patiënten met de ziekte van Gushing 
noch voor de controle groep een circadisch patroon te zien. Bij vergelijking 
van alle verkregen gegevens bleek dat de meting van Cortisol in bloed afge-
nomen omstreeks middernacht het meest discriminerend is voor het stellen van 
de diagnose ziekte van Gushing. 
Bestudering van de verandering in de hormonale bloedspiegels tussen 
900 uur en 1600 uur gaf weliswaar een significant lager gemiddelde waarde 
in I-ACTH, B-ACTH en Cortisol om 1600 uur te zien m beide controle groepen, 
individueel echter werden ook enkele hogere waarden gevonden. In de groep van 
patiënten met de ziekte van Cushing waren de gemiddelde hormonale waarden 
om 1600 uur niet significant verschillend van de waarden om 900 uur 's morgens: 
ongeveer evenveel waarden om 1600 uur waren hoger dan de waarden om 900 uur 
als lager. In de groep van patiënten met de ziekte van Addison waren alle 
I-ACTH plasma concentraties om 1600 uur lager dan die om 900 uur. Dit gold 
ook voor B-ACTH in 5 van de 6 onderzochte patiënten. 
In geen van de bestudeerde groepen werd een significant verschil gevonden 
tussen de ochtend- en middagwaarde van de I/B ratio. 
Bij metingen van de hormoon spiegels in bloed 's morgens in een tijds-
interval van een half uur bleken de waarden gemeten om 930 uur in beide 
controle groepen significant lager dan die te 900 uur. Bij de ziekte van 
Cushing echter werd een dergelijke significante verandering niet waargenomen. 
In geen van de bestudeerde groepen veranderde de l/B ratio in dit korte tijds-
interval. 
De veranderingen die werden waargenomen in de hormoon spiegels in bloed 
tussen 900 en 1600 uur kwamen kwalitatief overeen met die tussen 900 en 930 
uur. Het is de vraag of deze laatste variatie ook op rekening van de diurnale 
biologische klok moet worden geschreven, of toch een gevolg is van het effect 
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van herhaalde vena-puncties. Het is wellicht van belang hiernaar onderzoek 
te verrichten. Indien immers de variatie ook als uiting van het diurnale 
rhythme beschouwd mag worden zou het onderzoek daarnaar in de prakti]k sterk 
vereenvoudigd kunnen worden. 
Een van de onderzoekingen die in de diagnostiek van aandoeningen van de 
hypophyse-bi3nierschors-as vaak wordt gebruikt is de bestudering van het effect 
van een synthetisch corticosteroid (dexamethason) op de plasma spiegels van 
Cortisol en ACTH. B13 alle normale proefpersonen waren de plasma waarden 
voor I-ACTH, B-ACTH en Cortisol om 900 's morgens op de dag na inneming van 
dexamethason 's avonds te 2300 uur lager dan die op de morgen van de vooraf-
gaande dag. Bij de patiënten met de ziekte van Gushing waren alle waarden voor 
I-ACTH en Cortisol hoger dan die van de controle groep. 
In hoofdstuk VI werd de relatie tussen I-ACTH en B-ACTH bestudeerd bij 
controle patiënten tijdens een door insuline geïnduceerde hypoglycaemie. 
Volgens verwachting trad een snelle stijging van ACTH op rond 10 minuten nadat 
de hypoglycaemie was opgetreden. Een maximum werd bereikt 30 tot 45 minuten 
na toediening van insuline. Vervolgens daalden de ACTH spiegels, de B-ACTH 
waarden overigens sneller dan de I-ACTH waarden. Het was opmerkelijk dat de 
I/B ratio bij stijgende ACTH spiegels daalde (1,96). Na het bereiken van de 
maximale ACTH waarde steeg de I/B ratio significant hoger (6,54) dan de uit-
gangswaarde in het begin van het onderzoek (3,45). In hoofdstuk VI wordt met 
het nodige voorbehoud uiteengezet dat dit verschijnsel als volgt geïnterpre-
teerd moet worden: m situaties waarin ACTH afgifte actief wordt gestimuleerd 
neemt de bijdrage van B-ACTH toe. Bij dalen van ACTH spiegels na activering 
door hypoglycaemie blijkt de bijdrage van I-ACTH t.o.v. B-ACTH sterk toe te 
nemen. De hierdoor optredende stijging van de I/B ratio kan voor een aanzien-
lijk deel worden verklaard door een lagere half-waarde tijd van B-ACTH dan 
I-ACTH zoals ook bij dit onderzoek gevonden is. 
De resultaten in dit proefschrift kunnen als volgt samengevat worden: 
1) met de radioimmunoassay worden duidelijk hogere ACTH waarden gemeten dan 
met de bioassay. 
2) niettemin is voor klinisch-diagnostisch gebruik, meting door middel van 
immunoassay even bruikbaar gezien de hoge correlatie die er werd gevonden 
tussen de waarden verkregen met beide methoden zowel onder normale als patho-
logische omstandigheden. 
3) pas uit waarnemingen m het laatste hoofdstuk wordt duidelijk welke eigen 
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mentes de biologische ACTH meting heeft: onder omstandigheden waarbij bio-
logische prikkels de afgifte van ACTH door de hypophyse stimuleren blijkt eerst 
dat de stijgingen van Cortisol spiegels in bloed altijd werden voorafgegaan 
door een kortdurende relatief sterkere toeneming van biologisch dan van 
immunologisch meetbaar ACTH. 
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NAWOORD 
Bi] het verschijnen van dit proefschrift wil ik mijn waardering kenbaar 
maken voor eenieder die aan de totstandkoming ervan heeft bijgedragen. Dit 
geldt met name voor Gerard Pesman die steeds met niet aflatend enthousiasme, 
geduld en toewijding veel ondankbaar werk verrichtte en mee hielp beide assays 
te vervolmaken. In de ontwikkelingsfase van de radioimmunoassay werd met veel 
zwier bijstand verleend door Jan Rijken, die samen met Rob Hermsen zorg bleef 
dragen voor de jodering. Plasma Cortisol werd gemeten door Oda Voesten en 
Willy van de Velde-van Leeuwen. Anjelien van Geel zorgde steeds voor een accurate 
centrifugering van de binnengekomen bloedmonsters. Een speciaal woord van 
waardering geldt voor die medewerkers die op heldhaftige wijze hun bloed voor 
dit proefschrift hebben gegeven, spontaan dan wel na zachte doch nadrukkelijke 
aansporing mijnerzijds. Dit is beloond door hen te beschouwen als "normalen" 
tenminste wat betreft de hypophyse-bijmer as. 
De heren G M Busser, A W van de Berg en H M Eikholt droegen zorg voor de 
aanvoer van ratten, soms met kunst en vliegwerk, waarna Ρ В Spaan, H J M Janssen, 
Η Ρ N van Wezel of mevrouw J Η J Janssen-van Stiphout klaar stonden om mij een 
vervelend karwei uit handen te nemen. De tabellen en tekeningen van eigen hand 
werden verkleind door toedoen van de heren F J de Graaf, A T A Reynen en С A de 
Bruin. De heren E de Graaff en A H M Wolf hielpen bij het verzamelen van vele 
oude publicaties, de laatste behield daarnaast een hardnekkig optimisme omtrent 
de uiteindelijke bestemming van het door mij geleende. 
De definitieve versie van het manuscript werd met veel geduld persklaar 
gemaakt door Joke Peren-van Anholt, nadat enkele wijzigingen in de Engelse 
taal met veel toewijding en liefde waren aangebracht door G Goverde-Lips. 
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CURRICULUM VITAE 
De auteur van dit proefschrift 
werd op 3 april 1943 geboren te Oosterhout (N-Br), 
verwierf in 1962 het diploma gymnasium β aan het 
Onze Lieve Vrouwelyceum te Breda, 
ving in hetzelfde ]aar zijn studie Biologie aan aan de 
Rijksuniversiteit te Utrecht, 
behaalde zi]n kandidaatsexamen in december 1966, 
legde het doctoraalexamen met de bijvakken Anthropobiologie 
(prof. dr. J. Huizinga) en Microbiologie (prof. dr. P.G. de Haan) 
en het hoofdvak Vergelijkende Endocrinologie (prof. dr. 
P.G.W.J. van Oordt) af in december 1969, 
trad per augustus 1969 m dienst van de Medische Faculteit te 
Nijmegen, met onder meer als taak de practica Biologie en 
e 
Embryologie van 1 jaars studenten geneeskunde te leiden 
vanuit de afdeling Medische Biologie (dr. W.J. van Dongen), 
werd in 1979 benoemd als docent Biologie aan de 
Avondscholengemeenschap "Craneveldt" (dr. A.J.H. v. Wegen) 
en is sinds januari 1980 in dienst van de afdeling 
Experimentele en Chemische Endocrinologie (prof. dr. Th.J. Benraad). 
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STELLINGEN 
I 
Meting van immunoreactief ACTH met een antilichaam dat het centrale deel van 
het ACTH molecule herkent resulteert in gemeten waarden die hoger zi]n dan 
die verkregen met een meting die de steroidproducerende activiteit van ACTH 
als parameter neemt. 
dit proefschrift 
II 
Voor diagnostische doeleinden voldoet een ACTH radioimmunoassay gebruik makend 
van een antilichaam dat het centrale deel van het ACTH molecule herkent in 
gelijke mate als een biologische meting. 
dit proefschrift 
III 
Studies die betrekking hebben op de relatie tussen de structuur en de biolo­
gische activiteit van ACTH peptiden kunnen slechts tot een betrouwbaar resul­
taat lelden wanneer in het meetsysteem de afbraak van deze peptiden tot een 
minimum is teruggebracht. 
dit proefschrift 
IV 
Binnen het ACTH molecule bevinden zich twee sequenties die in staat zijn de 
steroidgenese in de bijnierschors te induceren. 
dit proefschrift 
V 
De metingen van "Big" ACTH in humaan plasma van normale proefpersonen zoals 
toegepast door Thoren et al dient met een "grote" korrel zout genomen te wor­
den. 
M Thoren, M Ajne & К Hall (1981) Acta Endocnnologica 96: 15 
VI 
Het voorkomen van ACTH in weefsels buiten de hypothalamus-hypophyse regio dj ent 
nauwkeurig geverifieerd te worden met behulp van een betrouwbare bioassay. 
E S Orwoll & J W Kendall (1979) Clin Research 27 23A 
L I Larsson (1978) Histochemistry 55. 225 
VII 
De titel "A sensitive radioimmunoassay for corticotropin using a fully biologi-
125 
cally active I-labeled ligand" wekt ten onrechte de indruk dat de gevoelig-
heid van de assay het gevolg is van het gebruik van de genoemde ligand. 
D J Buckley, J Hagman & J Ramachandran (1981) Endocrinology 109: 10 
VIII 
B13 kwaliteitscontrole van steroidhormoon-receptorbepalingen dient aandacht te 
worden besteed aan de nauwkeurigheid waarmee de "efficiency" van de radioactivi-
teitsmeting is vastgesteld. 
IX 
Bi] psychosomatische klachten zal raadpleging van een advocaat soms effectiever 
zi]n dan raadpleging van een arts. 
X 
Het gebruik om in de laatste stelling bi] een proefschrift blijk te geven van 
een overigens schijnbare aanwezigheid van humor bij de auteur dient afgeschaft 
te worden - zie stelling XV. 
XI 
Het "milieu exterieur" van een humaan embryo kan beschouwd worden als een phylo-
genetisch relict. 
XII 
Een consultatieve psychiatrische dienstverlening in een ziekenhuis draagt bi] 
tot kostenbeperking in de gezondheidszorg. 
S J Levitan & D Ξ Kornfeld (1981) Amer J Psychiatry 138: 790 
XIII 
De suggestie als zou verzet tegen de technocratie zijn als "blaffen tegen de 
maan" dient in het kader van een massaal verzet tegen plaatsing van kernwapens 
herzien te worden. 
Ph Hertens S H Koningsveld (1981) Wending september: 500 
XIV 
De in universitaire kring veel gebezigde termen "onderwijsbelasting" en 
"onderzoeksactiviteiten" geven een duidelijk inzicht in de mentaliteit die 
veel medewerkers met betrekking tot de aan hen toevertrouwde taken wensen ten 
toon te spreiden. 
H J M Coverde 15 december 1981 


